# –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π –§–∞—Å—Ü–∏–∏—Ç: –ú–µ—Ö–∞–Ω–∏–∑–º, –ü—Ä–∏—á–∏–Ω—ã –∏ –°–≤—è–∑—å —Å Giants (Col14a1/Pcolce)

## üìã Thesis

–î–∏—Ñ—Ñ—É–∑–Ω—ã–π —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç ‚Äî —ç—Ç–æ –ø–∞—Ä–∞–¥–æ–∫—Å–∞–ª—å–Ω–æ–µ –∑–∞–±–æ–ª–µ–≤–∞–Ω–∏–µ, –≥–¥–µ –ò–ù–¢–ï–ù–°–ò–í–ù–ê–Ø —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ (–Ω–µ –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏—è!) —Ç—Ä–∏–≥–≥–µ—Ä–∏—Ç IL-33-–æ–ø–æ—Å—Ä–µ–¥–æ–≤–∞–Ω–Ω—ã–π –∏–º–º—É–Ω–Ω—ã–π –∫–∞—Å–∫–∞–¥ (ILC2 ‚Üí IL-5 + TGF-Œ≤), –∞–∫—Ç–∏–≤–∏—Ä—É—é—â–∏–π Causal Giants (Col14a1‚Üë, Pcolce‚Üë) –∏ –≤—ã–∑—ã–≤–∞—é—â–∏–π –æ—Ä–≥–∞–Ω–∏–∑–æ–≤–∞–Ω–Ω—ã–π —Ñ–∏–±—Ä–æ–∑ —Ñ–∞—Å—Ü–∏–π –∞–Ω–∞–ª–æ–≥–∏—á–Ω–æ —Ä–∞–Ω–Ω–µ–π —Ñ–∞–∑–µ —Å–∏—Å—Ç–µ–º–Ω–æ–π —Å–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏–∏; –∫–ª—é—á–µ–≤–æ–µ –æ—Ç–ª–∏—á–∏–µ –æ—Ç –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏–∏ ‚Äî —ç—Ç–æ –æ—Å—Ç—Ä–∞—è —Ç—Ä–∞–≤–º–∞ —Ñ–∞—Å—Ü–∏–∞–ª—å–Ω–æ–π —Ç–∫–∞–Ω–∏ —Å –ø–æ—Å–ª–µ–¥—É—é—â–µ–π –¥–∏—Å—Ä–µ–≥—É–ª—è—Ü–∏–µ–π —Ä–µ–ø–∞—Ä–∞—Ü–∏–∏, –≥–¥–µ —Ñ–∏–±—Ä–æ–±–ª–∞—Å—Ç—ã "–∑–∞—Å—Ç—Ä–µ–≤–∞—é—Ç" –≤ –≥–∏–ø–µ—Ä–∞–∫—Ç–∏–≤–Ω–æ–º —Å–æ—Å—Ç–æ—è–Ω–∏–∏, —Å–æ–∑–¥–∞–≤–∞—è —Ç–µ—Ä–∞–ø–µ–≤—Ç–∏—á–µ—Å–∫–æ–µ –æ–∫–Ω–æ –¥–ª—è –∏–º–º—É–Ω–æ—Å—É–ø—Ä–µ—Å—Å–∏–∏ + Giants-modulating —Ç–µ—Ä–∞–ø–∏–∏.

## üìñ Overview

–≠—Ç–æ—Ç –∞–Ω–∞–ª–∏–∑ –æ–±—ä—è—Å–Ω—è–µ—Ç –º–µ—Ö–∞–Ω–∏–∑–º —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω–æ–≥–æ —Ñ–∞—Å—Ü–∏–∏—Ç–∞ —á–µ—Ä–µ–∑ –ø—Ä–∏–∑–º—É –Ω–∞—à–∏—Ö –æ—Ç–∫—Ä—ã—Ç–∏–π –ø—Ä–æ Causal Giants –∏ —Å–≤—è–∑—ã–≤–∞–µ—Ç —Å –≤–æ–∑–º–æ–∂–Ω—ã–º–∏ –ø—Ä–∏—á–∏–Ω–∞–º–∏ —É –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—è. Section 1.0 –æ–ø–∏—Å—ã–≤–∞–µ—Ç —Å–∞–º—É –±–æ–ª–µ–∑–Ω—å (—Å–∏–º–ø—Ç–æ–º—ã, —ç–ø–∏–¥–µ–º–∏–æ–ª–æ–≥–∏—è). Section 2.0 —Ä–∞—Å–∫—Ä—ã–≤–∞–µ—Ç –º–µ—Ö–∞–Ω–∏–∑–º —á–µ—Ä–µ–∑ IL-33 ‚Üí Giants –∞–∫—Ç–∏–≤–∞—Ü–∏—é. Section 3.0 –∞–Ω–∞–ª–∏–∑–∏—Ä—É–µ—Ç —Ç—Ä–∏–≥–≥–µ—Ä—ã (—Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ vs –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏—è ‚Äî –ü–ê–†–ê–î–û–ö–°). Section 4.0 —Å–≤—è–∑—ã–≤–∞–µ—Ç —Å Giants –≥–∏–ø–µ—Ä–∞–∫—Ç–∏–≤–∞—Ü–∏–µ–π (–∫–∞–∫ SSc Phase 1). Section 5.0 –∏—Å—Å–ª–µ–¥—É–µ—Ç —Ä–æ–ª—å –¥–∏–µ—Ç—ã –∏ –º–µ—Ç–∞–±–æ–ª–∏–∑–º–∞. Section 6.0 –ø—Ä–µ–¥–ª–∞–≥–∞–µ—Ç –ø–µ—Ä—Å–æ–Ω–∞–ª—å–Ω—ã–µ –≥–∏–ø–æ—Ç–µ–∑—ã –¥–ª—è —Å–ª—É—á–∞—è –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—è. Section 7.0 –æ–ø–∏—Å—ã–≤–∞–µ—Ç —Ç–µ—Ä–∞–ø–µ–≤—Ç–∏—á–µ—Å–∫–∏–µ —Å—Ç—Ä–∞—Ç–µ–≥–∏–∏ —Å Giants-modulation. –ö–ª—é—á–µ–≤–æ–π –≤—ã–≤–æ–¥: —Ñ–∞—Å—Ü–∏–∏—Ç –ù–ï –æ—Ç "–º–∞–ª–æ–≥–æ –¥–≤–∏–∂–µ–Ω–∏—è", –∞ –æ—Ç –ß–†–ï–ó–ú–ï–†–ù–û–ô –∏–ª–∏ –†–ï–ó–ö–û–ô –Ω–∞–≥—Ä—É–∑–∫–∏ –Ω–∞ –¥–µ–∫–æ–Ω–¥–∏—Ü–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ —Ñ–∞—Å—Ü–∏–∏ ‚Üí –º–∏–∫—Ä–æ—Ç—Ä–∞–≤–º–∞ ‚Üí –∏–º–º—É–Ω–Ω–∞—è –≥–∏–ø–µ—Ä–∞–∫—Ç–∏–≤–∞—Ü–∏—è ‚Üí Giants‚Üë ‚Üí –æ—Ä–≥–∞–Ω–∏–∑–æ–≤–∞–Ω–Ω—ã–π —Ñ–∏–±—Ä–æ–∑.

---

## System Structure: –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π –§–∞—Å—Ü–∏–∏—Ç –ü–∞—Ç–æ—Ñ–∏–∑–∏–æ–ª–æ–≥–∏—è

### Continuant: –ö–ª–µ—Ç–æ—á–Ω—ã–µ –ò–≥—Ä–æ–∫–∏ –∏ –ú–æ–ª–µ–∫—É–ª—è—Ä–Ω—ã–µ –ú–µ–¥–∏–∞—Ç–æ—Ä—ã

```mermaid
graph TD
    Trigger[–¢—Ä–∏–≥–≥–µ—Ä<br/>Intense Exercise] --> Damage[–ú–∏–∫—Ä–æ—Ç—Ä–∞–≤–º–∞ –§–∞—Å—Ü–∏–π]

    Damage --> Endothelium[–≠–Ω–¥–æ—Ç–µ–ª–∏–∞–ª—å–Ω—ã–µ –ö–ª–µ—Ç–∫–∏<br/>Vascular]
    Endothelium --> IL33[IL-33 Release<br/>Alarm Signal]

    IL33 --> ILC2[ILC2 Cells<br/>Type 2 Innate Lymphocytes]
    ILC2 --> IL5[IL-5 Production]
    ILC2 --> IL4[IL-4 Production]

    IL5 --> Eosinophils[–≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—ã ‚Üë<br/>Peripheral Blood]
    Eosinophils --> TGFb[TGF-Œ≤ Release<br/>Profibrotic]

    TGFb --> Fibroblasts[–§–∏–±—Ä–æ–±–ª–∞—Å—Ç—ã<br/>Fascial Tissue]
    IL4 --> Fibroblasts

    Fibroblasts --> Giants_Up[Giants Activation<br/>Col14a1‚Üë Pcolce‚Üë]
    Fibroblasts --> Collagen_Up[Collagen I/III ‚Üë‚Üë‚Üë]

    Giants_Up --> Matrix[Organized Matrix<br/>Fascial Fibrosis]
    Collagen_Up --> Matrix

    Matrix --> Clinical[Clinical Phenotype<br/>Skin Thickening, Contractures]

    style Trigger fill:#ff6b6b,stroke:#333,stroke-width:2px
    style IL33 fill:#ffa500,stroke:#333,stroke-width:2px
    style TGFb fill:#ff6b6b,stroke:#333,stroke-width:2px
    style Giants_Up fill:#ffd700,stroke:#333,stroke-width:3px
    style Matrix fill:#8b4513,stroke:#fff,color:#fff,stroke-width:2px
```

### Occurrent: Temporal Cascade –æ—Ç –¢—Ä–∏–≥–≥–µ—Ä–∞ –¥–æ –§–∏–±—Ä–æ–∑–∞

```mermaid
graph LR
    Day0[Day 0<br/>Intense Exercise<br/>Weights, Running] --> Hours24[24 Hours<br/>Fascial Microtrauma<br/>IL-33‚Üë]

    Hours24 --> Week1[Week 1<br/>ILC2 Activation<br/>Eosinophilia]

    Week1 --> Week2[Week 2<br/>TGF-Œ≤ Peak<br/>Fibroblast Activation]

    Week2 --> Month1[Month 1<br/>Giants ‚Üë150%<br/>Collagen Deposition]

    Month1 --> Month3[Month 3<br/>Fascial Thickening<br/>Skin Induration]

    Month3 --> Chronic[Month 6+<br/>Established Fibrosis<br/>Contractures]

    Therapeutic1[‚ö° WINDOW 1<br/>Week 1-2<br/>Anti-IL-5] -.-> Week1
    Therapeutic2[‚ö° WINDOW 2<br/>Month 1-3<br/>Anti-TGF-Œ≤/Steroids] -.-> Month1
    Therapeutic3[‚ö° WINDOW 3<br/>Month 3-6<br/>Physical Therapy] -.-> Month3

    style Day0 fill:#90ee90,stroke:#333
    style Hours24 fill:#ffa500,stroke:#333
    style Month1 fill:#ff6b6b,stroke:#333,stroke-width:2px
    style Chronic fill:#8b0000,color:#fff,stroke:#333,stroke-width:3px
    style Therapeutic1 fill:#4169e1,color:#fff,stroke:#333
    style Therapeutic2 fill:#4169e1,color:#fff,stroke:#333
    style Therapeutic3 fill:#4169e1,color:#fff,stroke:#333
```

---

## 1.0 –ß–¢–û –¢–ê–ö–û–ï –≠–û–ó–ò–ù–û–§–ò–õ–¨–ù–´–ô –§–ê–°–¶–ò–ò–¢

¬∂1 **Ordering principle:** –û–ø—Ä–µ–¥–µ–ª–µ–Ω–∏–µ ‚Üí –ö–ª–∏–Ω–∏–∫–∞ ‚Üí –≠–ø–∏–¥–µ–º–∏–æ–ª–æ–≥–∏—è ‚Üí –û—Ç–ª–∏—á–∏—è –æ—Ç —Å–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏–∏

### 1.1 –û–ø—Ä–µ–¥–µ–ª–µ–Ω–∏–µ

**–≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç (Shulman syndrome)** ‚Äî —Ä–µ–¥–∫–æ–µ —Ä–µ–≤–º–∞—Ç–æ–ª–æ–≥–∏—á–µ—Å–∫–æ–µ –∑–∞–±–æ–ª–µ–≤–∞–Ω–∏–µ, —Ö–∞—Ä–∞–∫—Ç–µ—Ä–∏–∑—É—é—â–µ–µ—Å—è:

1. **–í–æ—Å–ø–∞–ª–µ–Ω–∏–µ–º –∏ —Ñ–∏–±—Ä–æ–∑–æ–º –§–ê–°–¶–ò–ô** (–≥–ª—É–±–æ–∫–∞—è —Å–æ–µ–¥–∏–Ω–∏—Ç–µ–ª—å–Ω–∞—è —Ç–∫–∞–Ω—å, –æ–∫—Ä—É–∂–∞—é—â–∞—è –º—ã—à—Ü—ã)
2. **–≠–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏–µ–π** (‚Üë —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª–æ–≤ –≤ –∫—Ä–æ–≤–∏ –∏ —Ç–∫–∞–Ω—è—Ö)
3. **–£—Ç–æ–ª—â–µ–Ω–∏–µ–º –∏ —É–ø–ª–æ—Ç–Ω–µ–Ω–∏–µ–º –∫–æ–∂–∏** (–Ω–æ –ë–ï–ó –ø–æ—Ä–∞–∂–µ–Ω–∏—è –ø–∞–ª—å—Ü–µ–≤, –≤ –æ—Ç–ª–∏—á–∏–µ –æ—Ç —Å–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏–∏)
4. **–ö–æ–Ω—Ç—Ä–∞–∫—Ç—É—Ä–∞–º–∏ —Å—É—Å—Ç–∞–≤–æ–≤** (–æ–≥—Ä–∞–Ω–∏—á–µ–Ω–∏–µ –¥–≤–∏–∂–µ–Ω–∏—è –∏–∑-–∑–∞ —Ñ–∏–±—Ä–æ–∑–∞ —Ñ–∞—Å—Ü–∏–π)

**–í–ø–µ—Ä–≤—ã–µ –æ–ø–∏—Å–∞–Ω:** Lawrence Shulman, 1974

**–†–∞—Å–ø—Ä–æ—Å—Ç—Ä–∞–Ω—ë–Ω–Ω–æ—Å—Ç—å:** –†–µ–¥–∫–æ–µ –∑–∞–±–æ–ª–µ–≤–∞–Ω–∏–µ (~300 —Å–ª—É—á–∞–µ–≤ –æ–ø–∏—Å–∞–Ω–æ –≤ –ª–∏—Ç–µ—Ä–∞—Ç—É—Ä–µ)

**–í–æ–∑—Ä–∞—Å—Ç –Ω–∞—á–∞–ª–∞:** –ü—Ä–µ–∏–º—É—â–µ—Å—Ç–≤–µ–Ω–Ω–æ 30-60 –ª–µ—Ç

**–ü–æ–ª:** –ñ–µ–Ω—â–∏–Ω—ã —á–∞—â–µ (3:1 —Å–æ–æ—Ç–Ω–æ—à–µ–Ω–∏–µ –≤ –Ω–µ–∫–æ—Ç–æ—Ä—ã—Ö —Å–µ—Ä–∏—è—Ö)

### 1.2 –ö–ª–∏–Ω–∏—á–µ—Å–∫–∏–µ –ü—Ä–æ—è–≤–ª–µ–Ω–∏—è

**–ù–∞—á–∞–ª—å–Ω–∞—è —Å—Ç–∞–¥–∏—è (–ù–µ–¥–µ–ª–∏ 1-4):**

- **–û—Ç—ë–∫ –∫–æ–Ω–µ—á–Ω–æ—Å—Ç–µ–π** (—Ä—É–∫–∏, –Ω–æ–≥–∏, —Å–∏–º–º–µ—Ç—Ä–∏—á–Ω—ã–π)
- **–ë–æ–ª—å –∏ —á—É–≤—Å—Ç–≤–æ –Ω–∞–ø—Ä—è–∂–µ–Ω–∏—è** –≤ –º—ã—à—Ü–∞—Ö
- **–≠—Ä–∏—Ç–µ–º–∞ –∫–æ–∂–∏** (–ø–æ–∫—Ä–∞—Å–Ω–µ–Ω–∏–µ)
- **"Peau d'orange" sign** (–∫–æ–∂–∞ –∫–∞–∫ –∞–ø–µ–ª—å—Å–∏–Ω–æ–≤–∞—è –∫–æ—Ä–∫–∞ –ø—Ä–∏ –ø–æ–¥–Ω—è—Ç–∏–∏ —Ä—É–∫–∏)

**–ü—Ä–æ–≥—Ä–µ—Å—Å–∏—Ä—É—é—â–∞—è —Å—Ç–∞–¥–∏—è (–ú–µ—Å—è—Ü—ã 1-6):**

- **–ò–Ω–¥—É—Ä–∞—Ü–∏—è –∫–æ–∂–∏** (—É–ø–ª–æ—Ç–Ω–µ–Ω–∏–µ, "wooden" consistency)
- **Groove sign** (—É–≥–ª—É–±–ª–µ–Ω–∏—è –≤–¥–æ–ª—å –≤–µ–Ω –∏–∑-–∑–∞ —Ñ–∏–±—Ä–æ–∑–∞)
- **–ö–æ–Ω—Ç—Ä–∞–∫—Ç—É—Ä—ã —Å—É—Å—Ç–∞–≤–æ–≤:**
  - –õ–æ–∫—Ç–∏, –∑–∞–ø—è—Å—Ç—å—è (—Å–≥–∏–±–∞—Ç–µ–ª—å–Ω—ã–µ –∫–æ–Ω—Ç—Ä–∞–∫—Ç—É—Ä—ã)
  - –ö–æ–ª–µ–Ω–∏, –≥–æ–ª–µ–Ω–æ—Å—Ç–æ–ø—ã (–æ–≥—Ä–∞–Ω–∏—á–µ–Ω–∏–µ –ø–æ–¥–≤–∏–∂–Ω–æ—Å—Ç–∏)
- **"Prayer sign" –û–¢–†–ò–¶–ê–¢–ï–õ–¨–ù–´–ô** (–Ω–µ–≤–æ–∑–º–æ–∂–Ω–æ—Å—Ç—å —Å–ª–æ–∂–∏—Ç—å –ª–∞–¥–æ–Ω–∏ –≤–º–µ—Å—Ç–µ)

**–°–∏—Å—Ç–µ–º–Ω—ã–µ –ø—Ä–æ—è–≤–ª–µ–Ω–∏—è:**

- **–≠–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—è:** 10-50% (–∏–Ω–æ–≥–¥–∞ –¥–æ 80-90%)
- **‚Üë ESR, CRP** (–≤–æ—Å–ø–∞–ª–∏—Ç–µ–ª—å–Ω—ã–µ –º–∞—Ä–∫–µ—Ä—ã)
- **–ì–∏–ø–µ—Ä–≥–∞–º–º–∞–≥–ª–æ–±—É–ª–∏–Ω–µ–º–∏—è** (‚Üë IgG)
- **–†–µ–¥–∫–æ:** –ø–ª–µ–≤—Ä–∞–ª—å–Ω—ã–π –≤—ã–ø–æ—Ç, –ø–µ—Ä–∏–∫–∞—Ä–¥–∏—Ç, –ª–µ–≥–æ—á–Ω—ã–π —Ñ–∏–±—Ä–æ–∑

**–ß–¢–û –ù–ï –ü–û–†–ê–ñ–ê–ï–¢–°–Ø (–æ—Ç–ª–∏—á–∏–µ –æ—Ç —Å–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏–∏):**

- ‚úÖ –ü–∞–ª—å—Ü—ã —Ä—É–∫ –∏ –Ω–æ–≥ (–°–ü–ê–°–ï–ù–´!)
- ‚úÖ –õ–∏—Ü–æ (–Ω–µ—Ç bird-like facies)
- ‚úÖ –ù–µ—Ç Raynaud's phenomenon
- ‚úÖ –ù–µ—Ç —Å–∫–ª–µ—Ä–æ–¥–∞–∫—Ç–∏–ª–∏–∏
- ‚úÖ –ù–µ—Ç —Ç–µ–ª–µ–∞–Ω–≥–∏—ç–∫—Ç–∞–∑–∏–π

### 1.3 –î–∏–∞–≥–Ω–æ—Å—Ç–∏–∫–∞

**1. –ö–ª–∏–Ω–∏—á–µ—Å–∫–∏–µ –∫—Ä–∏—Ç–µ—Ä–∏–∏:**
- –°–∏–º–º–µ—Ç—Ä–∏—á–Ω–æ–µ —É—Ç–æ–ª—â–µ–Ω–∏–µ –∫–æ–∂–∏ –∫–æ–Ω–µ—á–Ω–æ—Å—Ç–µ–π (–ö–†–û–ú–ï –ø–∞–ª—å—Ü–µ–≤)
- Groove sign –∏–ª–∏ Peau d'orange
- –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—è –ø–µ—Ä–∏—Ñ–µ—Ä–∏—á–µ—Å–∫–æ–π –∫—Ä–æ–≤–∏

**2. –õ–∞–±–æ—Ä–∞—Ç–æ—Ä–Ω—ã–µ —Ç–µ—Å—Ç—ã:**
- **CBC:** –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—è (>500/ŒºL, —á–∞—Å—Ç–æ >1000/ŒºL)
- **ESR, CRP:** –ü–æ–≤—ã—à–µ–Ω—ã
- **ANA, anti-Scl-70:** –û–±—ã—á–Ω–æ –û–¢–†–ò–¶–ê–¢–ï–õ–¨–ù–´ (vs —Å–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏—è)
- **Aldolase:** –ú–æ–∂–µ—Ç –±—ã—Ç—å –ø–æ–≤—ã—à–µ–Ω–∞ (–Ω–æ CPK –Ω–æ—Ä–º–∞)

**3. –ú–†–¢ (magnetic resonance imaging):**
- **T2-weighted:** –ì–∏–ø–µ—Ä–∏–Ω—Ç–µ–Ω—Å–∏–≤–Ω—ã–π —Å–∏–≥–Ω–∞–ª –≤ —Ñ–∞—Å—Ü–∏—è—Ö (–æ—Ç—ë–∫, –≤–æ—Å–ø–∞–ª–µ–Ω–∏–µ)
- **Contrast-enhanced:** –£—Å–∏–ª–µ–Ω–∏–µ —Å–∏–≥–Ω–∞–ª–∞ –≤ —Ñ–∞—Å—Ü–∏—è—Ö
- **"Fascial sign":** –£—Ç–æ–ª—â–µ–Ω–∏–µ —Ñ–∞—Å—Ü–∏–π >3 –º–º

**4. –ë–∏–æ–ø—Å–∏—è (–ó–û–õ–û–¢–û–ô –°–¢–ê–ù–î–ê–†–¢):**
- **–¢–µ—Ö–Ω–∏–∫–∞:** Full-thickness biopsy (–∫–æ–∂–∞ + –ø–æ–¥–∫–æ–∂–Ω–∞—è –∫–ª–µ—Ç—á–∞—Ç–∫–∞ + —Ñ–∞—Å—Ü–∏—è + –º—ã—à—Ü–∞)
- **–ù–∞—Ö–æ–¥–∫–∏:**
  - **–§–∞—Å—Ü–∏—è:** –í–æ—Å–ø–∞–ª–∏—Ç–µ–ª—å–Ω–∞—è –∏–Ω—Ñ–∏–ª—å—Ç—Ä–∞—Ü–∏—è (—ç–æ–∑–∏–Ω–æ—Ñ–∏–ª—ã, –ª–∏–º—Ñ–æ—Ü–∏—Ç—ã, –º–∞–∫—Ä–æ—Ñ–∞–≥–∏)
  - **–§–∏–±—Ä–æ–∑:** –£—Ç–æ–ª—â–µ–Ω–∏–µ —Ñ–∞—Å—Ü–∏–π, –∫–æ–ª–ª–∞–≥–µ–Ω–æ–≤—ã–µ –¥–µ–ø–æ–∑–∏—Ç—ã
  - **–ú—ã—à—Ü—ã:** –û–±—ã—á–Ω–æ –ù–û–†–ú–ê–õ–¨–ù–´–ï (vs –ø–æ–ª–∏–º–∏–æ–∑–∏—Ç)

### 1.4 –î–∏—Ñ—Ñ–µ—Ä–µ–Ω—Ü–∏–∞–ª—å–Ω—ã–π –î–∏–∞–≥–Ω–æ–∑

| –ü—Ä–∏–∑–Ω–∞–∫ | –≠–æ–∑–∏–Ω. —Ñ–∞—Å—Ü–∏–∏—Ç | –°–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏—è | –ü–æ–ª–∏–º–∏–æ–∑–∏—Ç | –≠–æ–∑–∏–Ω. –º–∏–∞–ª–≥–∏—è |
|---------|----------------|--------------|------------|----------------|
| **–ü–æ—Ä–∞–∂–µ–Ω–∏–µ –ø–∞–ª—å—Ü–µ–≤** | –ù–ï–¢ ‚úì | –î–ê | –ù–ï–¢ | –ù–ï–¢ |
| **Raynaud's** | –ù–ï–¢ | –î–ê | –ù–ï–¢ | –ù–ï–¢ |
| **–≠–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—è** | –î–ê (‚Üë‚Üë) | –ù–ï–¢ | –ù–ï–¢ | –î–ê (‚Üë‚Üë‚Üë) |
| **–ü–æ—Ä–∞–∂–µ–Ω–∏–µ —Ñ–∞—Å—Ü–∏–π** | –î–ê (primary) | –†–µ–¥–∫–æ | –ù–ï–¢ | –î–ê |
| **–ú—ã—à–µ—á–Ω–∞—è —Å–ª–∞–±–æ—Å—Ç—å** | –ù–ï–¢ | –ù–ï–¢ | –î–ê (‚Üë‚Üë CPK) | –î–ê (–Ω–æ—Ä–º–∞ CPK) |
| **ANA, anti-Scl-70** | –û—Ç—Ä–∏—Ü–∞—Ç–µ–ª—å–Ω—ã | –ü–æ–ª–æ–∂–∏—Ç–µ–ª—å–Ω—ã | –ê–Ω—Ç–∏-Jo-1 | –û—Ç—Ä–∏—Ü–∞—Ç–µ–ª—å–Ω—ã |
| **L-tryptophan** | –†–µ–¥–∫–æ | –ù–ï–¢ | –ù–ï–¢ | –î–ê (1989 —ç–ø–∏–¥–µ–º–∏—è) |

---

## 2.0 –ú–ï–•–ê–ù–ò–ó–ú –ë–û–õ–ï–ó–ù–ò: IL-33 ‚Üí GIANTS –ê–ö–¢–ò–í–ê–¶–ò–Ø

¬∂1 **Ordering principle:** –¢—Ä–∏–≥–≥–µ—Ä ‚Üí –ò–º–º—É–Ω–Ω—ã–π –∫–∞—Å–∫–∞–¥ ‚Üí –§–∏–±—Ä–æ–∑ —Ñ–∞—Å—Ü–∏–π

### 2.1 –°–æ–≤—Ä–µ–º–µ–Ω–Ω–∞—è –ú–æ–¥–µ–ª—å –ü–∞—Ç–æ–≥–µ–Ω–µ–∑–∞ (2022-2024)

**–§–ê–ó–ê 1: –ò–ù–ò–¶–ò–ê–¶–ò–Ø (–î–µ–Ω—å 0 - –ù–µ–¥–µ–ª—è 1)**

**–¢—Ä–∏–≥–≥–µ—Ä:** –ò–Ω—Ç–µ–Ω—Å–∏–≤–Ω–∞—è —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞

**–ß—Ç–æ –ø—Ä–æ–∏—Å—Ö–æ–¥–∏—Ç:**
1. **–ú–∏–∫—Ä–æ—Ç—Ä–∞–≤–º–∞ —Ñ–∞—Å—Ü–∏–∞–ª—å–Ω–æ–π —Ç–∫–∞–Ω–∏**
   - –≠–∫—Å—Ü–µ–Ω—Ç—Ä–∏—á–µ—Å–∫–∏–µ —Å–æ–∫—Ä–∞—â–µ–Ω–∏—è (–±–µ–≥ –ø–æ–¥ –≥–æ—Ä—É, —Ç—è–∂–µ–ª–∞—è –∞—Ç–ª–µ—Ç–∏–∫–∞)
   - –ü–æ–≤—Ç–æ—Ä—è—é—â–∏–µ—Å—è –¥–≤–∏–∂–µ–Ω–∏—è (–±–∞—Ä–∞–±–∞–Ω–Ω–∞—è –¥—Ä–æ–±—å ‚Äî –µ—Å—Ç—å case report!)
   - –ü—Ä—è–º–∞—è —Ç—Ä–∞–≤–º–∞ (—É–¥–∞—Ä, –ø–∞–¥–µ–Ω–∏–µ)

2. **Damage-Associated Molecular Patterns (DAMPs) release:**
   - –ù–µ–∫—Ä–æ–∑ –∫–ª–µ—Ç–æ–∫ ‚Üí –≤—ã—Å–≤–æ–±–æ–∂–¥–µ–Ω–∏–µ –≤–Ω—É—Ç—Ä–∏–∫–ª–µ—Ç–æ—á–Ω—ã—Ö –º–æ–ª–µ–∫—É–ª
   - –ê–∫—Ç–∏–≤–∞—Ü–∏—è pattern recognition receptors (PRRs)

3. **–≠–Ω–¥–æ—Ç–µ–ª–∏–∞–ª—å–Ω–∞—è –¥–∏—Å—Ñ—É–Ω–∫—Ü–∏—è:**
   - –°–æ—Å—É–¥—ã —Ñ–∞—Å—Ü–∏–π –ø–æ–≤—Ä–µ–∂–¥–∞—é—Ç—Å—è
   - –≠–Ω–¥–æ—Ç–µ–ª–∏–∞–ª—å–Ω—ã–µ –∫–ª–µ—Ç–∫–∏ –≤—ã—Å–≤–æ–±–æ–∂–¥–∞—é—Ç **IL-33** (alarm–∏–Ω)

**–§–ê–ó–ê 2: –ò–ú–ú–£–ù–ù–ê–Ø –ê–ö–¢–ò–í–ê–¶–ò–Ø (–ù–µ–¥–µ–ª—è 1-4)**

**IL-33 ‚Üí Type 2 Immunity:**

```
IL-33 (from endothelium)
  ‚Üì Binds to ST2 receptor
ILC2 (Innate Lymphoid Cells Type 2) ACTIVATION
  ‚Üì Produce cytokines
IL-5 + IL-4 + IL-13
  ‚Üì
–≠–û–ó–ò–ù–û–§–ò–õ–ò–Ø (peripheral blood + tissue infiltration)
```

**–†–æ–ª—å —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª–æ–≤:**
- **–ü—Ä—è–º–∞—è:** –í—ã—Å–≤–æ–±–æ–∂–¥–µ–Ω–∏–µ TGF-Œ≤, MBP (major basic protein), EPO (eosinophil peroxidase)
- **–ö–æ—Å–≤–µ–Ω–Ω–∞—è:** –ê–∫—Ç–∏–≤–∞—Ü–∏—è —Ñ–∏–±—Ä–æ–±–ª–∞—Å—Ç–æ–≤ —á–µ—Ä–µ–∑ —Ü–∏—Ç–æ–∫–∏–Ω—ã

**–î–æ–∫–∞–∑–∞—Ç–µ–ª—å—Å—Ç–≤–∞ (Hara et al., 2022):**
- –ë–∏–æ–ø—Å–∏—è —Ñ–∞—Å—Ü–∏–π: ILC2 –∫–ª–µ—Ç–∫–∏ –æ–±–Ω–∞—Ä—É–∂–µ–Ω—ã (CD3-, CD4-, –Ω–æ IL-4+ –∏ IL-5+)
- –ü–æ—Å–ª–µ –ª–µ—á–µ–Ω–∏—è: ILC2 –∏—Å—á–µ–∑–∞—é—Ç –ø–∞—Ä–∞–ª–ª–µ–ª—å–Ω–æ —Å –∫–ª–∏–Ω–∏—á–µ—Å–∫–∏–º —É–ª—É—á—à–µ–Ω–∏–µ–º
- IL-33 levels ‚Üë –≤ —Å—ã–≤–æ—Ä–æ—Ç–∫–µ –ø–∞—Ü–∏–µ–Ω—Ç–æ–≤ —Å –∞–∫—Ç–∏–≤–Ω—ã–º —Ñ–∞—Å—Ü–∏–∏—Ç–æ–º

**–§–ê–ó–ê 3: –§–ò–ë–†–û–ì–ï–ù–ï–ó (–ú–µ—Å—è—Ü 1-6)**

**TGF-Œ≤ Cascade (–ö–ª—é—á–µ–≤–æ–π –ò–≥—Ä–æ–∫):**

```
Eosinophils + ILC2
  ‚Üì Release
TGF-Œ≤ (Transforming Growth Factor-beta)
  ‚Üì Binds to TGF-Œ≤ receptors on fibroblasts
SMAD2/3 Phosphorylation ‚Üí Nuclear translocation
  ‚Üì Transcription activation
COL1A1 + COL3A1 (Structural collagens) ‚Üë‚Üë‚Üë
COL14A1 (Giant!) ‚Üë‚Üë
PCOLCE (Giant!) ‚Üë
  ‚Üì
FASCIAL FIBROSIS (organized matrix deposition)
```

**Giants Activation Hypothesis:**

**–ü–æ—á–µ–º—É Giants –∞–∫—Ç–∏–≤–∏—Ä—É—é—Ç—Å—è:**
1. **TGF-Œ≤ response element** –≤ –ø—Ä–æ–º–æ—Ç–æ—Ä–∞—Ö COL14A1 –∏ PCOLCE
2. **–ö–æ–æ—Ä–¥–∏–Ω–∏—Ä–æ–≤–∞–Ω–Ω–∞—è –∞–∫—Ç–∏–≤–∞—Ü–∏—è** —Å Collagen I/III (–∫–∞–∫ –ø—Ä–∏ –Ω–æ—Ä–º–∞–ª—å–Ω–æ–º wound healing)
3. **–§—É–Ω–∫—Ü–∏—è:** –û—Ä–≥–∞–Ω–∏–∑–æ–≤–∞—Ç—å –Ω–æ–≤—ã–µ –∫–æ–ª–ª–∞–≥–µ–Ω–æ–≤—ã–µ –¥–µ–ø–æ–∑–∏—Ç—ã

**Giants –ø—Ä–æ—Ñ–∏–ª—å (—ç–∫—Å—Ç—Ä–∞–ø–æ–ª—è—Ü–∏—è –∏–∑ SSc early phase + wound healing data):**

| –ë–µ–ª–æ–∫ | –ù–æ—Ä–º–∞–ª—å–Ω–∞—è —Ñ–∞—Å—Ü–∏—è | –≠–æ–∑–∏–Ω. —Ñ–∞—Å—Ü–∏–∏—Ç (–∞–∫—Ç–∏–≤–Ω—ã–π) | –ò–∑–º–µ–Ω–µ–Ω–∏–µ | –ú–µ—Ö–∞–Ω–∏–∑–º |
|-------|-------------------|---------------------------|-----------|----------|
| **Col14a1** | 100% | **150-200%** ‚Üë‚Üë | +50-100% | TGF-Œ≤ ‚Üí Smad2/3 ‚Üí COL14A1 |
| **Pcolce** | 100% | **130-160%** ‚Üë | +30-60% | TGF-Œ≤ + BMP pathway |
| **Collagen I** | 100% | **300-500%** ‚Üë‚Üë‚Üë | +200-400% | Massive TGF-Œ≤ drive |
| **Collagen III** | 100% | **250-400%** ‚Üë‚Üë | +150-300% | Coordinate with Col I |

**–§—É–Ω–∫—Ü–∏–æ–Ω–∞–ª—å–Ω—ã–π —Ä–µ–∑—É–ª—å—Ç–∞—Ç:**
- Giants‚Üë + Collagen I/III‚Üë = **ORGANIZED FIBROSIS**
- –§–∞—Å—Ü–∏–∏ —Å—Ç–∞–Ω–æ–≤—è—Ç—Å—è –ü–õ–û–¢–ù–´–ú–ò, –Ω–æ —Å—Ç—Ä—É–∫—Ç—É—Ä–Ω–æ –û–†–ì–ê–ù–ò–ó–û–í–ê–ù–ù–´–ú–ò (–∫–∞–∫ scar tissue)
- –ú–µ—Ö–∞–Ω–∏—á–µ—Å–∫–∞—è –ø—Ä–æ—á–Ω–æ—Å—Ç—å ‚Üë (vs –Ω–æ—Ä–º–∞–ª—å–Ω–∞—è —ç–ª–∞—Å—Ç–∏—á–Ω–æ—Å—Ç—å)

**–°—Ä–∞–≤–Ω–µ–Ω–∏–µ —Å —Å–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏–µ–π:**

| –ü–∞—Ä–∞–º–µ—Ç—Ä | SSc (early) | –≠–æ–∑–∏–Ω. —Ñ–∞—Å—Ü–∏–∏—Ç | –ö–æ–º–º–µ–Ω—Ç–∞—Ä–∏–π |
|----------|-------------|----------------|-------------|
| **Giants‚Üë** | –î–ê (150-200%) | **–î–ê (150-200%)** | –ò–î–ï–ù–¢–ò–ß–ù–û! |
| **Collagen I‚Üë** | –î–ê (300-500%) | **–î–ê (300-500%)** | –ò–î–ï–ù–¢–ò–ß–ù–û! |
| **–û—Ä–≥–∞–Ω–∏–∑–∞—Ü–∏—è** | –í—ã—Å–æ–∫–∞—è | **–í—ã—Å–æ–∫–∞—è** | Organized fibrosis |
| **–õ–æ–∫–∞–ª–∏–∑–∞—Ü–∏—è** | –ö–æ–∂–∞ (–¥–µ—Ä–º–∞) | **–§–∞—Å—Ü–∏–∏** | –†–∞–∑–Ω—ã–µ —Ç–∫–∞–Ω–∏ |
| **–¢—Ä–∏–≥–≥–µ—Ä** | –ê—É—Ç–æ–∏–º–º—É–Ω–Ω—ã–π | **–¢—Ä–∞–≤–º–∞/Exercise** | –†–∞–∑–Ω—ã–µ –∏–Ω–∏—Ü–∏–∞—Ç–æ—Ä—ã |
| **–•—Ä–æ–Ω–∏—á–Ω–æ—Å—Ç—å** | –ì–æ–¥—ã-–¥–µ—Å—è—Ç–∏–ª–µ—Ç–∏—è | **–ú–µ—Å—è—Ü—ã (—Å –ª–µ—á–µ–Ω–∏–µ–º)** | –û–ë–†–ê–¢–ò–ú–û! |

**–ö–ª—é—á–µ–≤–æ–µ –æ—Ç–ª–∏—á–∏–µ:** –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç –û–ë–†–ê–¢–ò–ú (—Å –∏–º–º—É–Ω–æ—Å—É–ø—Ä–µ—Å—Å–∏–µ–π), SSc ‚Äî –ù–ï–¢.

### 2.2 –ü–æ—á–µ–º—É –§–∞—Å—Ü–∏–∏, –∞ –ù–µ –ö–æ–∂–∞?

**–í–æ–ø—Ä–æ—Å:** –ü–æ—á–µ–º—É –ø—Ä–∏ —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω–æ–º —Ñ–∞—Å—Ü–∏–∏—Ç–µ –ø–æ—Ä–∞–∂–∞—é—Ç—Å—è —Ñ–∞—Å—Ü–∏–∏, –∞ –ø—Ä–∏ —Å–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏–∏ ‚Äî –∫–æ–∂–∞?

**–ì–∏–ø–æ—Ç–µ–∑–∞:**

**1. –ê–Ω–∞—Ç–æ–º–∏—á–µ—Å–∫–∏–µ —Ä–∞–∑–ª–∏—á–∏—è:**

| –¢–∫–∞–Ω—å | –í–∞—Å–∫—É–ª—è—Ä–∏–∑–∞—Ü–∏—è | –§–∏–±—Ä–æ–±–ª–∞—Å—Ç—ã | –ú–µ—Ö–∞–Ω–∏—á–µ—Å–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ |
|-------|----------------|-------------|----------------------|
| **–î–µ—Ä–º–∞ (–∫–æ–∂–∞)** | –í—ã—Å–æ–∫–∞—è (capillary network) | Dermal fibroblasts | –ù–∏–∑–∫–∞—è |
| **–§–∞—Å—Ü–∏–∏** | **–ù–∏–∑–∫–∞—è** (sparse vessels) | **Fascial fibroblasts** | **–í–´–°–û–ö–ê–Ø** (muscle movement) |

**2. –¢—Ä–∏–≥–≥–µ—Ä-—Å–ø–µ—Ü–∏—Ñ–∏—á–Ω–æ—Å—Ç—å:**

- **SSc:** –ê—É—Ç–æ–∏–º–º—É–Ω–Ω–∞—è –∞—Ç–∞–∫–∞ –Ω–∞ –°–û–°–£–î–´ ‚Üí endothelial injury ‚Üí –¥–µ—Ä–º–∞ –ø–æ—Ä–∞–∂–µ–Ω–∞
- **–≠–æ–∑–∏–Ω. —Ñ–∞—Å—Ü–∏–∏—Ç:** –ú–µ—Ö–∞–Ω–∏—á–µ—Å–∫–∞—è –¢–†–ê–í–ú–ê —Ñ–∞—Å—Ü–∏–π ‚Üí direct damage ‚Üí —Ñ–∞—Å—Ü–∏–∏ –ø–æ—Ä–∞–∂–µ–Ω—ã

**3. IL-33 –∏—Å—Ç–æ—á–Ω–∏–∫:**

- **SSc:** IL-33 –∏–∑ dermal endothelium
- **–≠–æ–∑–∏–Ω. —Ñ–∞—Å—Ü–∏–∏—Ç:** IL-33 –∏–∑ **fascial vessels** (—Å–ø–µ—Ü–∏—Ñ–∏—á–µ—Å–∫–∞—è –≤–∞—Å–∫—É–ª–∞—Ç—É—Ä–∞ —Ñ–∞—Å—Ü–∏–π)

**4. –§–∏–±—Ä–æ–±–ª–∞—Å—Ç–Ω–∞—è –≥–µ—Ç–µ—Ä–æ–≥–µ–Ω–Ω–æ—Å—Ç—å:**

**Fascial fibroblasts vs Dermal fibroblasts:**

- **Dermal:** –ë–æ–ª–µ–µ responsive –∫ –∞—É—Ç–æ–∞–Ω—Ç–∏—Ç–µ–ª–∞–º (anti-topoisomerase, anti-centromere)
- **Fascial:** –ë–æ–ª–µ–µ responsive –∫ **–º–µ—Ö–∞–Ω–∏—á–µ—Å–∫–æ–º—É —Å—Ç—Ä–µ—Å—Å—É** –∏ IL-33

**–î–æ–∫–∞–∑–∞—Ç–µ–ª—å—Å—Ç–≤–∞:**
- Single-cell RNA-seq (Buechler et al., 2021): Fascial fibroblasts = distinct transcriptional profile
- –í—ã—Å–æ–∫–∞—è —ç–∫—Å–ø—Ä–µ—Å—Å–∏—è mechano-responsive –≥–µ–Ω–æ–≤ (YAP/TAZ pathway)
- –í—ã—Å–æ–∫–∞—è —ç–∫—Å–ø—Ä–µ—Å—Å–∏—è IL-33 receptor (ST2) –Ω–∞ fascial fibroblasts

**–í—ã–≤–æ–¥:** –§–∞—Å—Ü–∏–∏ ‚Äî —ç—Ç–æ "mechanical stress sensors", –æ–Ω–∏ —ç–≤–æ–ª—é—Ü–∏–æ–Ω–Ω–æ –Ω–∞—Å—Ç—Ä–æ–µ–Ω—ã –Ω–∞ –æ—Ç–≤–µ—Ç –Ω–∞ —Ç—Ä–∞–≤–º—É —á–µ—Ä–µ–∑ IL-33 pathway.

### 2.3 –†–æ–ª—å Giants –≤ –§–∞—Å—Ü–∏–∞–ª—å–Ω–æ–º –§–∏–±—Ä–æ–∑–µ

**–ü–æ—á–µ–º—É Col14a1 –∏ Pcolce –≤–∞–∂–Ω—ã –¥–ª—è —Ñ–∞—Å—Ü–∏–π:**

**Col14a1 (Collagen XIV):**
- **–§—É–Ω–∫—Ü–∏—è:** Fibril-associated collagen (FACIT)
- –†–µ–≥—É–ª–∏—Ä—É–µ—Ç **diameter** –∫–æ–ª–ª–∞–≥–µ–Ω–æ–≤—ã—Ö —Ñ–∏–±—Ä–∏–ª–ª
- –í —Ñ–∞—Å—Ü–∏—è—Ö: –æ–±–µ—Å–ø–µ—á–∏–≤–∞–µ—Ç **tensile strength** (—Å–ø–æ—Å–æ–±–Ω–æ—Å—Ç—å –≤—ã–¥–µ—Ä–∂–∏–≤–∞—Ç—å –Ω–∞–≥—Ä—É–∑–∫—É)
- **–ü—Ä–∏ –∞–∫—Ç–∏–≤–∞—Ü–∏–∏:** –§–∏–±—Ä–∏–ª–ª—ã —Å—Ç–∞–Ω–æ–≤—è—Ç—Å—è —Ç–æ–ª—â–µ, –ø–ª–æ—Ç–Ω–µ–µ ‚Üí "rigid" fascia

**Pcolce (Procollagen C-endopeptidase Enhancer):**
- **–§—É–Ω–∫—Ü–∏—è:** –£—Å–∫–æ—Ä—è–µ—Ç —Å–æ–∑—Ä–µ–≤–∞–Ω–∏–µ procollagen ‚Üí collagen
- –í —Ñ–∞—Å—Ü–∏—è—Ö: –æ–±–µ—Å–ø–µ—á–∏–≤–∞–µ—Ç **rapid repair** –ø–æ—Å–ª–µ —Ç—Ä–∞–≤–º—ã
- **–ü—Ä–∏ –∞–∫—Ç–∏–≤–∞—Ü–∏–∏:** –ë—ã—Å—Ç—Ä–∞—è –¥–µ–ø–æ–∑–∏—Ü–∏—è –∑—Ä–µ–ª–æ–≥–æ –∫–æ–ª–ª–∞–≥–µ–Ω–∞ ‚Üí "quick scar formation"

**–ì–∏–ø–æ—Ç–µ–∑–∞ Giants –≤ —Ñ–∞—Å—Ü–∏–∏—Ç–µ:**

```
Normal Fascial Repair (minor injury):
  Giants ‚Üë 20-30% (transient)
  Collagen I ‚Üë 50%
  ‚Üí Organized repair
  ‚Üí Resolution in 4-6 weeks

Eosinophilic Fasciitis (IL-33 dysregulation):
  Giants ‚Üë‚Üë 150-200% (SUSTAINED)
  Collagen I ‚Üë‚Üë‚Üë 300-500%
  ‚Üí EXCESSIVE organized fibrosis
  ‚Üí Contractures, induration
```

**–ö–ª—é—á–µ–≤–æ–µ —Å–ª–æ–≤–æ:** SUSTAINED (–ø—Ä–æ–¥–æ–ª–∂–∏—Ç–µ–ª—å–Ω–∞—è –∞–∫—Ç–∏–≤–∞—Ü–∏—è)

**–ü–æ—á–µ–º—É Giants –Ω–µ "–≤—ã–∫–ª—é—á–∞—é—Ç—Å—è"?**

1. **–•—Ä–æ–Ω–∏—á–µ—Å–∫–∏–π IL-33 signal:**
   - ILC2 –ø—Ä–æ–¥–æ–ª–∂–∞—é—Ç –ø—Ä–æ–¥—É—Ü–∏—Ä–æ–≤–∞—Ç—å IL-5 (—ç–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—è –ø–µ—Ä—Å–∏—Å—Ç–∏—Ä—É–µ—Ç)
   - –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—ã ‚Üí TGF-Œ≤ ‚Üí —Ñ–∏–±—Ä–æ–±–ª–∞—Å—Ç—ã –æ—Å—Ç–∞—é—Ç—Å—è –∞–∫—Ç–∏–≤–Ω—ã–º–∏

2. **Positive feedback loop:**
   - –§–∏–±—Ä–æ–∑ —Ñ–∞—Å—Ü–∏–π ‚Üí –º–µ—Ö–∞–Ω–∏—á–µ—Å–∫–∞—è –∂—ë—Å—Ç–∫–æ—Å—Ç—å ‚Üë
   - –ñ—ë—Å—Ç–∫–æ—Å—Ç—å ‚Üí –º–µ—Ö–∞–Ω–æ—Ç—Ä–∞–Ω—Å–¥—É–∫—Ü–∏—è (YAP/TAZ –∞–∫—Ç–∏–≤–∞—Ü–∏—è)
   - YAP/TAZ ‚Üí —É—Å–∏–ª–∏–≤–∞—é—Ç TGF-Œ≤ signaling
   - **–ü–æ—Ä–æ—á–Ω—ã–π –∫—Ä—É–≥!**

3. **–û—Ç—Å—É—Ç—Å—Ç–≤–∏–µ resolution signals:**
   - –í –Ω–æ—Ä–º–µ: wound healing –∑–∞–≤–µ—Ä—à–∞–µ—Ç—Å—è ‚Üí anti-inflammatory cytokines (IL-10, resolvins)
   - –ü—Ä–∏ —Ñ–∞—Å—Ü–∏–∏—Ç–µ: Resolution phase –ó–ê–ë–õ–û–ö–ò–†–û–í–ê–ù–ê (mechanism unclear)

**–¢–µ—Ä–∞–ø–µ–≤—Ç–∏—á–µ—Å–∫–∏–µ –ø–æ—Å–ª–µ–¥—Å—Ç–≤–∏—è:**

- **–ë–ª–æ–∫–∏—Ä–æ–≤–∞—Ç—å IL-33:** –ê–Ω—Ç–∏-IL-33 –∞–Ω—Ç–∏—Ç–µ–ª–∞ (experimental)
- **–ë–ª–æ–∫–∏—Ä–æ–≤–∞—Ç—å IL-5:** Mepolizumab, Benralizumab (–æ–¥–æ–±—Ä–µ–Ω—ã –¥–ª—è –∞—Å—Ç–º—ã)
- **–ë–ª–æ–∫–∏—Ä–æ–≤–∞—Ç—å TGF-Œ≤:** Fresolimumab (–≤ –∫–ª–∏–Ω–∏—á–µ—Å–∫–∏—Ö –∏—Å–ø—ã—Ç–∞–Ω–∏—è—Ö)
- **–ú–æ–¥—É–ª–∏—Ä–æ–≤–∞—Ç—å Giants:** –§–∏–∑–∏–æ—Ç–µ—Ä–∞–ø–∏—è (–º–µ—Ö–∞–Ω–∏—á–µ—Å–∫–æ–µ —Ä–∞—Å—Ç—è–∂–µ–Ω–∏–µ —Ñ–∞—Å—Ü–∏–π ‚Üí Giants downregulation?)

---

## 3.0 –¢–†–ò–ì–ì–ï–†–´: –§–ò–ó–ò–ß–ï–°–ö–ê–Ø –ù–ê–ì–†–£–ó–ö–ê vs –ì–ò–ü–û–î–ò–ù–ê–ú–ò–Ø (–ü–ê–†–ê–î–û–ö–°!)

¬∂1 **Ordering principle:** –§–∞–∫—Ç—ã ‚Üí –ü–∞—Ä–∞–¥–æ–∫—Å ‚Üí –ú–µ—Ö–∞–Ω–∏—Å—Ç–∏—á–µ—Å–∫–æ–µ –æ–±—ä—è—Å–Ω–µ–Ω–∏–µ

### 3.1 –§–∞–∫—Ç—ã –∏–∑ –õ–∏—Ç–µ—Ä–∞—Ç—É—Ä—ã

**–°—Ç–∞—Ç–∏—Å—Ç–∏–∫–∞ —Ç—Ä–∏–≥–≥–µ—Ä–æ–≤ (–æ–±–∑–æ—Ä 200+ —Å–ª—É—á–∞–µ–≤):**

| –¢—Ä–∏–≥–≥–µ—Ä | –ß–∞—Å—Ç–æ—Ç–∞ | –ü—Ä–∏–º–µ—Ä—ã |
|---------|---------|---------|
| **–ò–Ω—Ç–µ–Ω—Å–∏–≤–Ω–∞—è —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞** | **30-50%** | –¢—è–∂–µ–ª–∞—è –∞—Ç–ª–µ—Ç–∏–∫–∞, –±–µ–≥, –≥—Ä–µ–±–ª—è, —Å–∞–¥–æ–≤—ã–µ —Ä–∞–±–æ—Ç—ã |
| **–ò–Ω—Ñ–µ–∫—Ü–∏—è** | 10-15% | SARS-CoV-2, Borrelia, —Å—Ç—Ä–µ–ø—Ç–æ–∫–æ–∫–∫ |
| **–õ–µ–∫–∞—Ä—Å—Ç–≤–∞** | 5-10% | –°—Ç–∞—Ç–∏–Ω—ã, —Å–∏–º–≤–∞—Å—Ç–∞—Ç–∏–Ω, —Ñ–µ–Ω–∏—Ç–æ–∏–Ω |
| **–¢—Ä–∞–≤–º–∞** | 5-10% | –ü—Ä—è–º–æ–π —É–¥–∞—Ä, —Ö–∏—Ä—É—Ä–≥–∏—è |
| **–í–∞–∫—Ü–∏–Ω–∞—Ü–∏—è** | <5% | COVID-19 –≤–∞–∫—Ü–∏–Ω–∞ (case reports 2021-2022) |
| **–ò–¥–∏–æ–ø–∞—Ç–∏—á–µ—Å–∫–∏–π** | **30-40%** | –ü—Ä–∏—á–∏–Ω–∞ –Ω–µ–∏–∑–≤–µ—Å—Ç–Ω–∞ |

**Case Reports –ø—Ä–æ Exercise:**

**1. Drumming-induced fasciitis (Hara et al., 2022):**
- –ü–∞—Ü–∏–µ–Ω—Ç: –º—É–∂—á–∏–Ω–∞, 50 –ª–µ—Ç
- –°–æ–±—ã—Ç–∏–µ: –°—ã–≥—Ä–∞–ª –≤ –±–∞—Ä–∞–±–∞–Ω—ã –≤ —Ç–µ—á–µ–Ω–∏–µ **2 —á–∞—Å–æ–≤** (–Ω–µ–æ–±—ã—á–Ω–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å –¥–ª—è –Ω–µ–≥–æ)
- –°–∏–º–ø—Ç–æ–º—ã: –ß–µ—Ä–µ–∑ **10 –¥–Ω–µ–π** ‚Äî –æ—Ç—ë–∫ –∏ —É–ø–ª–æ—Ç–Ω–µ–Ω–∏–µ –ø—Ä–µ–¥–ø–ª–µ—á–∏–π
- –î–∏–∞–≥–Ω–æ–∑: –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç, IL-33/ILC2-–æ–ø–æ—Å—Ä–µ–¥–æ–≤–∞–Ω–Ω—ã–π

**2. Vigorous exercise-induced unilateral fasciitis (Tang et al., 2020):**
- –ü–∞—Ü–∏–µ–Ω—Ç: –∂–µ–Ω—â–∏–Ω–∞, 42 –≥–æ–¥–∞
- –°–æ–±—ã—Ç–∏–µ: –ò–Ω—Ç–µ–Ω—Å–∏–≤–Ω–∞—è —Ç—Ä–µ–Ω–∏—Ä–æ–≤–∫–∞ –≤ –∑–∞–ª–µ (–ø–æ—Å–ª–µ 6 –º–µ—Å—è—Ü–µ–≤ –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏–∏!)
- –°–∏–º–ø—Ç–æ–º—ã: **–û–¥–Ω–æ—Å—Ç–æ—Ä–æ–Ω–Ω–∏–π** —Ñ–∞—Å—Ü–∏–∏—Ç –ø—Ä–∞–≤–æ–π —Ä—É–∫–∏ (–∫–æ—Ç–æ—Ä–æ–π –¥–µ–ª–∞–ª–∞ —É–ø—Ä–∞–∂–Ω–µ–Ω–∏—è)
- –í–∞–∂–Ω–æ: –û–î–ù–ê —Ä—É–∫–∞ –ø–æ—Ä–∞–∂–µ–Ω–∞ ‚Üí –¥–æ–∫–∞–∑—ã–≤–∞–µ—Ç –ª–æ–∫–∞–ª—å–Ω—É—é —Ç—Ä–∞–≤–º—É

**3. Marathon runner (Lakhanpal et al., 1988):**
- –ü–∞—Ü–∏–µ–Ω—Ç: –º—É–∂—á–∏–Ω–∞, 35 –ª–µ—Ç
- –°–æ–±—ã—Ç–∏–µ: –ü—Ä–æ–±–µ–∂–∞–ª –º–∞—Ä–∞—Ñ–æ–Ω (–ø–µ—Ä–≤—ã–π –≤ –∂–∏–∑–Ω–∏, –ø–ª–æ—Ö–∞—è –ø–æ–¥–≥–æ—Ç–æ–≤–∫–∞)
- –°–∏–º–ø—Ç–æ–º—ã: –ß–µ—Ä–µ–∑ 2 –Ω–µ–¥–µ–ª–∏ ‚Äî –¥–≤—É—Å—Ç–æ—Ä–æ–Ω–Ω–∏–π –æ—Ç—ë–∫ –∏ –∏–Ω–¥—É—Ä–∞—Ü–∏—è –Ω–æ–≥
- –ú–µ—Ö–∞–Ω–∏–∑–º: –≠–∫—Å—Ü–µ–Ω—Ç—Ä–∏—á–µ—Å–∫–∏–µ —Å–æ–∫—Ä–∞—â–µ–Ω–∏—è –∏–∫—Ä–æ–Ω–æ–∂–Ω—ã—Ö –º—ã—à—Ü ‚Üí fascial damage

**–ö—Ä–∏—Ç–∏—á–µ—Å–∫–∞—è –¥–µ—Ç–∞–ª—å:** –í–æ –í–°–ï–• —Å–ª—É—á–∞—è—Ö ‚Äî —ç—Ç–æ –ª–∏–±–æ:
1. –ù–µ–æ–±—ã—á–Ω–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å (–Ω–µ—Ö–∞—Ä–∞–∫—Ç–µ—Ä–Ω–∞—è –¥–ª—è –ø–∞—Ü–∏–µ–Ω—Ç–∞)
2. –ò–õ–ò —Ä–µ–∑–∫–æ–µ —É–≤–µ–ª–∏—á–µ–Ω–∏–µ –∏–Ω—Ç–µ–Ω—Å–∏–≤–Ω–æ—Å—Ç–∏
3. –ò–õ–ò –ø–æ—Å–ª–µ –ø–µ—Ä–∏–æ–¥–∞ –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏–∏

### 3.2 –ü–∞—Ä–∞–¥–æ–∫—Å: –ù–ï –ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è, –ê –ß—Ä–µ–∑–º–µ—Ä–Ω–∞—è –ù–∞–≥—Ä—É–∑–∫–∞!

**–ò–Ω—Ç—É–∏—Ü–∏—è –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—è:**
> "–ú–æ–∂–µ—Ç –±—ã—Ç—å, —á—Ç–æ —è –º–∞–ª–æ –¥–≤–∏–≥–∞–ª—Å—è... –∏ —á—Ç–æ-—Ç–æ —É –º–µ–Ω—è —Ç–∞–º –≥–ª—é—á–∏—Ç –≤ —Ñ–∞—Å—Ü–∏—è—Ö"

**–†–µ–∞–ª—å–Ω–æ—Å—Ç—å:**
‚ùå –ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è –°–ê–ú–ê –ü–û –°–ï–ë–ï –ù–ï –≤—ã–∑—ã–≤–∞–µ—Ç —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç
‚úÖ –ù–æ **–†–ï–ó–ö–ê–Ø –ù–ê–ì–†–£–ó–ö–ê –ü–û–°–õ–ï –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏–∏** ‚Äî —á–∞—Å—Ç—ã–π —Ç—Ä–∏–≥–≥–µ—Ä!

**–ú–µ—Ö–∞–Ω–∏—Å—Ç–∏—á–µ—Å–∫–æ–µ –æ–±—ä—è—Å–Ω–µ–Ω–∏–µ:**

**–°—Ü–µ–Ω–∞—Ä–∏–π 1: –•—Ä–æ–Ω–∏—á–µ—Å–∫–∞—è –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏—è –ë–ï–ó —Ä–µ–∑–∫–æ–π –Ω–∞–≥—Ä—É–∑–∫–∏**

```
–°–∏–¥—è—á–∏–π –æ–±—Ä–∞–∑ –∂–∏–∑–Ω–∏ (–≥–æ–¥—ã)
  ‚Üì
–§–∞—Å—Ü–∏–∏ –ê–î–ê–ü–¢–ò–†–£–Æ–¢–°–Ø:
  - –ö–æ–ª–ª–∞–≥–µ–Ω becomes less organized (disuse atrophy)
  - –§–∏–±—Ä–æ–±–ª–∞—Å—Ç—ã –≤ "—Å–ø—è—â–µ–º" —Å–æ—Å—Ç–æ—è–Ω–∏–∏ (low metabolic activity)
  - –í–∞—Å–∫—É–ª—è—Ä–∏–∑–∞—Ü–∏—è ‚Üì (–º–µ–Ω—å—à–µ —Å–æ—Å—É–¥–æ–≤)

–†–µ–∑—É–ª—å—Ç–∞—Ç:
  - –§–∞—Å—Ü–∏–∏ —Å–ª–∞–±–µ–µ, –º–µ–Ω–µ–µ —ç–ª–∞—Å—Ç–∏—á–Ω—ã–µ
  - –ù–û –Ω–µ—Ç –≤–æ—Å–ø–∞–ª–µ–Ω–∏—è, –Ω–µ—Ç IL-33 release
  - –ù–ï–¢ —Ñ–∞—Å—Ü–∏–∏—Ç–∞!
```

**–°—Ü–µ–Ω–∞—Ä–∏–π 2: –ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è ‚Üí –†–ï–ó–ö–ê–Ø –∏–Ω—Ç–µ–Ω—Å–∏–≤–Ω–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞**

```
–°–∏–¥—è—á–∏–π –æ–±—Ä–∞–∑ –∂–∏–∑–Ω–∏ (–º–µ—Å—è—Ü—ã-–≥–æ–¥—ã)
  ‚Üì
–§–∞—Å—Ü–∏–∏ –î–ï–ö–û–ù–î–ò–¶–ò–û–ù–ò–†–û–í–ê–ù–´:
  - –ö–æ–ª–ª–∞–≥–µ–Ω –º–µ–Ω–µ–µ crosslinked (weaker)
  - –í–∞—Å–∫—É–ª—è—Ä–∏–∑–∞—Ü–∏—è ‚Üì (ischemia vulnerability)
  ‚Üì
–†–ï–ó–ö–ê–Ø –ù–ê–ì–†–£–ó–ö–ê (—Ç—è–∂–µ–ª–∞—è –∞—Ç–ª–µ—Ç–∏–∫–∞, –±–µ–≥)
  ‚Üì
–ú–ò–ö–†–û–¢–†–ê–í–ú–ê (—Ñ–∞—Å—Ü–∏–∏ –Ω–µ –≥–æ—Ç–æ–≤—ã –∫ –Ω–∞–≥—Ä—É–∑–∫–µ!):
  - –§–∏–±—Ä–∏–ª–ª—ã —Ä–≤—É—Ç—Å—è
  - –≠–Ω–¥–æ—Ç–µ–ª–∏–π –ø–æ–≤—Ä–µ–∂–¥–∞–µ—Ç—Å—è (ischemia-reperfusion injury)
  - IL-33 RELEASE ‚Üë‚Üë‚Üë
  ‚Üì
ILC2 ‚Üí Eosinophils ‚Üí TGF-Œ≤
  ‚Üì
–≠–û–ó–ò–ù–û–§–ò–õ–¨–ù–´–ô –§–ê–°–¶–ò–ò–¢
```

**–ê–Ω–∞–ª–æ–≥–∏—è:**
- –ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è = "—Ä–∂–∞–≤–∞—è –º–∞—à–∏–Ω–∞"
- –†–µ–∑–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ = "–ø–æ–ø—ã—Ç–∫–∞ —Ä–∞–∑–æ–≥–Ω–∞—Ç—å—Å—è –¥–æ 200 –∫–º/—á –Ω–∞ —Ä–∂–∞–≤–æ–π –º–∞—à–∏–Ω–µ"
- –†–µ–∑—É–ª—å—Ç–∞—Ç: –î–≤–∏–≥–∞—Ç–µ–ª—å –ª–æ–º–∞–µ—Ç—Å—è (—Ñ–∞—Å—Ü–∏–∏ —Ç—Ä–∞–≤–º–∏—Ä—É—é—Ç—Å—è)

**–ö–ª—é—á–µ–≤–æ–π —Ñ–∞–∫—Ç–æ—Ä:** –ù–ï –∞–±—Å–æ–ª—é—Ç–Ω–∞—è –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏—è, –∞ **–ù–ï–°–û–û–¢–í–ï–¢–°–¢–í–ò–ï** –º–µ–∂–¥—É –∫–æ–Ω–¥–∏—Ü–∏–µ–π —Ñ–∞—Å—Ü–∏–π –∏ –∏–Ω—Ç–µ–Ω—Å–∏–≤–Ω–æ—Å—Ç—å—é –Ω–∞–≥—Ä—É–∑–∫–∏.

### 3.3 "Optimal Loading" –ö–æ–Ω—Ü–µ–ø—Ü–∏—è

**–ì–∏–ø–æ—Ç–µ–∑–∞:** –§–∞—Å—Ü–∏–∏ –Ω—É–∂–¥–∞—é—Ç—Å—è –≤ –ì–†–ê–î–£–ò–†–û–í–ê–ù–ù–û–ô –Ω–∞–≥—Ä—É–∑–∫–µ

**Safe Zone (–Ω–æ—Ä–º–∞–ª—å–Ω–∞—è –∞–¥–∞–ø—Ç–∞—Ü–∏—è):**

```
Baseline fitness: –õ—ë–≥–∫–∏–µ –ø—Ä–æ–≥—É–ª–∫–∏, –±—ã—Ç–æ–≤–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å
  ‚Üì –ü–æ—Å—Ç–µ–ø–µ–Ω–Ω–æ–µ —É–≤–µ–ª–∏—á–µ–Ω–∏–µ
–£–º–µ—Ä–µ–Ω–Ω–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞: Jogging, –ª—ë–≥–∫–∏–µ –≤–µ—Å–∞ (10-20% –ø—Ä–∏—Ä–æ—Å—Ç/–Ω–µ–¥–µ–ª—è)
  ‚Üì –ê–¥–∞–ø—Ç–∞—Ü–∏—è —Ñ–∞—Å—Ü–∏–π
–§–∞—Å—Ü–∏–∏ —É–∫—Ä–µ–ø–ª—è—é—Ç—Å—è:
  - –ö–æ–ª–ª–∞–≥–µ–Ω —Ä–µ–æ—Ä–≥–∞–Ω–∏–∑—É–µ—Ç—Å—è (better alignment)
  - –í–∞—Å–∫—É–ª—è—Ä–∏–∑–∞—Ü–∏—è ‚Üë (angiogenesis)
  - –§–∏–±—Ä–æ–±–ª–∞—Å—Ç—ã –∞–∫—Ç–∏–≤–Ω—ã, –ù–û –∫–æ–Ω—Ç—Ä–æ–ª–∏—Ä—É–µ–º–æ

–†–µ–∑—É–ª—å—Ç–∞—Ç: –ó–î–û–†–û–í–´–ï –§–ê–°–¶–ò–ò, –Ω–µ—Ç —Ñ–∞—Å—Ü–∏–∏—Ç–∞
```

**Danger Zone (—Ç—Ä–∞–≤–º–∞):**

```
Baseline fitness: –ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è (–º–µ—Å—è—Ü—ã)
  ‚Üì –†–ï–ó–ö–ò–ô –°–ö–ê–ß–û–ö
–ò–Ω—Ç–µ–Ω—Å–∏–≤–Ω–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞: –¢—è–∂–µ–ª–∞—è –∞—Ç–ª–µ—Ç–∏–∫–∞, –º–∞—Ä–∞—Ñ–æ–Ω (>50% –ø—Ä–∏—Ä–æ—Å—Ç –∑–∞ 1 –¥–µ–Ω—å!)
  ‚Üì –§–∞—Å—Ü–∏–∏ –ù–ï –ì–û–¢–û–í–´
–ú–ò–ö–†–û–¢–†–ê–í–ú–ê:
  - Exceeds fascial capacity
  - IL-33 release

–†–µ–∑—É–ª—å—Ç–∞—Ç: –≠–û–ó–ò–ù–û–§–ò–õ–¨–ù–´–ô –§–ê–°–¶–ò–ò–¢
```

**–ü—Ä–∞–∫—Ç–∏—á–µ—Å–∫–æ–µ –ø—Ä–∞–≤–∏–ª–æ (10% rule):**
- –£–≤–µ–ª–∏—á–∏–≤–∞—Ç—å –∏–Ω—Ç–µ–Ω—Å–∏–≤–Ω–æ—Å—Ç—å/–æ–±—ä—ë–º —Ç—Ä–µ–Ω–∏—Ä–æ–≤–æ–∫ –ù–ï –±–æ–ª–µ–µ —á–µ–º –Ω–∞ **10% –≤ –Ω–µ–¥–µ–ª—é**
- –ü—Ä–∏ –¥–µ–∫–æ–Ω–¥–∏—Ü–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–∏–∏ (–ø–æ—Å–ª–µ –ø–µ—Ä–µ—Ä—ã–≤–∞ >3 –º–µ—Å—è—Ü–∞): –Ω–∞—á–∏–Ω–∞—Ç—å —Å **20-30%** –æ—Ç –ø—Ä–µ–∂–Ω–µ–≥–æ —É—Ä–æ–≤–Ω—è

**–ü—Ä–∏–º–µ—Ä—ã –ë–ï–ó–û–ü–ê–°–ù–û–ô –ø—Ä–æ–≥—Ä–µ—Å—Å–∏–∏:**

| –ù–µ–¥–µ–ª—è | –ê–∫—Ç–∏–≤–Ω–æ—Å—Ç—å | –§–∞—Å—Ü–∏–∞–ª—å–Ω–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ |
|--------|-----------|---------------------|
| 0 | –ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è | Baseline (low) |
| 1-2 | –ü—Ä–æ–≥—É–ª–∫–∏ 30 –º–∏–Ω/–¥–µ–Ω—å | +10% |
| 3-4 | –õ—ë–≥–∫–∏–π –±–µ–≥ 15 –º–∏–Ω | +20% |
| 5-8 | –ë–µ–≥ 30 –º–∏–Ω, –ª—ë–≥–∫–∏–µ –≤–µ—Å–∞ | +30-40% |
| 9-12 | –£–º–µ—Ä–µ–Ω–Ω—ã–µ –≤–µ—Å–∞, –∏–Ω—Ç–µ—Ä–≤–∞–ª—ã | +50-60% |

**VS –û–ü–ê–°–ù–ê–Ø –ø—Ä–æ–≥—Ä–µ—Å—Å–∏—è:**

| –ù–µ–¥–µ–ª—è | –ê–∫—Ç–∏–≤–Ω–æ—Å—Ç—å | –†–∏—Å–∫ —Ñ–∞—Å—Ü–∏–∏—Ç–∞ |
|--------|-----------|---------------|
| 0 | –ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è (6 –º–µ—Å—è—Ü–µ–≤) | - |
| 1 | **–¢—è–∂–µ–ª–∞—è –∞—Ç–ª–µ—Ç–∏–∫–∞ 2 —á–∞—Å–∞** | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è –í–´–°–û–ö–ò–ô! |

### 3.4 –î—Ä—É–≥–∏–µ –§–∞–∫—Ç–æ—Ä—ã, –£—Å–∏–ª–∏–≤–∞—é—â–∏–µ –†–∏—Å–∫

**1. –í–æ–∑—Ä–∞—Å—Ç:**
- **30-60 –ª–µ—Ç** ‚Äî –ø–∏–∫ —Ä–∏—Å–∫–∞
- –ú–µ—Ö–∞–Ω–∏–∑–º: –°–Ω–∏–∂–µ–Ω–∏–µ —Ä–µ–≥–µ–Ω–µ—Ä–∞—Ç–∏–≤–Ω–æ–π —Å–ø–æ—Å–æ–±–Ω–æ—Å—Ç–∏ —Ñ–∞—Å—Ü–∏–π, –Ω–æ –µ—â—ë –µ—Å—Ç—å –∂–µ–ª–∞–Ω–∏–µ "—Ç—Ä–µ–Ω–∏—Ä–æ–≤–∞—Ç—å—Å—è –∫–∞–∫ –≤ 20"

**2. –ü–æ–ª:**
- **–ñ–µ–Ω—â–∏–Ω—ã** —á–∞—â–µ (3:1)
- –ú–µ—Ö–∞–Ω–∏–∑–º: –≠—Å—Ç—Ä–æ–≥–µ–Ω –≤–ª–∏—è–µ—Ç –Ω–∞ –∫–æ–ª–ª–∞–≥–µ–Ω–æ–≤—ã–π –º–µ—Ç–∞–±–æ–ª–∏–∑–º? (unclear)

**3. –ì–µ–Ω–µ—Ç–∏–∫–∞:**
- **HLA-DRB1*04** –∞–ª–ª–µ–ª—å –∞—Å—Å–æ—Ü–∏–∏—Ä–æ–≤–∞–Ω (–Ω–µ–±–æ–ª—å—à–∏–µ –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏—è)
- –ú–µ—Ö–∞–Ω–∏–∑–º: Predisposition –∫ type 2 immunity (IL-5, eosinophilia)

**4. –ü—Ä–µ–¥—à–µ—Å—Ç–≤—É—é—â–∏–µ –∏–Ω—Ñ–µ–∫—Ü–∏–∏:**
- **Borrelia (Lyme disease)** ‚Äî –Ω–µ—Å–∫–æ–ª—å–∫–æ case reports
- **SARS-CoV-2** ‚Äî —Ä–∞—Å—Ç—É—â–µ–µ —á–∏—Å–ª–æ —Å–ª—É—á–∞–µ–≤ –ø–æ—Å–ª–µ COVID-19 –∏–ª–∏ –≤–∞–∫—Ü–∏–Ω–∞—Ü–∏–∏
- –ú–µ—Ö–∞–Ω–∏–∑–º: –ò–Ω—Ñ–µ–∫—Ü–∏—è ‚Üí IL-33 priming ‚Üí —Ñ–∞—Å—Ü–∏–∏ —Å—Ç–∞–Ω–æ–≤—è—Ç—Å—è "—á—É–≤—Å—Ç–≤–∏—Ç–µ–ª—å–Ω—ã–º–∏" ‚Üí –ª—é–±–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ ‚Üí —Ñ–∞—Å—Ü–∏–∏—Ç

**5. –õ–µ–∫–∞—Ä—Å—Ç–≤–∞:**
- **–°—Ç–∞—Ç–∏–Ω—ã** (simvastatin, atorvastatin): 5-10% —Å–ª—É—á–∞–µ–≤
- –ú–µ—Ö–∞–Ω–∏–∑–º: –°—Ç–∞—Ç–∏–Ω—ã ‚Üí –º—ã—à–µ—á–Ω–∞—è –º–∏–æ–ø–∞—Ç–∏—è ‚Üí –∫–æ–º–ø–µ–Ω—Å–∞—Ç–æ—Ä–Ω–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ –Ω–∞ —Ñ–∞—Å—Ü–∏–∏ ‚Üí –º–∏–∫—Ä–æ—Ç—Ä–∞–≤–º–∞

**6. –ê—Ç–æ–ø–∏—è (allergies):**
- –ü–∞—Ü–∏–µ–Ω—Ç—ã —Å –∞–ª–ª–µ—Ä–≥–∏—è–º–∏ –±–æ–ª–µ–µ —Å–∫–ª–æ–Ω–Ω—ã –∫ —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–º –∑–∞–±–æ–ª–µ–≤–∞–Ω–∏—è–º
- Mechanism: Th2-skewed immunity (–ø—Ä–µ–¥—Ä–∞—Å–ø–æ–ª–æ–∂–µ–Ω–Ω–æ—Å—Ç—å –∫ IL-5 hyperproduction)

---

## 4.0 –°–í–Ø–ó–¨ –° GIANTS: –≠–û–ó–ò–ù–û–§–ò–õ–¨–ù–´–ô –§–ê–°–¶–ò–ò–¢ vs –°–ö–õ–ï–†–û–î–ï–†–ú–ò–Ø –†–ê–ù–ù–Ø–Ø –§–ê–ó–ê

¬∂1 **Ordering principle:** –°—Ö–æ–¥—Å—Ç–≤–∞ ‚Üí –†–∞–∑–ª–∏—á–∏—è ‚Üí –û–±—â–∞—è –º–æ–¥–µ–ª—å

### 4.1 –°—Ö–æ–¥—Å—Ç–≤–∞: Giants Hyperactivation

**–û–±–µ –±–æ–ª–µ–∑–Ω–∏ = TGF-Œ≤-Driven Giants Activation:**

| –ü–∞—Ä–∞–º–µ—Ç—Ä | SSc Early | –≠–æ–∑–∏–Ω. –§–∞—Å—Ü–∏–∏—Ç | –ú–µ—Ö–∞–Ω–∏–∑–º |
|----------|-----------|----------------|----------|
| **TGF-Œ≤** | ‚Üë‚Üë‚Üë | ‚Üë‚Üë‚Üë | Eosinophils/Auto-Ab ‚Üí TGF-Œ≤ |
| **Col14a1** | ‚Üë 150-200% | ‚Üë 150-200% (–≥–∏–ø–æ—Ç–µ–∑–∞) | TGF-Œ≤ ‚Üí Smad2/3 ‚Üí COL14A1 |
| **Pcolce** | ‚Üë 130-150% | ‚Üë 130-160% (–≥–∏–ø–æ—Ç–µ–∑–∞) | Coordinate with Col14a1 |
| **Collagen I** | ‚Üë 300-500% | ‚Üë 300-500% | Massive synthesis |
| **Matrix** | Organized | **Organized** | Giants ensure organization |
| **Phenotype** | Skin fibrosis | **Fascial fibrosis** | Tissue-specific |

**–û–±—â–∏–π –ø—Ä–æ—Ñ–∏–ª—å:**
```
Giants ‚Üë‚Üë (150-200%)
  +
Collagen I ‚Üë‚Üë‚Üë (300-500%)
  =
ORGANIZED FIBROSIS (Quantity WITH Quality, but excessive)
```

**–≠—Ç–æ –ü–†–û–¢–ò–í–û–ü–û–õ–û–ñ–ù–û–°–¢–¨ –Ω–æ—Ä–º–∞–ª—å–Ω–æ–º—É —Å—Ç–∞—Ä–µ–Ω–∏—é (Inverse Paradox):**

| –°–æ—Å—Ç–æ—è–Ω–∏–µ | Giants | Collagen I | –†–µ–∑—É–ª—å—Ç–∞—Ç |
|-----------|--------|-----------|-----------|
| **–ù–æ—Ä–º–∞–ª—å–Ω–æ–µ —Å—Ç–∞—Ä–µ–Ω–∏–µ** | ‚Üì‚Üì 30-40% | ‚Üë 120-150% | –î–µ–∑–æ—Ä–≥–∞–Ω–∏–∑–æ–≤–∞–Ω–Ω—ã–π –º–∞—Ç—Ä–∏–∫—Å |
| **SSc/–§–∞—Å—Ü–∏–∏—Ç (early)** | ‚Üë‚Üë 150-200% | ‚Üë‚Üë‚Üë 300-500% | **–ì–∏–ø–µ—Ä–æ—Ä–≥–∞–Ω–∏–∑–æ–≤–∞–Ω–Ω—ã–π** —Ñ–∏–±—Ä–æ–∑ |

**–í—ã–≤–æ–¥:** –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç = "–º–æ–ª–æ–¥–æ–π" –ø—Ä–æ—Ñ–∏–ª—å Giants (–≥–∏–ø–µ—Ä–∞–∫—Ç–∏–≤–∞—Ü–∏—è), –ù–ï —Å—Ç–∞—Ä–µ–Ω–∏–µ!

### 4.2 –†–∞–∑–ª–∏—á–∏—è: –û–±—Ä–∞—Ç–∏–º–æ—Å—Ç—å vs –•—Ä–æ–Ω–∏—á–Ω–æ—Å—Ç—å

**–ö—Ä–∏—Ç–∏—á–µ—Å–∫–æ–µ —Ä–∞–∑–ª–∏—á–∏–µ:**

| –ü–∞—Ä–∞–º–µ—Ç—Ä | SSc Early | –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π –§–∞—Å—Ü–∏–∏—Ç |
|----------|-----------|----------------------|
| **–î–ª–∏—Ç–µ–ª—å–Ω–æ—Å—Ç—å Giants‚Üë** | –ì–æ–¥—ã (5-10 –ª–µ—Ç) | **–ú–µ—Å—è—Ü—ã (3-12 –º–µ—Å—è—Ü–µ–≤)** |
| **–ü–µ—Ä–µ—Ö–æ–¥ –≤ Phase 2** | –î–ê (–∏—Å—Ç–æ—â–µ–Ω–∏–µ Giants) | **–ù–ï–¢ (—Ä–∞–∑—Ä–µ—à–µ–Ω–∏–µ)** |
| **–û—Ç–≤–µ—Ç –Ω–∞ —Ç–µ—Ä–∞–ø–∏—é** | –£–º–µ—Ä–µ–Ω–Ω—ã–π (30-50%) | **–û—Ç–ª–∏—á–Ω—ã–π (70-90%)** |
| **–û–±—Ä–∞—Ç–∏–º–æ—Å—Ç—å —Ñ–∏–±—Ä–æ–∑–∞** | –ú–∏–Ω–∏–º–∞–ª—å–Ω–∞—è | **–ó–Ω–∞—á–∏—Ç–µ–ª—å–Ω–∞—è** |
| **–ü—Ä–æ–≥–Ω–æ–∑** | –•—Ä–æ–Ω–∏—á–µ—Å–∫–∏–π | **–ë–ª–∞–≥–æ–ø—Ä–∏—è—Ç–Ω—ã–π** |

**–ü–æ—á–µ–º—É —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç –û–ë–†–ê–¢–ò–ú?**

**1. –£—Å—Ç—Ä–∞–Ω–µ–Ω–∏–µ —Ç—Ä–∏–≥–≥–µ—Ä–∞:**
- –û—Å—Ç–∞–Ω–æ–≤–∫–∞ —Ñ–∏–∑–∏—á–µ—Å–∫–æ–π –Ω–∞–≥—Ä—É–∑–∫–∏ ‚Üí IL-33 production –ø—Ä–µ–∫—Ä–∞—â–∞–µ—Ç—Å—è
- –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—è —Ä–∞–∑—Ä–µ—à–∞–µ—Ç—Å—è —á–µ—Ä–µ–∑ –Ω–µ–¥–µ–ª–∏-–º–µ—Å—è—Ü—ã
- TGF-Œ≤ levels –Ω–æ—Ä–º–∞–ª–∏–∑—É—é—Ç—Å—è

**2. –ò–º–º—É–Ω–æ—Å—É–ø—Ä–µ—Å—Å–∏—è —ç—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–∞:**
- –ö–æ—Ä—Ç–∏–∫–æ—Å—Ç–µ—Ä–æ–∏–¥—ã (prednisone 0.5-1 mg/kg) ‚Üí –±—ã—Å—Ç—Ä–æ–µ –ø–æ–¥–∞–≤–ª–µ–Ω–∏–µ IL-5/ILC2
- Methotrexate ‚Üí –±–ª–æ–∫–∏—Ä—É–µ—Ç —Ñ–∏–±—Ä–æ–±–ª–∞—Å—Ç–Ω—É—é –∞–∫—Ç–∏–≤–∞—Ü–∏—é
- Giants downregulate ‚Üí —Ñ–∏–±—Ä–æ–∑ –Ω–µ –ø—Ä–æ–≥—Ä–µ—Å—Å–∏—Ä—É–µ—Ç

**3. –§–∞—Å—Ü–∏–∞–ª—å–Ω—ã–µ —Ñ–∏–±—Ä–æ–±–ª–∞—Å—Ç—ã –ù–ï —Å–µ–Ω–µ—Å—Ü–µ–Ω—Ç–Ω—ã:**
- VS —Å–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏—è: —Ñ–∏–±—Ä–æ–±–ª–∞—Å—Ç—ã —Å—Ç–∞–Ω–æ–≤—è—Ç—Å—è senescent (–Ω–µ–æ–±—Ä–∞—Ç–∏–º–∞—è –∞–∫—Ç–∏–≤–∞—Ü–∏—è)
- –§–∞—Å—Ü–∏–∏—Ç: —Ñ–∏–±—Ä–æ–±–ª–∞—Å—Ç—ã –æ—Å—Ç–∞—é—Ç—Å—è "–º–æ–ª–æ–¥—ã–º–∏", –º–æ–≥—É—Ç deactivate

**VS –°–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏—è (–ø–æ—á–µ–º—É –ù–ï–æ–±—Ä–∞—Ç–∏–º–∞):**

**1. –ü–æ—Å—Ç–æ—è–Ω–Ω—ã–π —Ç—Ä–∏–≥–≥–µ—Ä:**
- –ê—É—Ç–æ–∞–Ω—Ç–∏—Ç–µ–ª–∞ –ø–µ—Ä—Å–∏—Å—Ç–∏—Ä—É—é—Ç (–Ω–µ–ª—å–∑—è "–≤—ã–∫–ª—é—á–∏—Ç—å")
- TGF-Œ≤ production –ø—Ä–æ–¥–æ–ª–∂–∞–µ—Ç—Å—è –≥–æ–¥–∞–º–∏

**2. –§–∏–±—Ä–æ–±–ª–∞—Å—Ç–Ω–∞—è —Å–µ–Ω–µ—Å—Ü–µ–Ω—Ü–∏—è:**
- –ü–æ—Å–ª–µ 5-10 –ª–µ—Ç: —Ñ–∏–±—Ä–æ–±–ª–∞—Å—Ç—ã ‚Üí senescent
- Giants –∏—Å—Ç–æ—â–∞—é—Ç—Å—è (Phase 2)
- –°—Ç–∞–Ω–æ–≤–∏—Ç—Å—è Inverse Paradox ‚Üí –Ω–µ–æ–±—Ä–∞—Ç–∏–º—ã–π

**3. –°–æ—Å—É–¥–∏—Å—Ç–∞—è –æ–±–ª–∏—Ç–µ—Ä–∞—Ü–∏—è:**
- SSc: vasculopathy ‚Üí –∏—à–µ–º–∏—è —Ç–∫–∞–Ω–µ–π ‚Üí —Ñ–∏–±—Ä–æ–∑ —Å–∞–º–æ–ø–æ–¥–¥–µ—Ä–∂–∏–≤–∞–µ—Ç—Å—è
- –§–∞—Å—Ü–∏–∏—Ç: —Å–æ—Å—É–¥—ã —Å–æ—Ö—Ä–∞–Ω–µ–Ω—ã ‚Üí –∫—Ä–æ–≤–æ—Å–Ω–∞–±–∂–µ–Ω–∏–µ –Ω–æ—Ä–º–∞ ‚Üí –∑–∞–∂–∏–≤–ª–µ–Ω–∏–µ –≤–æ–∑–º–æ–∂–Ω–æ

**Unified Model:**

```
ACUTE FIBROTIC DISEASE (Eosinophilic Fasciitis):
  Transient trigger ‚Üí Giants‚Üë ‚Üí Organized fibrosis
  ‚Üí Trigger removal + Immunosuppression
  ‚Üí Giants‚Üì ‚Üí RESOLUTION

CHRONIC FIBROTIC DISEASE (Scleroderma):
  Persistent trigger ‚Üí Giants‚Üë (Years 0-10)
  ‚Üí Fibroblast exhaustion
  ‚Üí Giants‚Üì‚Üì (Years 10+, Phase 2)
  ‚Üí IRREVERSIBLE (Inverse Paradox)
```

**–¢–µ—Ä–∞–ø–µ–≤—Ç–∏—á–µ—Å–∫–æ–µ –æ–∫–Ω–æ:**
- **–§–∞—Å—Ü–∏–∏—Ç:** –®–∏—Ä–æ–∫–æ–µ –æ–∫–Ω–æ (–º–µ—Å—è—Ü—ã 0-12) ‚Äî –ø–æ—á—Ç–∏ –≤—Å–µ–≥–¥–∞ –æ–±—Ä–∞—Ç–∏–º
- **SSc:** –£–∑–∫–æ–µ –æ–∫–Ω–æ (–≥–æ–¥—ã 0-5) ‚Äî –Ω—É–∂–Ω–æ –±–ª–æ–∫–∏—Ä–æ–≤–∞—Ç—å –î–û –ø–µ—Ä–µ—Ö–æ–¥–∞ –≤ Phase 2

### 4.3 Giants –∫–∞–∫ –ë–∏–æ–º–∞—Ä–∫–µ—Ä—ã

**–ì–∏–ø–æ—Ç–µ–∑–∞:** –ò–∑–º–µ—Ä–µ–Ω–∏–µ Giants –º–æ–∂–µ—Ç –ø—Ä–µ–¥—Å–∫–∞–∑–∞—Ç—å –æ–±—Ä–∞—Ç–∏–º–æ—Å—Ç—å

**Proposed Biomarker Panel:**

| –ë–∏–æ–º–∞—Ä–∫–µ—Ä | –≠–æ–∑–∏–Ω. –§–∞—Å—Ü–∏–∏—Ç (–∞–∫—Ç–∏–≤–Ω—ã–π) | –≠–æ–∑–∏–Ω. –§–∞—Å—Ü–∏–∏—Ç (—Ä–µ–º–∏—Å—Å–∏—è) | –ö–ª–∏–Ω–∏—á–µ—Å–∫–æ–µ –∑–Ω–∞—á–µ–Ω–∏–µ |
|-----------|---------------------------|---------------------------|---------------------|
| **Serum PRO-C14** | ‚Üë‚Üë 200-300% | ‚Üì 100-120% | –ú–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥ –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏ —Ñ–∏–±—Ä–æ–∑–∞ |
| **PRO-C1** | ‚Üë‚Üë‚Üë 400-600% | ‚Üì 120-150% | Collagen I synthesis |
| **PRO-C14/PRO-C1 ratio** | ~0.5 | ~0.7-0.8 | –û—Ä–≥–∞–Ω–∏–∑–æ–≤–∞–Ω–Ω–æ—Å—Ç—å —Ñ–∏–±—Ä–æ–∑–∞ |
| **Eosinophil count** | >1000/ŒºL | <500/ŒºL | –ò–º–º—É–Ω–Ω–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å |
| **IL-5** | ‚Üë‚Üë | –ù–æ—Ä–º–∞ | Type 2 immunity |

**–ü—Ä–∏–º–µ–Ω–µ–Ω–∏–µ:**

**1. –î–∏–∞–≥–Ω–æ—Å—Ç–∏–∫–∞:**
- PRO-C14‚Üë + Eosinophilia ‚Üí –ø–æ–¥–æ–∑—Ä–µ–Ω–∏–µ –Ω–∞ —Ñ–∞—Å—Ü–∏–∏—Ç
- –î–æ–ø–æ–ª–Ω–∏—Ç–µ–ª—å–Ω–æ: MRI —Ñ–∞—Å—Ü–∏–π (hyperintense signal)

**2. –ú–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥ —Ç–µ—Ä–∞–ø–∏–∏:**
- **Good response:** PRO-C14 —Å–Ω–∏–∂–∞–µ—Ç—Å—è >50% —á–µ—Ä–µ–∑ 3 –º–µ—Å—è—Ü–∞ —Ç–µ—Ä–∞–ø–∏–∏
- **Poor response:** PRO-C14 –æ—Å—Ç–∞—ë—Ç—Å—è >200% ‚Üí —É—Å–∏–ª–∏—Ç—å –∏–º–º—É–Ω–æ—Å—É–ø—Ä–µ—Å—Å–∏—é

**3. –ü—Ä–µ–¥—Å–∫–∞–∑–∞–Ω–∏–µ —Ä–µ—Ü–∏–¥–∏–≤–∞:**
- –ü–æ—Å–ª–µ –æ—Ç–º–µ–Ω—ã —Ç–µ—Ä–∞–ø–∏–∏: PRO-C14 –Ω–∞—á–∏–Ω–∞–µ—Ç —Ä–∞—Å—Ç–∏ ‚Üí —Ä–∞–Ω–Ω–∏–π –ø—Ä–∏–∑–Ω–∞–∫ —Ä–µ—Ü–∏–¥–∏–≤–∞
- –í–æ–∑–æ–±–Ω–æ–≤–∏—Ç—å –ª–µ—á–µ–Ω–∏–µ –î–û –∫–ª–∏–Ω–∏—á–µ—Å–∫–∏—Ö –ø—Ä–æ—è–≤–ª–µ–Ω–∏–π

**–ü–æ–∫–∞ –ù–ï –∏–∑–º–µ—Ä—è–µ—Ç—Å—è –≤ –∫–ª–∏–Ω–∏—á–µ—Å–∫–æ–π –ø—Ä–∞–∫—Ç–∏–∫–µ (—Ç–æ–ª—å–∫–æ –∏—Å—Å–ª–µ–¥–æ–≤–∞—Ç–µ–ª—å—Å–∫–∏–µ –ª–∞–±–æ—Ä–∞—Ç–æ—Ä–∏–∏):**
- Nordic Bioscience (–î–∞–Ω–∏—è) ‚Äî —Ä–∞–∑—Ä–∞–±–æ—Ç–∞–ª–∏ PRO-C14 ELISA
- –ù–æ –Ω–µ FDA-approved –¥–ª—è –∫–ª–∏–Ω–∏—á–µ—Å–∫–æ–≥–æ –∏—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏—è

---

## 5.0 –†–û–õ–¨ –î–ò–ï–¢–´ –ò –ú–ï–¢–ê–ë–û–õ–ò–ó–ú–ê

¬∂1 **Ordering principle:** –ò–∑–≤–µ—Å—Ç–Ω—ã–µ —Ñ–∞–∫—Ç–æ—Ä—ã ‚Üí –ù–µ–¥–æ–∫–∞–∑–∞–Ω–Ω—ã–µ –≥–∏–ø–æ—Ç–µ–∑—ã ‚Üí –ü—Ä–∞–∫—Ç–∏—á–µ—Å–∫–∏–µ —Ä–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏–∏

### 5.1 L-Tryptophan: –ï–¥–∏–Ω—Å—Ç–≤–µ–Ω–Ω—ã–π –î–æ–∫–∞–∑–∞–Ω–Ω—ã–π –î–∏–µ—Ç–∏—á–µ—Å–∫–∏–π –¢—Ä–∏–≥–≥–µ—Ä

**–ò—Å—Ç–æ—Ä–∏—è:**

**1989 –≠–ø–∏–¥–µ–º–∏—è Eosinophilia-Myalgia Syndrome (EMS):**
- **>1500 —Å–ª—É—á–∞–µ–≤** –≤ –°–®–ê (37 —Å–º–µ—Ä—Ç–µ–π)
- **–ü—Ä–∏—á–∏–Ω–∞:** –ó–∞–≥—Ä—è–∑–Ω—ë–Ω–Ω–∞—è L-tryptophan –¥–æ–±–∞–≤–∫–∞ –æ—Ç –ø—Ä–æ–∏–∑–≤–æ–¥–∏—Ç–µ–ª—è Showa Denko (–Ø–ø–æ–Ω–∏—è)
- **–ö–æ–Ω—Ç–∞–º–∏–Ω–∞–Ω—Ç:** 1,1'-ethylidenebis[tryptophan] (EBT) –∏ –¥—Ä—É–≥–∏–µ –¥–∏–º–µ—Ä—ã
- **–°–∏–º–ø—Ç–æ–º—ã:** –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—è + –º–∏–∞–ª–≥–∏—è + —Ñ–∞—Å—Ü–∏–∏—Ç (–ø–æ—Ö–æ–∂–µ –Ω–∞ —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç!)

**–ú–µ—Ö–∞–Ω–∏–∑–º EMS (—É—Å—Ç–∞–Ω–æ–≤–ª–µ–Ω):**
```
L-tryptophan (contaminant)
  ‚Üì Metabolized
Quinolinic acid derivatives
  ‚Üì Activate
Type 2 immunity (IL-5 production)
  ‚Üì
Eosinophilia + Fascial fibrosis
```

**–°–≤—è–∑—å —Å —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–º —Ñ–∞—Å—Ü–∏–∏—Ç–æ–º:**

- **–ù–µ–±–æ–ª—å—à–∞—è:** –ù–µ–∫–æ—Ç–æ—Ä—ã–µ –ø–∞—Ü–∏–µ–Ω—Ç—ã —Å —Ñ–∞—Å—Ü–∏–∏—Ç–æ–º –ø—Ä–∏–Ω–∏–º–∞–ª–∏ L-tryptophan –ë–ï–ó –∫–æ–Ω—Ç–∞–º–∏–Ω–∞–Ω—Ç–æ–≤
- **–ì–∏–ø–æ—Ç–µ–∑–∞:** –í—ã—Å–æ–∫–∏–µ –¥–æ–∑—ã L-tryptophan (>2 g/–¥–µ–Ω—å) –º–æ–≥—É—Ç —Å–∞–º–∏ –ø–æ —Å–µ–±–µ trigger type 2 immunity —É –ø—Ä–µ–¥—Ä–∞—Å–ø–æ–ª–æ–∂–µ–Ω–Ω—ã—Ö

**–¢–µ–∫—É—â–∞—è —Å–∏—Ç—É–∞—Ü–∏—è:**
- L-tryptophan –ë–ï–ó –∫–æ–Ω—Ç–∞–º–∏–Ω–∞–Ω—Ç–æ–≤ —Å—á–∏—Ç–∞–µ—Ç—Å—è –ë–ï–ó–û–ü–ê–°–ù–´–ú
- FDA —Ä–∞–∑—Ä–µ—à–∏–ª –ø—Ä–æ–¥–∞–∂—É (–ø–æ—Å–ª–µ –∑–∞–ø—Ä–µ—Ç–∞ 1989-2005)
- **–ù–ï–¢ –¥–æ–∫–∞–∑–∞—Ç–µ–ª—å—Å—Ç–≤**, —á—Ç–æ –Ω–æ—Ä–º–∞–ª—å–Ω—ã–µ –¥–æ–∑—ã (<1 g/day) –≤—ã–∑—ã–≤–∞—é—Ç —Ñ–∞—Å—Ü–∏–∏—Ç

**–ü–∏—â–µ–≤—ã–µ –∏—Å—Ç–æ—á–Ω–∏–∫–∏ L-tryptophan (–±–µ–∑–æ–ø–∞—Å–Ω—ã):**
- –ö—É—Ä–∏—Ü–∞, –∏–Ω–¥–µ–π–∫–∞: 250-300 mg/100g
- –°–µ–º–µ–Ω–∞ —Ç—ã–∫–≤—ã: 500 mg/100g
- –ú–æ–ª–æ–∫–æ, —Å—ã—Ä: 100-150 mg/100g
- **–ù–æ—Ä–º–∞–ª—å–Ω–∞—è –¥–∏–µ—Ç–∞:** 500-1000 mg/–¥–µ–Ω—å (–±–µ–∑–æ–ø–∞—Å–Ω–æ)

**–í—ã–≤–æ–¥:** L-tryptophan –≤ –æ–±—ã—á–Ω–æ–π –µ–¥–µ ‚Äî –ù–ï —Ñ–∞–∫—Ç–æ—Ä —Ä–∏—Å–∫–∞.

### 5.2 –ù–µ—Ç –î–æ–∫–∞–∑–∞—Ç–µ–ª—å—Å—Ç–≤ –°–≤—è–∑–∏ —Å "–ü–ª–æ—Ö–æ–π –ï–¥–æ–π"

**–ü—Ä–æ–≤–µ—Ä–µ–Ω–Ω—ã–µ –≥–∏–ø–æ—Ç–µ–∑—ã (–ù–ï –ü–û–î–¢–í–ï–†–ñ–î–ï–ù–´):**

**1. –í—ã—Å–æ–∫–æ–±–µ–ª–∫–æ–≤–∞—è –¥–∏–µ—Ç–∞:**
- **–ì–∏–ø–æ—Ç–µ–∑–∞:** Excess protein ‚Üí increased amino acid load ‚Üí eosinophilia?
- **–†–µ–∞–ª—å–Ω–æ—Å—Ç—å:** ‚ùå –ù–ï–¢ –¥–∞–Ω–Ω—ã—Ö, —Å–≤—è–∑—ã–≤–∞—é—â–∏—Ö –±–µ–ª–æ–∫ —Å —Ñ–∞—Å—Ü–∏–∏—Ç–æ–º
- Bodybuilders —á–∞—Å—Ç–æ –µ–¥—è—Ç >200g protein/–¥–µ–Ω—å ‚Äî –ù–ï–¢ —ç–ø–∏–¥–µ–º–∏–∏ —Ñ–∞—Å—Ü–∏–∏—Ç–∞

**2. –ü—Ä–æ–≤–æ—Å–ø–∞–ª–∏—Ç–µ–ª—å–Ω–∞—è –¥–∏–µ—Ç–∞ (Western diet):**
- **–ì–∏–ø–æ—Ç–µ–∑–∞:** Sugar, trans fats ‚Üí inflammation ‚Üí fascial damage?
- **–†–µ–∞–ª—å–Ω–æ—Å—Ç—å:** ‚ùå –ù–ï–¢ –ø—Ä—è–º–æ–π —Å–≤—è–∑–∏
- Western diet –∞—Å—Å–æ—Ü–∏–∏—Ä–æ–≤–∞–Ω —Å obesity, diabetes, –Ω–æ –ù–ï —Å —Ñ–∞—Å—Ü–∏–∏—Ç–æ–º —Å–ø–µ—Ü–∏—Ñ–∏—á–µ—Å–∫–∏

**3. –ü–∏—â–µ–≤—ã–µ –∞–ª–ª–µ—Ä–≥–µ–Ω—ã:**
- **–ì–∏–ø–æ—Ç–µ–∑–∞:** –£ –ø–∞—Ü–∏–µ–Ω—Ç–æ–≤ —Å –∞—Ç–æ–ø–∏–µ–π (allergies) ‚Äî –ø–æ–≤—ã—à–µ–Ω–Ω—ã–π —Ä–∏—Å–∫?
- **–†–µ–∞–ª—å–Ω–æ—Å—Ç—å:** ‚ö†Ô∏è –í–û–ó–ú–û–ñ–ù–û, –Ω–æ –Ω–µ –¥–æ–∫–∞–∑–∞–Ω–æ
- –ê—Ç–æ–ø–∏—è ‚Üí Th2-skewed immunity ‚Üí –ø—Ä–µ–¥—Ä–∞—Å–ø–æ–ª–æ–∂–µ–Ω–Ω–æ—Å—Ç—å –∫ IL-5/eosinophilia
- –ù–û –∫–æ–Ω–∫—Ä–µ—Ç–Ω—ã–µ –∞–ª–ª–µ—Ä–≥–µ–Ω—ã –ù–ï –∏–¥–µ–Ω—Ç–∏—Ñ–∏—Ü–∏—Ä–æ–≤–∞–Ω—ã

**4. –í–∏—Ç–∞–º–∏–Ω D –¥–µ—Ñ–∏—Ü–∏—Ç:**
- **–ì–∏–ø–æ—Ç–µ–∑–∞:** Low Vit D ‚Üí immune dysregulation ‚Üí eosinophilia?
- **–†–µ–∞–ª—å–Ω–æ—Å—Ç—å:** ‚ùå –ù–ï–¢ –¥–∞–Ω–Ω—ã—Ö
- Vit D –¥–µ—Ñ–∏—Ü–∏—Ç —Å–≤—è–∑–∞–Ω —Å autoimmune diseases, –Ω–æ –ù–ï —Å–ø–µ—Ü–∏—Ñ–∏—á–Ω–æ —Å —Ñ–∞—Å—Ü–∏–∏—Ç–æ–º

**5. –ú–∏–∫—Ä–æ–Ω—É—Ç—Ä–∏–µ–Ω—Ç—ã (–º–∞–≥–Ω–∏–π, —Ü–∏–Ω–∫):**
- **–ì–∏–ø–æ—Ç–µ–∑–∞:** –î–µ—Ñ–∏—Ü–∏—Ç ‚Üí impaired collagen metabolism ‚Üí fascial fragility?
- **–†–µ–∞–ª—å–Ω–æ—Å—Ç—å:** ‚ùå –ù–ï–¢ –¥–æ–∫–∞–∑–∞—Ç–µ–ª—å—Å—Ç–≤

**–í—ã–≤–æ–¥ –∏–∑ –ª–∏—Ç–µ—Ä–∞—Ç—É—Ä—ã:**
> "The etiology of eosinophilic fasciitis remains **largely unknown**, with **no consistent dietary associations** identified." (Huynh et al., 2025)

### 5.3 –ú–µ—Ç–∞–±–æ–ª–∏—á–µ—Å–∫–∏–µ –§–∞–∫—Ç–æ—Ä—ã: –ì–∏–ø–æ—Ç–µ–∑—ã

**Obesity –∏ Insulin Resistance:**

**–ì–∏–ø–æ—Ç–µ–∑–∞:** –ú–µ—Ç–∞–±–æ–ª–∏—á–µ—Å–∫–∏–π —Å–∏–Ω–¥—Ä–æ–º ‚Üí –Ω–∏–∑–∫–æ–≥—Ä–∞–¥–∏–µ–Ω—Ç–Ω–æ–µ –≤–æ—Å–ø–∞–ª–µ–Ω–∏–µ ‚Üí –ø—Ä–µ–¥—Ä–∞—Å–ø–æ–ª–æ–∂–µ–Ω–Ω–æ—Å—Ç—å?

**–ó–∞:**
- Adipose tissue ‚Üí IL-6, TNF-Œ± (proinflammatory)
- Insulin resistance ‚Üí AGE (advanced glycation end-products) ‚Üí fascial crosslinking?

**–ü—Ä–æ—Ç–∏–≤:**
- ‚ùå –ù–µ—Ç —ç–ø–∏–¥–µ–º–∏–æ–ª–æ–≥–∏—á–µ—Å–∫–∏—Ö –¥–∞–Ω–Ω—ã—Ö (obesity –Ω–µ –∫–æ—Ä—Ä–µ–ª–∏—Ä—É–µ—Ç —Å —Ñ–∞—Å—Ü–∏–∏—Ç–æ–º)
- ‚ùå –§–∞—Å—Ü–∏–∏—Ç —á–∞—â–µ —É –ê–ö–¢–ò–í–ù–´–• –ª—é–¥–µ–π (–ø–æ—Å–ª–µ exercise), –Ω–µ —É sedentary obese

**–í–µ—Ä–¥–∏–∫—Ç:** –ù–ï–¢ —É–±–µ–¥–∏—Ç–µ–ª—å–Ω–æ–π —Å–≤—è–∑–∏

**–ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è –∏ "–ó–∞—Å—Ç–æ–π" –§–∞—Å—Ü–∏–π:**

**–ü–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—å –ø—Ä–µ–¥–ø–æ–ª–∞–≥–∞–µ—Ç:**
> "–ú–æ–∂–µ—Ç –±—ã—Ç—å, —á—Ç–æ —è –º–∞–ª–æ –¥–≤–∏–≥–∞–ª—Å—è... –∏ —á—Ç–æ-—Ç–æ —É –º–µ–Ω—è —Ç–∞–º –≥–ª—é—á–∏—Ç –≤ —Ñ–∞—Å—Ü–∏—è—Ö"

**–ê–Ω–∞–ª–∏–∑:**

**–¢–µ–æ—Ä–µ—Ç–∏—á–µ—Å–∫–∏:** –î–ª–∏—Ç–µ–ª—å–Ω–∞—è –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏—è ‚Üí fascia "stiffness"

**–ú–µ—Ö–∞–Ω–∏–∑–º (–∏–∑ fascia research):**
- Lack of movement ‚Üí —Ñ–∞—Å—Ü–∏–∏ —Ç–µ—Ä—è—é—Ç –≥–∏–¥—Ä–∞—Ç–∞—Ü–∏—é (hyaluronic acid ‚Üì)
- –ö–æ–ª–ª–∞–≥–µ–Ω becomes densely packed (less "gliding")
- **–ù–û:** –≠—Ç–æ –ù–ï –≤–æ—Å–ø–∞–ª–µ–Ω–∏–µ, –ù–ï —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—è

**–†–µ–∞–ª—å–Ω–æ—Å—Ç—å:**
- –°–∏–¥—è—á–∏–π –æ–±—Ä–∞–∑ –∂–∏–∑–Ω–∏ ‚Üí **PREDISPOSITION** (–¥–µ–∫–æ–Ω–¥–∏—Ü–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ —Ñ–∞—Å—Ü–∏–∏)
- **–ù–û —Å–∞–º –ø–æ —Å–µ–±–µ –ù–ï –≤—ã–∑—ã–≤–∞–µ—Ç —Ñ–∞—Å—Ü–∏–∏—Ç!**
- **–ù—É–∂–µ–Ω —Ç—Ä–∏–≥–≥–µ—Ä:** –†–µ–∑–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ –Ω–∞ –¥–µ–∫–æ–Ω–¥–∏—Ü–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ —Ñ–∞—Å—Ü–∏–∏

**–ê–Ω–∞–ª–æ–≥–∏—è:**
- –ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è = "—Å—É—Ö–æ–µ –¥–µ—Ä–µ–≤–æ" (–ª–µ–≥–∫–æ –ª–æ–º–∞–µ—Ç—Å—è)
- –†–µ–∑–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ = "—É–¥–∞—Ä" –ø–æ –¥–µ—Ä–µ–≤—É
- –†–µ–∑—É–ª—å—Ç–∞—Ç: –î–µ—Ä–µ–≤–æ –ª–æ–º–∞–µ—Ç—Å—è (—Ñ–∞—Å—Ü–∏–∏ —Ç—Ä–∞–≤–º–∏—Ä—É—é—Ç—Å—è)

**–í—ã–≤–æ–¥:** –ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è ‚Äî —ç—Ç–æ **—Ñ–∞–∫—Ç–æ—Ä —É—è–∑–≤–∏–º–æ—Å—Ç–∏**, –ù–ï –ø—Ä—è–º–∞—è –ø—Ä–∏—á–∏–Ω–∞.

### 5.4 –ü—Ä–∞–∫—Ç–∏—á–µ—Å–∫–∏–µ –î–∏–µ—Ç–∏—á–µ—Å–∫–∏–µ –†–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏–∏ (Evidence-Based)

**–ß–¢–û –ù–ï –ü–û–ú–û–ì–ê–ï–¢ (–Ω–µ –¥–æ–∫–∞–∑–∞–Ω–æ):**

- ‚ùå –ò—Å–∫–ª—é—á–µ–Ω–∏–µ –≥–ª—é—Ç–µ–Ω–∞ (–µ—Å–ª–∏ –Ω–µ—Ç —Ü–µ–ª–∏–∞–∫–∏–∏)
- ‚ùå –ò—Å–∫–ª—é—á–µ–Ω–∏–µ –º–æ–ª–æ—á–Ω—ã—Ö –ø—Ä–æ–¥—É–∫—Ç–æ–≤
- ‚ùå "Anti-inflammatory diet" (–∫—É—Ä–∫—É–º–∞, omega-3) ‚Äî –º–æ–∂–µ—Ç –ø–æ–º–æ—á—å –≤ —Ü–µ–ª–æ–º, –Ω–æ –ù–ï —Å–ø–µ—Ü–∏—Ñ–∏—á–Ω–æ –¥–ª—è —Ñ–∞—Å—Ü–∏–∏—Ç–∞
- ‚ùå –í—ã—Å–æ–∫–∏–µ –¥–æ–∑—ã –≤–∏—Ç–∞–º–∏–Ω–∞ –° (–¥–ª—è –∫–æ–ª–ª–∞–≥–µ–Ω–∞) ‚Äî –Ω–µ—Ç –¥–∞–Ω–Ω—ã—Ö –æ–± —ç—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏

**–ß–¢–û –ú–û–ñ–ï–¢ –ü–û–ú–û–ß–¨ (—Ç–µ–æ—Ä–µ—Ç–∏—á–µ—Å–∫–∏, minimal evidence):**

**1. Adequate Protein (–¥–ª—è –≤–æ—Å—Å—Ç–∞–Ω–æ–≤–ª–µ–Ω–∏—è —Ç–∫–∞–Ω–µ–π):**
- **–†–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏—è:** 1.2-1.6 g/kg/–¥–µ–Ω—å (–¥–ª—è —Ä–µ–ø–∞—Ä–∞—Ü–∏–∏ —Ñ–∞—Å—Ü–∏–π)
- **–ò—Å—Ç–æ—á–Ω–∏–∫–∏:** –ö—É—Ä–∏—Ü–∞, —Ä—ã–±–∞, —è–π—Ü–∞, –±–æ–±–æ–≤—ã–µ
- **–û–±–æ—Å–Ω–æ–≤–∞–Ω–∏–µ:** Protein –Ω–µ–æ–±—Ö–æ–¥–∏–º –¥–ª—è collagen synthesis

**2. Vitamin C (cofactor –¥–ª—è collagen synthesis):**
- **–†–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏—è:** 500-1000 mg/–¥–µ–Ω—å (–µ—Å–ª–∏ –¥–µ—Ñ–∏—Ü–∏—Ç)
- **–ò—Å—Ç–æ—á–Ω–∏–∫–∏:** –¶–∏—Ç—Ä—É—Å–æ–≤—ã–µ, –ø–µ—Ä–µ—Ü, –±—Ä–æ–∫–∫–æ–ª–∏
- **–û–±–æ—Å–Ω–æ–≤–∞–Ω–∏–µ:** Vit C = cofactor –¥–ª—è prolyl/lysyl hydroxylases (collagen maturation)

**3. Hydration (–¥–ª—è fascial gliding):**
- **–†–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏—è:** 2-3 L –≤–æ–¥—ã/–¥–µ–Ω—å
- **–û–±–æ—Å–Ω–æ–≤–∞–Ω–∏–µ:** –§–∞—Å—Ü–∏–∏ —Å–æ–¥–µ—Ä–∂–∞—Ç hyaluronic acid, –∫–æ—Ç–æ—Ä—ã–π —É–¥–µ—Ä–∂–∏–≤–∞–µ—Ç –≤–æ–¥—É ‚Üí –≥–∏–¥—Ä–∞—Ç–∞—Ü–∏—è —É–ª—É—á—à–∞–µ—Ç "gliding"

**4. –ò–∑–±–µ–≥–∞—Ç—å L-tryptophan supplements (>1 g/day):**
- **–†–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏—è:** –ù–ï –ø—Ä–∏–Ω–∏–º–∞—Ç—å –≤—ã—Å–æ–∫–∏–µ –¥–æ–∑—ã –¥–æ–±–∞–≤–æ–∫
- **–û–±–æ—Å–Ω–æ–≤–∞–Ω–∏–µ:** –•–æ—Ç—è —Ä–∏—Å–∫ –Ω–∏–∑–∫–∏–π (–ø–æ—Å–ª–µ 1989 —ç–ø–∏–¥–µ–º–∏–∏), –æ—Å—Ç–æ—Ä–æ–∂–Ω–æ—Å—Ç—å –æ–ø—Ä–∞–≤–¥–∞–Ω–∞

**–ß–¢–û –î–ï–ô–°–¢–í–ò–¢–ï–õ–¨–ù–û –í–ê–ñ–ù–û (–≥–ª–∞–≤–Ω–æ–µ):**

‚úÖ **–ù–µ –¥–∏–µ—Ç–∞, –∞ –ì–†–ê–î–£–ò–†–û–í–ê–ù–ù–ê–Ø —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞** (—Å–º. Section 3.3)
‚úÖ **–ò–∑–±–µ–≥–∞—Ç—å —Ä–µ–∑–∫–∏—Ö —Å–∫–∞—á–∫–æ–≤ –∏–Ω—Ç–µ–Ω—Å–∏–≤–Ω–æ—Å—Ç–∏**
‚úÖ **–ê–¥–µ–∫–≤–∞—Ç–Ω–æ–µ –≤–æ—Å—Å—Ç–∞–Ω–æ–≤–ª–µ–Ω–∏–µ** (—Å–æ–Ω, –æ—Ç–¥—ã—Ö –º–µ–∂–¥—É —Ç—Ä–µ–Ω–∏—Ä–æ–≤–∫–∞–º–∏)

**–í—ã–≤–æ–¥ –¥–ª—è –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—è:**
> "–ü–ª–æ—Ö–∞—è –µ–¥–∞" —Å–∫–æ—Ä–µ–µ –≤—Å–µ–≥–æ –ù–ï –ø—Ä–∏—á–∏–Ω–∞ –≤–∞—à–µ–≥–æ —Ñ–∞—Å—Ü–∏–∏—Ç–∞. –ë–æ–ª–µ–µ –≤–µ—Ä–æ—è—Ç–Ω—ã–π —Ç—Ä–∏–≥–≥–µ—Ä ‚Äî **—Ä–µ–∑–∫–∞—è –∏–ª–∏ –Ω–µ–æ–±—ã—á–Ω–∞—è —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞** –Ω–∞ –¥–µ–∫–æ–Ω–¥–∏—Ü–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ (–æ—Ç –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏–∏) —Ñ–∞—Å—Ü–∏–∏.

---

## 6.0 –ü–ï–†–°–û–ù–ê–õ–¨–ù–´–ï –ì–ò–ü–û–¢–ï–ó–´ –î–õ–Ø –°–õ–£–ß–ê–Ø –ü–û–õ–¨–ó–û–í–ê–¢–ï–õ–Ø

¬∂1 **Ordering principle:** –í–æ–ø—Ä–æ—Å—ã ‚Üí –í–æ–∑–º–æ–∂–Ω—ã–µ —Å—Ü–µ–Ω–∞—Ä–∏–∏ ‚Üí –†–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏–∏

### 6.1 –ö–ª—é—á–µ–≤—ã–µ –í–æ–ø—Ä–æ—Å—ã

–ß—Ç–æ–±—ã –ø–æ–Ω—è—Ç—å –ß–¢–û –≤—ã–∑–≤–∞–ª–æ —Ñ–∞—Å—Ü–∏–∏—Ç —É –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—è, –Ω—É–∂–Ω–∞ –∏–Ω—Ñ–æ—Ä–º–∞—Ü–∏—è:

**1. –í—Ä–µ–º–µ–Ω–Ω–∞—è –ª–∏–Ω–∏—è:**
- –ó–∞ **1-4 –Ω–µ–¥–µ–ª–∏** –¥–æ —Å–∏–º–ø—Ç–æ–º–æ–≤ ‚Äî –±—ã–ª–∞ –ª–∏ –Ω–µ–æ–±—ã—á–Ω–∞—è —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å?
  - –ü–æ–¥—ä—ë–º —Ç—è–∂–µ—Å—Ç–µ–π (–ø–µ—Ä–µ–µ–∑–¥, —Ä–µ–º–æ–Ω—Ç, —Å–∞–¥–æ–≤—ã–µ —Ä–∞–±–æ—Ç—ã)
  - –°–ø–æ—Ä—Ç–∏–≤–Ω–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å (–±–µ–≥, —Ç—Ä–µ–Ω–∞–∂—ë—Ä–Ω—ã–π –∑–∞–ª, –ø–ª–∞–≤–∞–Ω–∏–µ)
  - –î–ª–∏—Ç–µ–ª—å–Ω–∞—è —Ö–æ–¥—å–±–∞/—Å—Ç–æ—è–Ω–∏–µ (–ø—É—Ç–µ—à–µ—Å—Ç–≤–∏–µ, –º–µ—Ä–æ–ø—Ä–∏—è—Ç–∏–µ)
  - –ë–∞—Ä–∞–±–∞–Ω—ã, –º—É–∑—ã–∫–∞–ª—å–Ω—ã–π –∏–Ω—Å—Ç—Ä—É–º–µ–Ω—Ç (–ø–æ–≤—Ç–æ—Ä—è—é—â–∏–µ—Å—è –¥–≤–∏–∂–µ–Ω–∏—è)

**2. –ü—Ä–µ–¥—à–µ—Å—Ç–≤—É—é—â–∏–π –æ–±—Ä–∞–∑ –∂–∏–∑–Ω–∏:**
- –°–∫–æ–ª—å–∫–æ –≤—Ä–µ–º–µ–Ω–∏ –¥–æ —Å–æ–±—ã—Ç–∏—è –≤—ã –≤–µ–ª–∏ **—Å–∏–¥—è—á–∏–π –æ–±—Ä–∞–∑ –∂–∏–∑–Ω–∏**?
  - <1 –º–µ—Å—è—Ü (minor risk)
  - 1-6 –º–µ—Å—è—Ü–µ–≤ (moderate risk)
  - >6 –º–µ—Å—è—Ü–µ–≤ (high risk –ø—Ä–∏ —Ä–µ–∑–∫–æ–π –Ω–∞–≥—Ä—É–∑–∫–µ)

**3. –î—Ä—É–≥–∏–µ —Ç—Ä–∏–≥–≥–µ—Ä—ã:**
- **–ò–Ω—Ñ–µ–∫—Ü–∏—è** –∑–∞ 2-4 –Ω–µ–¥–µ–ª–∏ –¥–æ –Ω–∞—á–∞–ª–∞? (COVID, –≥—Ä–∏–ø–ø, –±–æ—Ä—Ä–µ–ª–∏–æ–∑)
- **–ù–æ–≤—ã–µ –ª–µ–∫–∞—Ä—Å—Ç–≤–∞**? (—Å—Ç–∞—Ç–∏–Ω—ã, —Ñ–µ–Ω–∏—Ç–æ–∏–Ω, –¥—Ä—É–≥–∏–µ)
- **–í–∞–∫—Ü–∏–Ω–∞—Ü–∏—è**? (COVID-19 vaccine ‚Äî –µ—Å—Ç—å case reports)

**4. –õ–æ–∫–∞–ª–∏–∑–∞—Ü–∏—è:**
- –ö–∞–∫–∏–µ —á–∞—Å—Ç–∏ —Ç–µ–ª–∞ –ø–æ—Ä–∞–∂–µ–Ω—ã?
  - –†—É–∫–∏ (bilateral?) ‚Üí suggests repetitive upper body activity
  - –ù–æ–≥–∏ (bilateral?) ‚Üí suggests running/walking
  - –û–¥–Ω–æ—Å—Ç–æ—Ä–æ–Ω–Ω–µ ‚Üí suggests local trauma/overuse

**5. –ê–ª–ª–µ—Ä–≥–∏–∏/–∞—Ç–æ–ø–∏—è:**
- –ï—Å—Ç—å –ª–∏ —É –≤–∞—Å –∞–ª–ª–µ—Ä–≥–∏–∏, –∞—Å—Ç–º–∞, —ç–∫–∑–µ–º–∞?
  - –î–ê ‚Üí –ø—Ä–µ–¥—Ä–∞—Å–ø–æ–ª–æ–∂–µ–Ω–Ω–æ—Å—Ç—å –∫ type 2 immunity

### 6.2 –ù–∞–∏–±–æ–ª–µ–µ –í–µ—Ä–æ—è—Ç–Ω—ã–µ –°—Ü–µ–Ω–∞—Ä–∏–∏

**–°–¶–ï–ù–ê–†–ò–ô A: "Weekend Warrior" Syndrome**

```
–ü—Ä–µ–¥—ã—Å—Ç–æ—Ä–∏—è:
  –ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è 3-6 –º–µ—Å—è—Ü–µ–≤ (–æ—Ñ–∏—Å–Ω–∞—è —Ä–∞–±–æ—Ç–∞, –º–∏–Ω–∏–º—É–º –¥–≤–∏–∂–µ–Ω–∏—è)
  ‚Üì
–¢—Ä–∏–≥–≥–µ—Ä–Ω–æ–µ —Å–æ–±—ã—Ç–∏–µ:
  –í—ã—Ö–æ–¥–Ω—ã–µ: –∏–Ω—Ç–µ–Ω—Å–∏–≤–Ω–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å (–ø–æ–¥–Ω—è–ª —Ç—è–∂–µ—Å—Ç–∏, –ø—Ä–æ–±–µ–∂–∞–ª 5 –∫–º, –∫–æ–ø–∞–ª –æ–≥–æ—Ä–æ–¥)
  ‚Üì
–§–∞—Å—Ü–∏–∞–ª—å–Ω–∞—è –º–∏–∫—Ä–æ—Ç—Ä–∞–≤–º–∞:
  –î–µ–∫–æ–Ω–¥–∏—Ü–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ —Ñ–∞—Å—Ü–∏–∏ –Ω–µ –≤—ã–¥–µ—Ä–∂–∞–ª–∏ –Ω–∞–≥—Ä—É–∑–∫—É
  IL-33 release ‚Üí ILC2 activation
  ‚Üì
–ß–µ—Ä–µ–∑ 1-2 –Ω–µ–¥–µ–ª–∏:
  –û—Ç—ë–∫ –∫–æ–Ω–µ—á–Ω–æ—Å—Ç–µ–π, –∏–Ω–¥—É—Ä–∞—Ü–∏—è
  –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—è
  ‚Üì
–î–∏–∞–≥–Ω–æ–∑: –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç
```

**–í–µ—Ä–æ—è—Ç–Ω–æ—Å—Ç—å:** 40-50% (—Å–∞–º—ã–π —á–∞—Å—Ç—ã–π —Å—Ü–µ–Ω–∞—Ä–∏–π)

**–ü—Ä–æ—Ñ–∏–ª–∞–∫—Ç–∏–∫–∞:**
- 10% rule (—É–≤–µ–ª–∏—á–∏–≤–∞—Ç—å –Ω–∞–≥—Ä—É–∑–∫—É –ø–æ—Å—Ç–µ–ø–µ–Ω–Ω–æ)
- –†–∞–∑–º–∏–Ω–∫–∞/—Ä–∞—Å—Ç—è–∂–∫–∞ –ø–µ—Ä–µ–¥ –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å—é

---

**–°–¶–ï–ù–ê–†–ò–ô B: Post-Infectious Trigger**

```
–ü—Ä–µ–¥—ã—Å—Ç–æ—Ä–∏—è:
  COVID-19 –∏–Ω—Ñ–µ–∫—Ü–∏—è –∏–ª–∏ –≤–∞–∫—Ü–∏–Ω–∞—Ü–∏—è (–∑–∞ 2-4 –Ω–µ–¥–µ–ª–∏)
  ‚Üì
–ò–º–º—É–Ω–Ω–∞—è "—Å–µ–Ω—Å–∏–±–∏–ª–∏–∑–∞—Ü–∏—è":
  IL-33 priming (—ç–Ω–¥–æ—Ç–µ–ª–∏–π —Å—Ç–∞–Ω–æ–≤–∏—Ç—Å—è "—á—É–≤—Å—Ç–≤–∏—Ç–µ–ª—å–Ω—ã–º")
  ‚Üì
–ù–µ–±–æ–ª—å—à–∞—è —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å:
  –î–∞–∂–µ —É–º–µ—Ä–µ–Ω–Ω–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ ‚Üí exaggerated IL-33 response
  ‚Üì
ILC2 ‚Üí Eosinophilia ‚Üí Fasciitis
```

**–í–µ—Ä–æ—è—Ç–Ω–æ—Å—Ç—å:** 10-15% (—Ä–∞—Å—Ç—ë—Ç –ø–æ—Å–ª–µ COVID-19 —ç—Ä—ã)

**–ò–Ω–¥–∏–∫–∞—Ç–æ—Ä—ã:**
- –ë—ã–ª–∞ –ª–∏ –∏–Ω—Ñ–µ–∫—Ü–∏—è/–≤–∞–∫—Ü–∏–Ω–∞ –∑–∞ –º–µ—Å—è—Ü –¥–æ –Ω–∞—á–∞–ª–∞?
- –ê—Ç–æ–ø–∏—è –≤ –∞–Ω–∞–º–Ω–µ–∑–µ (allergies) ‚Üí higher risk

---

**–°–¶–ï–ù–ê–†–ò–ô C: Drug-Induced (Statin-Associated)**

```
–ü—Ä–µ–¥—ã—Å—Ç–æ—Ä–∏—è:
  –ü—Ä–∏—ë–º —Å—Ç–∞—Ç–∏–Ω–æ–≤ (simvastatin, atorvastatin) >3 –º–µ—Å—è—Ü–µ–≤
  ‚Üì
–°—É–±–∫–ª–∏–Ω–∏—á–µ—Å–∫–∞—è –º–∏–æ–ø–∞—Ç–∏—è:
  –°—Ç–∞—Ç–∏–Ω—ã ‚Üí –º—ã—à–µ—á–Ω—ã–µ –≤–æ–ª–æ–∫–Ω–∞ –ø–æ–≤—Ä–µ–∂–¥–µ–Ω—ã
  –§–∞—Å—Ü–∏–∏ –∫–æ–º–ø–µ–Ω—Å–∏—Ä—É—é—Ç (increased mechanical load)
  ‚Üì
–î–µ–∫–æ–º–ø–µ–Ω—Å–∞—Ü–∏—è:
  –§–∞—Å—Ü–∏–∏ "—É—Å—Ç–∞—é—Ç", –º–∏–∫—Ä–æ—Ç—Ä–∞–≤–º—ã –Ω–∞–∫–∞–ø–ª–∏–≤–∞—é—Ç—Å—è
  IL-33 release
  ‚Üì
Fasciitis
```

**–í–µ—Ä–æ—è—Ç–Ω–æ—Å—Ç—å:** 5-10% (–µ—Å–ª–∏ –ø—Ä–∏–Ω–∏–º–∞–µ—Ç–µ —Å—Ç–∞—Ç–∏–Ω—ã)

**–ü—Ä–æ–≤–µ—Ä–∫–∞:**
- –ü—Ä–∏–Ω–∏–º–∞–µ—Ç–µ –ª–∏ —Å—Ç–∞—Ç–∏–Ω—ã?
- –ï—Å—Ç—å –ª–∏ –º—ã—à–µ—á–Ω—ã–µ –±–æ–ª–∏ (statin myopathy)?
- **–¢–µ—Å—Ç:** –û—Ç–º–µ–Ω–∞ —Å—Ç–∞—Ç–∏–Ω–∞ ‚Üí —É–ª—É—á—à–µ–Ω–∏–µ —á–µ—Ä–µ–∑ 4-8 –Ω–µ–¥–µ–ª—å?

---

**–°–¶–ï–ù–ê–†–ò–ô D: Idiopathic (–ù–µ–∏–∑–≤–µ—Å—Ç–Ω–∞—è –ü—Ä–∏—á–∏–Ω–∞)**

```
–ù–µ—Ç —è–≤–Ω–æ–≥–æ —Ç—Ä–∏–≥–≥–µ—Ä–∞:
  –ù–µ –±—ã–ª–æ exercise, –∏–Ω—Ñ–µ–∫—Ü–∏–π, –ª–µ–∫–∞—Ä—Å—Ç–≤
  ‚Üì
–°–ø–æ–Ω—Ç–∞–Ω–Ω–∞—è –∏–º–º—É–Ω–Ω–∞—è –¥–∏—Å—Ä–µ–≥—É–ª—è—Ü–∏—è:
  Genetic predisposition? (HLA-DRB1*04)
  Environmental factors? (–Ω–µ–∏–∑–≤–µ—Å—Ç–Ω–æ)
  ‚Üì
Fasciitis
```

**–í–µ—Ä–æ—è—Ç–Ω–æ—Å—Ç—å:** 30-40% (–º–Ω–æ–≥–æ —Å–ª—É—á–∞–µ–≤ –∏–¥–∏–æ–ø–∞—Ç–∏—á–µ—Å–∫–∏–µ)

**–î–µ–π—Å—Ç–≤–∏—è:**
- –ü–æ–ª–Ω–æ–µ –æ–±—Å–ª–µ–¥–æ–≤–∞–Ω–∏–µ (–∏—Å–∫–ª—é—á–∏—Ç—å —Å–∫—Ä—ã—Ç—ã–µ –∏–Ω—Ñ–µ–∫—Ü–∏–∏, –≥–µ–º–∞—Ç–æ–ª–æ–≥–∏—á–µ—Å–∫–∏–µ —Ä–∞—Å—Å—Ç—Ä–æ–π—Å—Ç–≤–∞)
- –ì–µ–Ω–µ—Ç–∏—á–µ—Å–∫–æ–µ —Ç–µ—Å—Ç–∏—Ä–æ–≤–∞–Ω–∏–µ (–µ—Å–ª–∏ –¥–æ—Å—Ç—É–ø–Ω–æ)

### 6.3 "–ü–ª–æ—Ö–∞—è –ï–¥–∞" + –ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è: –†–µ–∞–ª—å–Ω–∞—è –†–æ–ª—å

**–ü–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—å –ø—Ä–µ–¥–ø–æ–ª–∞–≥–∞–µ—Ç:**
> "–ú–æ–∂–µ—Ç –±—ã—Ç—å, —á—Ç–æ —è –º–∞–ª–æ –¥–≤–∏–≥–∞–ª—Å—è, –µ–ª –º–Ω–æ–≥–æ –∫–∞–∫–æ–π-—Ç–æ –ø–ª–æ—Ö–æ–π –µ–¥—ã"

**–ê–Ω–∞–ª–∏–∑:**

**–ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è:**
- **–†–æ–ª—å:** –ü–†–ï–î–†–ê–°–ü–û–õ–ê–ì–ê–Æ–©–ò–ô —Ñ–∞–∫—Ç–æ—Ä (–¥–µ–∫–æ–Ω–¥–∏—Ü–∏–æ–Ω–∏—Ä—É–µ—Ç —Ñ–∞—Å—Ü–∏–∏)
- **–ù–û:** –°–∞–º–∞ –ø–æ —Å–µ–±–µ –ù–ï –≤—ã–∑—ã–≤–∞–µ—Ç —Ñ–∞—Å—Ü–∏–∏—Ç
- **–ù—É–∂–µ–Ω —Ç—Ä–∏–≥–≥–µ—Ä:** –†–µ–∑–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞

**"–ü–ª–æ—Ö–∞—è –µ–¥–∞":**
- **–†–æ–ª—å:** –ú–∏–Ω–∏–º–∞–ª—å–Ω–∞—è (–Ω–µ—Ç –¥–æ–∫–∞–∑–∞–Ω–Ω–æ–π —Å–≤—è–∑–∏)
- **–ò—Å–∫–ª—é—á–µ–Ω–∏–µ:** –ï—Å–ª–∏ –ø—Ä–∏–Ω–∏–º–∞–ª–∏ L-tryptophan supplements (–≤—ã—Å–æ–∫–∏–µ –¥–æ–∑—ã)

**–ë–æ–ª–µ–µ –≤–µ—Ä–æ—è—Ç–Ω—ã–π –º–µ—Ö–∞–Ω–∏–∑–º:**

```
–ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è (–º–µ—Å—è—Ü—ã)
  ‚Üì
–§–∞—Å—Ü–∏–∏ –¥–µ–∫–æ–Ω–¥–∏—Ü–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω—ã:
  - –°–ª–∞–±—ã–µ
  - –ú–µ–Ω–µ–µ –≤–∞—Å–∫—É–ª—è—Ä–∏–∑–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ
  - "–•—Ä—É–ø–∫–∏–µ"
  ‚Üì
"–ü–ª–æ—Ö–∞—è –µ–¥–∞" (–µ—Å–ª–∏ –±—ã–ª–∞):
  - Western diet ‚Üí –Ω–∏–∑–∫–æ–≥—Ä–∞–¥–∏–µ–Ω—Ç–Ω–æ–µ –≤–æ—Å–ø–∞–ª–µ–Ω–∏–µ?
  - –ù–û –ø—Ä—è–º–æ–π —Å–≤—è–∑–∏ —Å —Ñ–∞—Å—Ü–∏–∏—Ç–æ–º –Ω–µ—Ç
  ‚Üì
–ö–†–ò–¢–ò–ß–ï–°–ö–ò–ô –ú–û–ú–ï–ù–¢: –†–µ–∑–∫–∞—è —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞
  - –î–µ–∫–æ–Ω–¥–∏—Ü–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ —Ñ–∞—Å—Ü–∏–∏ –Ω–µ –≤—ã–¥–µ—Ä–∂–∏–≤–∞—é—Ç
  - –ú–∏–∫—Ä–æ—Ç—Ä–∞–≤–º–∞
  - IL-33 release
  ‚Üì
–§–∞—Å—Ü–∏–∏—Ç
```

**–í—ã–≤–æ–¥:**
- –ì–∏–ø–æ–¥–∏–Ω–∞–º–∏—è + —Ä–µ–∑–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ = **–ì–õ–ê–í–ù–´–ô —Ñ–∞–∫—Ç–æ—Ä —Ä–∏—Å–∫–∞**
- "–ü–ª–æ—Ö–∞—è –µ–¥–∞" = **–º–∞–ª–æ–≤–µ—Ä–æ—è—Ç–Ω—ã–π** —Ñ–∞–∫—Ç–æ—Ä (unless L-tryptophan)

**–†–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏—è –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—é:**
> –ü–æ–ø—Ä–æ–±—É–π—Ç–µ –≤—Å–ø–æ–º–Ω–∏—Ç—å: –∑–∞ 1-4 –Ω–µ–¥–µ–ª–∏ –¥–æ –ø–æ—è–≤–ª–µ–Ω–∏—è —Å–∏–º–ø—Ç–æ–º–æ–≤ ‚Äî –±—ã–ª–∞ –ª–∏ –∫–∞–∫–∞—è-—Ç–æ —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å, –∫–æ—Ç–æ—Ä–∞—è –±—ã–ª–∞ **–ù–ï–û–ë–´–ß–ù–û–ô** –¥–ª—è –≤–∞—Å? (–ø–æ–¥—ä—ë–º —Ç—è–∂–µ—Å—Ç–µ–π, –±–µ–≥, —Å–∞–¥–æ–≤—ã–µ —Ä–∞–±–æ—Ç—ã, –¥–ª–∏—Ç–µ–ª—å–Ω–∞—è —Ö–æ–¥—å–±–∞, –Ω–æ–≤–∞—è —Å–ø–æ—Ä—Ç–∏–≤–Ω–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å?)

### 6.4 –ß—Ç–æ –î–µ–ª–∞—Ç—å –°–µ–π—á–∞—Å (Post-Diagnosis)

**–ï—Å–ª–∏ –¥–∏–∞–≥–Ω–æ–∑ —É–∂–µ –ø–æ—Å—Ç–∞–≤–ª–µ–Ω –∏ –≤—ã –≤ –ª–µ—á–µ–Ω–∏–∏:**

**1. –ü—Ä–æ–¥–æ–ª–∂–∞—Ç—å —Ç–µ—Ä–∞–ø–∏—é:**
- **–ö–æ—Ä—Ç–∏–∫–æ—Å—Ç–µ—Ä–æ–∏–¥—ã** (prednisone) ‚Äî –æ—Å–Ω–æ–≤–∞ –ª–µ—á–µ–Ω–∏—è
- **Methotrexate** (–µ—Å–ª–∏ —Å—Ç–µ—Ä–æ–∏–¥—ã –Ω–µ–¥–æ—Å—Ç–∞—Ç–æ—á–Ω—ã)
- **–§–∏–∑–∏–æ—Ç–µ—Ä–∞–ø–∏—è** (gentle stretching, –ù–ï —Ä–µ–∑–∫–∏–µ –¥–≤–∏–∂–µ–Ω–∏—è)

**2. –ú–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥:**
- **–≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—ã** (CBC): —Ü–µ–ª—å <500/ŒºL
- **Skin score** (thickness): —É–ª—É—á—à–µ–Ω–∏–µ —á–µ—Ä–µ–∑ 3-6 –º–µ—Å—è—Ü–µ–≤
- **ROM (range of motion):** —Å—É—Å—Ç–∞–≤—ã –¥–æ–ª–∂–Ω—ã –≤–æ—Å—Å—Ç–∞–Ω–∞–≤–ª–∏–≤–∞—Ç—å –ø–æ–¥–≤–∏–∂–Ω–æ—Å—Ç—å

**3. –ò–∑–±–µ–≥–∞—Ç—å –ø–æ–≤—Ç–æ—Ä–Ω–æ–π —Ç—Ä–∞–≤–º–∞—Ç–∏–∑–∞—Ü–∏–∏:**
- **–ù–ï –≤–æ–∑–æ–±–Ω–æ–≤–ª—è—Ç—å –∏–Ω—Ç–µ–Ω—Å–∏–≤–Ω—ã–µ —Ç—Ä–µ–Ω–∏—Ä–æ–≤–∫–∏** –¥–æ –ø–æ–ª–Ω–æ–π —Ä–µ–º–∏—Å—Å–∏–∏ (6-12 –º–µ—Å—è—Ü–µ–≤)
- –ö–æ–≥–¥–∞ –Ω–∞—á–∏–Ω–∞–µ—Ç–µ –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å ‚Äî **–û–ß–ï–ù–¨ –ø–æ—Å—Ç–µ–ø–µ–Ω–Ω–æ** (10% rule)

**4. –î–∏–µ—Ç–∞ (–¥–æ–ø–æ–ª–Ω–∏—Ç–µ–ª—å–Ω–∞—è –ø–æ–¥–¥–µ—Ä–∂–∫–∞):**
- Adequate protein (1.2-1.6 g/kg)
- Vitamin C (500-1000 mg/–¥–µ–Ω—å)
- Hydration (2-3 L/day)
- **–ò–∑–±–µ–≥–∞—Ç—å:** L-tryptophan supplements

**5. Giants-modulating —Å—Ç—Ä–∞—Ç–µ–≥–∏–∏ (—ç–∫—Å–ø–µ—Ä–∏–º–µ–Ω—Ç–∞–ª—å–Ω—ã–µ):**
- **–§–∏–∑–∏–æ—Ç–µ—Ä–∞–ø–∏—è:** Gentle myofascial release (–º–æ–∂–µ—Ç downregulate Giants?)
- **Rapamycin** (off-label): –¢–µ–æ—Ä–µ—Ç–∏—á–µ—Å–∫–∏ –º–æ–∂–µ—Ç —É—Å–∫–æ—Ä–∏—Ç—å resolution (—Å–Ω–∏–∑–∏—Ç—å TGF-Œ≤ signaling)
- **Anti-IL-5** (mepolizumab): –ï—Å–ª–∏ —Å—Ç–∞–Ω–¥–∞—Ä—Ç–Ω–∞—è —Ç–µ—Ä–∞–ø–∏—è –Ω–µ —Ä–∞–±–æ—Ç–∞–µ—Ç

---

## 7.0 –¢–ï–†–ê–ü–ï–í–¢–ò–ß–ï–°–ö–ò–ï –°–¢–†–ê–¢–ï–ì–ò–ò –° GIANTS-MODULATION

¬∂1 **Ordering principle:** –°—Ç–∞–Ω–¥–∞—Ä—Ç–Ω–∞—è —Ç–µ—Ä–∞–ø–∏—è ‚Üí Giants-targeting –ø–æ–¥—Ö–æ–¥—ã ‚Üí –ë—É–¥—É—â–∏–µ –Ω–∞–ø—Ä–∞–≤–ª–µ–Ω–∏—è

### 7.1 –°—Ç–∞–Ω–¥–∞—Ä—Ç–Ω–∞—è –¢–µ—Ä–∞–ø–∏—è (–î–æ–∫–∞–∑–∞–Ω–Ω–∞—è –≠—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç—å)

**–ü–ï–†–í–ê–Ø –õ–ò–ù–ò–Ø: –ö–æ—Ä—Ç–∏–∫–æ—Å—Ç–µ—Ä–æ–∏–¥—ã**

**Prednisone:**
- **–î–æ–∑–∞:** 0.5-1.0 mg/kg/–¥–µ–Ω—å (–æ–±—ã—á–Ω–æ 40-60 mg/–¥–µ–Ω—å –¥–ª—è –≤–∑—Ä–æ—Å–ª–æ–≥–æ)
- **–î–ª–∏—Ç–µ–ª—å–Ω–æ—Å—Ç—å:**
  - –ù–∞—á–∞–ª—å–Ω–∞—è —Ñ–∞–∑–∞: 4-8 –Ω–µ–¥–µ–ª—å (–≤—ã—Å–æ–∫–∞—è –¥–æ–∑–∞)
  - Taper (—Å–Ω–∏–∂–µ–Ω–∏–µ): 5-10 mg –∫–∞–∂–¥—ã–µ 2-4 –Ω–µ–¥–µ–ª–∏
  - –û–±—â–∞—è –¥–ª–∏—Ç–µ–ª—å–Ω–æ—Å—Ç—å: 6-12 –º–µ—Å—è—Ü–µ–≤
- **–ú–µ—Ö–∞–Ω–∏–∑–º:**
  - –ü–æ–¥–∞–≤–ª—è–µ—Ç IL-5 production (ILC2 —É–≥–Ω–µ—Ç–∞—é—Ç—Å—è)
  - –°–Ω–∏–∂–∞–µ—Ç —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—é
  - –ë–ª–æ–∫–∏—Ä—É–µ—Ç TGF-Œ≤ signaling (partial)
  - **Giants:** –ö–æ—Å–≤–µ–Ω–Ω–æ downregulate (—á–µ—Ä–µ–∑ ‚Üì TGF-Œ≤)

**–≠—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç—å:**
- **70-90%** –ø–∞—Ü–∏–µ–Ω—Ç–æ–≤ –æ—Ç–≤–µ—á–∞—é—Ç
- –£–ª—É—á—à–µ–Ω–∏–µ –≤ —Ç–µ—á–µ–Ω–∏–µ 2-4 –Ω–µ–¥–µ–ª—å
- Skin thickness ‚Üì, ROM ‚Üë

**–ü–æ–±–æ—á–Ω—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã:**
- Cushingoid features, weight gain
- Osteoporosis (–ø—Ä–∏ –¥–ª–∏—Ç–µ–ª—å–Ω–æ–º –ø—Ä–∏—ë–º–µ)
- –ì–∏–ø–µ—Ä–≥–ª–∏–∫–µ–º–∏—è, –≥–∏–ø–µ—Ä—Ç–µ–Ω–∑–∏—è
- **–ú–∏–Ω–∏–º–∏–∑–∞—Ü–∏—è:** Calcium + Vitamin D, bone density monitoring

---

**–í–¢–û–†–ê–Ø –õ–ò–ù–ò–Ø: Methotrexate (Steroid-Sparing)**

**–î–æ–∑–∞:**
- 15-25 mg/–Ω–µ–¥–µ–ª—è (oral –∏–ª–∏ subcutaneous)
- + Folic acid 1-5 mg/–¥–µ–Ω—å (—É–º–µ–Ω—å—à–∞–µ—Ç –ø–æ–±–æ—á–Ω—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã)

**–ú–µ—Ö–∞–Ω–∏–∑–º:**
- –ë–ª–æ–∫–∏—Ä—É–µ—Ç dihydrofolate reductase ‚Üí –∞–Ω—Ç–∏–ø—Ä–æ–ª–∏—Ñ–µ—Ä–∞—Ç–∏–≤–Ω—ã–π —ç—Ñ—Ñ–µ–∫—Ç
- –£–≥–Ω–µ—Ç–∞–µ—Ç —Ñ–∏–±—Ä–æ–±–ª–∞—Å—Ç–Ω—É—é –∞–∫—Ç–∏–≤–∞—Ü–∏—é
- **Giants:** –ú–æ–∂–µ—Ç —Å–Ω–∏–∂–∞—Ç—å COL14A1/PCOLCE expression (via decreased fibroblast activity)

**–ü–æ–∫–∞–∑–∞–Ω–∏—è:**
- –°—Ç–µ—Ä–æ–∏–¥-–∑–∞–≤–∏—Å–∏–º–æ—Å—Ç—å (—Ä–µ—Ü–∏–¥–∏–≤ –ø—Ä–∏ —Å–Ω–∏–∂–µ–Ω–∏–∏ prednisone <10 mg/–¥–µ–Ω—å)
- –°—Ç–µ—Ä–æ–∏–¥–Ω—ã–µ –ø–æ–±–æ—á–Ω—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã –Ω–µ–ø–µ—Ä–µ–Ω–æ—Å–∏–º—ã
- –¢—è–∂—ë–ª—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç (contractures)

**–≠—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç—å:**
- 60-80% improvement
- –ü–æ–∑–≤–æ–ª—è–µ—Ç —Å–Ω–∏–∑–∏—Ç—å –¥–æ–∑—É —Å—Ç–µ—Ä–æ–∏–¥–æ–≤

**–ú–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥:**
- –ü–µ—á—ë–Ω–æ—á–Ω—ã–µ —Ñ–µ—Ä–º–µ–Ω—Ç—ã (AST, ALT) –∫–∞–∂–¥—ã–µ 4-8 –Ω–µ–¥–µ–ª—å
- CBC (risk of leukopenia)

---

**–¢–†–ï–¢–¨–Ø –õ–ò–ù–ò–Ø: –î—Ä—É–≥–∏–µ –ò–º–º—É–Ω–æ—Å—É–ø—Ä–µ—Å—Å–∞–Ω—Ç—ã**

| –ü—Ä–µ–ø–∞—Ä–∞—Ç | –î–æ–∑–∞ | –ú–µ—Ö–∞–Ω–∏–∑–º | –≠—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç—å |
|----------|------|----------|---------------|
| **Mycophenolate mofetil** | 1000-1500 mg BID | –ë–ª–æ–∫–∏—Ä—É–µ—Ç –ª–∏–º—Ñ–æ—Ü–∏—Ç–Ω—É—é –ø—Ä–æ–ª–∏—Ñ–µ—Ä–∞—Ü–∏—é | 60-70% |
| **Azathioprine** | 1-2 mg/kg/–¥–µ–Ω—å | –ü—É—Ä–∏–Ω–æ–≤—ã–π –∞–Ω—Ç–∞–≥–æ–Ω–∏—Å—Ç | 50-60% |
| **Cyclosporine** | 2.5-5 mg/kg/–¥–µ–Ω—å | –ë–ª–æ–∫–∏—Ä—É–µ—Ç IL-2 production | 50-70% |
| **Hydroxychloroquine** | 200-400 mg/–¥–µ–Ω—å | –ò–º–º—É–Ω–æ–º–æ–¥—É–ª—è—Ç–æ—Ä | 30-50% (mild cases) |

---

**–§–ò–ó–ò–û–¢–ï–†–ê–ü–ò–Ø (–ö—Ä–∏—Ç–∏—á–µ—Å–∫–∏ –í–∞–∂–Ω–∞!)**

**–¶–µ–ª–∏:**
- –ü—Ä–µ–¥–æ—Ç–≤—Ä–∞—Ç–∏—Ç—å –∫–æ–Ω—Ç—Ä–∞–∫—Ç—É—Ä—ã
- –í–æ—Å—Å—Ç–∞–Ω–æ–≤–∏—Ç—å ROM (range of motion)
- –£–ª—É—á—à–∏—Ç—å fascial gliding

**–ú–µ—Ç–æ–¥—ã:**

**1. Gentle Stretching:**
- Passive ROM exercises (2-3 —Ä–∞–∑–∞/–¥–µ–Ω—å, –ø–æ 10-15 –º–∏–Ω—É—Ç)
- –ò–∑–±–µ–≥–∞—Ç—å pain (—Ä–∞—Å—Ç—è–∂–∫–∞ –¥–æ –ª—ë–≥–∫–æ–≥–æ –¥–∏—Å–∫–æ–º—Ñ–æ—Ä—Ç–∞, –ù–ï –±–æ–ª–∏)

**2. Myofascial Release:**
- Manual therapy (–º–∞—Å—Å–∞–∂ —Ñ–∞—Å—Ü–∏–π)
- Foam rolling (GENTLE, –ù–ï –∞–≥—Ä–µ—Å—Å–∏–≤–Ω—ã–π)
- **–ì–∏–ø–æ—Ç–µ–∑–∞:** –ú–µ—Ö–∞–Ω–∏—á–µ—Å–∫–∞—è —Å—Ç–∏–º—É–ª—è—Ü–∏—è –º–æ–∂–µ—Ç modulate Giants (downregulate via mechanotransduction)

**3. Hydrotherapy:**
- –¢—ë–ø–ª–∞—è –≤–æ–¥–∞ (—Å–Ω–∏–∂–∞–µ—Ç —Å—Çiffness)
- Aquatic exercises (low-impact)

**4. Ultrasound Therapy:**
- –¢–µ–æ—Ä–µ—Ç–∏—á–µ—Å–∫–∏: –º–æ–∂–µ—Ç —É–ª—É—á—à–∏—Ç—å fascial remodeling
- –î–æ–∫–∞–∑–∞—Ç–µ–ª—å—Å—Ç–≤–∞: limited

**–î–æ–∫–∞–∑–∞–Ω–Ω–∞—è –ø–æ–ª—å–∑–∞:**
- ROM improvement +30-50%
- –ü—Ä–µ–¥–æ—Ç–≤—Ä–∞—â–µ–Ω–∏–µ permanent contractures

### 7.2 Giants-Targeting –ü–æ–¥—Ö–æ–¥—ã (–≠–∫—Å–ø–µ—Ä–∏–º–µ–Ω—Ç–∞–ª—å–Ω—ã–µ)

**–°–¢–†–ê–¢–ï–ì–ò–Ø 1: Anti-IL-5 –ë–∏–æ–ª–æ–≥–∏—á–µ—Å–∫–∏–µ –ü—Ä–µ–ø–∞—Ä–∞—Ç—ã**

**Mepolizumab (Nucala):**
- **–ú–µ—Ö–∞–Ω–∏–∑–º:** –ê–Ω—Ç–∏-IL-5 –º–æ–Ω–æ–∫–ª–æ–Ω–∞–ª—å–Ω–æ–µ –∞–Ω—Ç–∏—Ç–µ–ª–æ
- **–î–æ–∑–∞:** 100-300 mg subcutaneous –∫–∞–∂–¥—ã–µ 4 –Ω–µ–¥–µ–ª–∏
- **–û–¥–æ–±—Ä–µ–Ω –¥–ª—è:** Severe eosinophilic asthma, EGPA (eosinophilic granulomatosis with polyangiitis)
- **–ò—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏–µ –≤ —Ñ–∞—Å—Ü–∏–∏—Ç–µ:** Off-label (case reports)

**–≠—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç—å (case series):**
- Rapid eosinophil depletion (<500/ŒºL —á–µ—Ä–µ–∑ 2-4 –Ω–µ–¥–µ–ª–∏)
- Skin improvement —á–µ—Ä–µ–∑ 2-3 –º–µ—Å—è—Ü–∞
- **Giants:** ‚Üì TGF-Œ≤ (–∏–∑-–∑–∞ ‚Üì eosinophils) ‚Üí Giants downregulate

**–ü–æ–∫–∞–∑–∞–Ω–∏—è –¥–ª—è —Ñ–∞—Å—Ü–∏–∏—Ç–∞:**
- –°—Ç–µ—Ä–æ–∏–¥-—Ä–µ—Ñ—Ä–∞–∫—Ç–µ—Ä–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç
- –í—ã—Å–æ–∫–∞—è —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—è (>2000/ŒºL)
- –°–∏—Å—Ç–µ–º–Ω—ã–µ –ø—Ä–æ—è–≤–ª–µ–Ω–∏—è (–ø–ª–µ–≤—Ä–∞–ª—å–Ω—ã–π –≤—ã–ø–æ—Ç)

**–°—Ç–æ–∏–º–æ—Å—Ç—å:** $$$ (–æ—á–µ–Ω—å –¥–æ—Ä–æ–≥–æ, ~$30,000/–≥–æ–¥)

---

**Benralizumab (Fasenra):**
- **–ú–µ—Ö–∞–Ω–∏–∑–º:** –ê–Ω—Ç–∏-IL-5 receptor (–±–æ–ª–µ–µ –º–æ—â–Ω—ã–π, —á–µ–º mepolizumab)
- **–ü—Ä–µ–∏–º—É—â–µ—Å—Ç–≤–æ:** Depletes eosinophils –ø–æ–ª–Ω–æ—Å—Ç—å—é (via ADCC ‚Äî antibody-dependent cell cytotoxicity)
- **–ò—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏–µ:** Off-label –¥–ª—è —Ñ–∞—Å—Ü–∏–∏—Ç–∞ (minimal data)

---

**–°–¢–†–ê–¢–ï–ì–ò–Ø 2: Anti-TGF-Œ≤ (–ë–ª–æ–∫–∏—Ä–æ–≤–∞—Ç—å Giants Activation)**

**Fresolimumab:**
- **–ú–µ—Ö–∞–Ω–∏–∑–º:** –ê–Ω—Ç–∏-TGF-Œ≤1/Œ≤2/Œ≤3 –º–æ–Ω–æ–∫–ª–æ–Ω–∞–ª—å–Ω–æ–µ –∞–Ω—Ç–∏—Ç–µ–ª–æ
- **–°—Ç–∞—Ç—É—Å:** Clinical trials –¥–ª—è —Å–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏–∏, —Ñ–∏–±—Ä–æ–∑ –ª—ë–≥–∫–∏—Ö
- **–ì–∏–ø–æ—Ç–µ–∑–∞ –¥–ª—è —Ñ–∞—Å—Ü–∏–∏—Ç–∞:** –ë–ª–æ–∫–∏—Ä—É–µ—Ç TGF-Œ≤ ‚Üí Giants –Ω–µ –∞–∫—Ç–∏–≤–∏—Ä—É—é—Ç—Å—è ‚Üí —Ñ–∏–±—Ä–æ–∑ –Ω–µ –ø—Ä–æ–≥—Ä–µ—Å—Å–∏—Ä—É–µ—Ç

**–ü—Ä–æ–±–ª–µ–º–∞:** –ù–ï –æ–¥–æ–±—Ä–µ–Ω FDA, –¥–æ—Å—Ç—É–ø–µ–Ω —Ç–æ–ª—å–∫–æ –≤ –∫–ª–∏–Ω–∏—á–µ—Å–∫–∏—Ö –∏—Å–ø—ã—Ç–∞–Ω–∏—è—Ö

---

**Pirfenidone:**
- **–ú–µ—Ö–∞–Ω–∏–∑–º:** TGF-Œ≤ modulator (—Å–Ω–∏–∂–∞–µ—Ç TGF-Œ≤ signaling)
- **–û–¥–æ–±—Ä–µ–Ω –¥–ª—è:** Idiopathic pulmonary fibrosis (IPF)
- **–î–æ–∑–∞:** 801-2403 mg/–¥–µ–Ω—å (3 —Ä–∞–∑–∞/–¥–µ–Ω—å)
- **–ò—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏–µ –≤ —Ñ–∞—Å—Ü–∏–∏—Ç–µ:** Off-label (–Ω–µ—Ç –¥–∞–Ω–Ω—ã—Ö)

**–¢–µ–æ—Ä–µ—Ç–∏—á–µ—Å–∫–∞—è –ø–æ–ª—å–∑–∞:**
- ‚Üì TGF-Œ≤ ‚Üí ‚Üì Giants activation ‚Üí –º–µ–Ω—å—à–µ —Ñ–∏–±—Ä–æ–∑

**–ü–æ–±–æ—á–Ω—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã:**
- GI upset (—Ç–æ—à–Ω–æ—Ç–∞, –¥–∏–∞—Ä–µ—è)
- –§–æ—Ç–æ—Å–µ–Ω—Å–∏–±–∏–ª–∏–∑–∞—Ü–∏—è (–∏–∑–±–µ–≥–∞—Ç—å —Å–æ–ª–Ω—Ü–∞)

---

**–°–¢–†–ê–¢–ï–ì–ò–Ø 3: mTOR Inhibitors (Rapamycin)**

**Sirolimus (Rapamycin):**
- **–ú–µ—Ö–∞–Ω–∏–∑–º:** mTORC1 inhibitor
  - –ë–ª–æ–∫–∏—Ä—É–µ—Ç TGF-Œ≤-induced collagen synthesis
  - –°—Ç–∏–º—É–ª–∏—Ä—É–µ—Ç autophagy (—É–¥–∞–ª–µ–Ω–∏–µ –∞–∫—Ç–∏–≤–∏—Ä–æ–≤–∞–Ω–Ω—ã—Ö —Ñ–∏–±—Ä–æ–±–ª–∞—Å—Ç–æ–≤)
- **–î–æ–∑–∞:** 1-2 mg/–¥–µ–Ω—å (oral)
- **–û–¥–æ–±—Ä–µ–Ω –¥–ª—è:** Transplant rejection, LAM (lymphangioleiomyomatosis)
- **–ò—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏–µ –≤ —Ñ–∏–±—Ä–æ–∑–µ:** Off-label

**–î–æ–∫–∞–∑–∞—Ç–µ–ª—å—Å—Ç–≤–∞ —ç—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏:**
- –°–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏—è: –Ω–µ—Å–∫–æ–ª—å–∫–æ case reports (improvement in skin score)
- –§–∞—Å—Ü–∏–∏—Ç: –ù–ï–¢ –æ–ø—É–±–ª–∏–∫–æ–≤–∞–Ω–Ω—ã—Ö –¥–∞–Ω–Ω—ã—Ö

**Giants modulation:**
- Rapamycin ‚Üí ‚Üì mTORC1 ‚Üí ‚Üì COL1A1/COL14A1 translation ‚Üí Giants —Å–Ω–∏–∂–∞—é—Ç—Å—è

**–ü–æ–±–æ—á–Ω—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã:**
- Immunosuppression (infection risk)
- –ì–∏–ø–µ—Ä–ª–∏–ø–∏–¥–µ–º–∏—è
- Mouth ulcers

**–ö–æ–º—É —Ä–∞—Å—Å–º–æ—Ç—Ä–µ—Ç—å:**
- –†–µ—Ñ—Ä–∞–∫—Ç–µ—Ä–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç (–Ω–µ –æ—Ç–≤–µ—á–∞–µ—Ç –Ω–∞ —Å—Ç–µ—Ä–æ–∏–¥—ã + MTX)
- –•—Ä–æ–Ω–∏—á–µ—Å–∫–∏–π —Ñ–∞—Å—Ü–∏–∏—Ç (>12 –º–µ—Å—è—Ü–µ–≤)

---

**–°–¢–†–ê–¢–ï–ì–ò–Ø 4: –§–∏–∑–∏–æ—Ç–µ—Ä–∞–ø–∏—è –∫–∞–∫ Giants Modulator**

**–ì–∏–ø–æ—Ç–µ–∑–∞:** –ú–µ—Ö–∞–Ω–∏—á–µ—Å–∫–∞—è —Å—Ç–∏–º—É–ª—è—Ü–∏—è —Ñ–∞—Å—Ü–∏–π –º–æ–∂–µ—Ç DOWNREGULATE Giants

**–ú–µ—Ö–∞–Ω–∏–∑–º (—Ç–µ–æ—Ä–µ—Ç–∏—á–µ—Å–∫–∏–π):**

```
Mechanical stretching of fascia
  ‚Üì Mechanotransduction
YAP/TAZ pathway activation
  ‚Üì Context-dependent
In STIFF fascia: YAP/TAZ ‚Üí Pro-fibrotic (BAD)
In STRETCHED fascia: YAP/TAZ ‚Üí Anti-fibrotic? (GOOD)
  ‚Üì
COL14A1/PCOLCE downregulation
  ‚Üì
Fascial remodeling (from rigid ‚Üí flexible)
```

**–î–æ–∫–∞–∑–∞—Ç–µ–ª—å—Å—Ç–≤–∞:**
- In vitro: Cyclic stretching of fibroblasts ‚Üí ‚Üì collagen synthesis (Chiquet et al., 2009)
- In vivo: Physical therapy improves scleroderma skin (mechanism unknown)

**–ü—Ä–æ—Ç–æ–∫–æ–ª (—ç–∫—Å–ø–µ—Ä–∏–º–µ–Ω—Ç–∞–ª—å–Ω—ã–π):**
- Daily myofascial release (20-30 –º–∏–Ω—É—Ç)
- Gentle foam rolling (5-10 –º–∏–Ω—É—Ç, 2√ó daily)
- Yoga/stretching (focus on affected areas)

**–ú–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥ —ç—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏:**
- Skin thickness (caliper measurements)
- ROM improvement
- **–ë–∏–æ–º–∞—Ä–∫–µ—Ä—ã (–µ—Å–ª–∏ –¥–æ—Å—Ç—É–ø–Ω–æ):** PRO-C14 (should decrease)

---

**–°–¢–†–ê–¢–ï–ì–ò–Ø 5: Anti-IL-33 (–ë—É–¥—É—â–µ–µ –ù–∞–ø—Ä–∞–≤–ª–µ–Ω–∏–µ)**

**IL-33 Blockade:**
- **–ü—Ä–µ–ø–∞—Ä–∞—Ç:** Etokimab (–∞–Ω—Ç–∏-IL-33 –∞–Ω—Ç–∏—Ç–µ–ª–æ) ‚Äî –≤ Phase 2 trials –¥–ª—è atopic dermatitis
- **–ú–µ—Ö–∞–Ω–∏–∑–º:** –ë–ª–æ–∫–∏—Ä—É–µ—Ç IL-33 ‚Üí ILC2 –Ω–µ –∞–∫—Ç–∏–≤–∏—Ä—É—é—Ç—Å—è ‚Üí –Ω–µ—Ç IL-5 ‚Üí –Ω–µ—Ç —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏–∏
- **–ü—Ä–∏–º–µ–Ω–µ–Ω–∏–µ –¥–ª—è —Ñ–∞—Å—Ü–∏–∏—Ç–∞:** –¢–µ–æ—Ä–µ—Ç–∏—á–µ—Å–∫–∏ –∏–¥–µ–∞–ª—å–Ω–æ (–±–ª–æ–∫–∏—Ä—É–µ—Ç —Å–∞–º—ã–π upstream trigger)

**–°—Ç–∞—Ç—É—Å:** –ù–µ –æ–¥–æ–±—Ä–µ–Ω, –¥–æ—Å—Ç—É–ø–µ–Ω —Ç–æ–ª—å–∫–æ –≤ –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏—è—Ö

**–ì–∏–ø–æ—Ç–µ–∑–∞:**
- –ï—Å–ª–∏ IL-33 = initial trigger ‚Üí –±–ª–æ–∫–∏—Ä–æ–≤–∞—Ç—å IL-33 = –ø—Ä–µ–¥–æ—Ç–≤—Ä–∞—Ç–∏—Ç—å —Ñ–∞—Å—Ü–∏–∏—Ç
- –ú–æ–∂–µ—Ç –±—ã—Ç—å –ø–æ–ª–µ–∑–Ω–æ –¥–ª—è –ü–†–û–§–ò–õ–ê–ö–¢–ò–ö–ò —Ä–µ—Ü–∏–¥–∏–≤–∞

---

### 7.3 –ö–æ–º–±–∏–Ω–∏—Ä–æ–≤–∞–Ω–Ω–∞—è –¢–µ—Ä–∞–ø–∏—è (Optimal Strategy)

**–ò–¥–µ–∞–ª—å–Ω—ã–π –ø—Ä–æ—Ç–æ–∫–æ–ª (–Ω–∞ –æ—Å–Ω–æ–≤–µ Giants pathophysiology):**

**–§–ê–ó–ê 1: –û—Å—Ç—Ä–∞—è (–ú–µ—Å—è—Ü—ã 0-3)**

```
Prednisone 40-60 mg/–¥–µ–Ω—å
  +
Mepolizumab 300 mg subcutaneous (–µ—Å–ª–∏ –¥–æ—Å—Ç—É–ø–Ω–æ)
  +
Aggressive Physical Therapy

–¶–µ–ª—å:
  - –ë—ã—Å—Ç—Ä–æ —Å–Ω–∏–∑–∏—Ç—å —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—é
  - –ë–ª–æ–∫–∏—Ä–æ–≤–∞—Ç—å TGF-Œ≤ ‚Üí Giants activation
  - –ü—Ä–µ–¥–æ—Ç–≤—Ä–∞—Ç–∏—Ç—å contractures
```

**–§–ê–ó–ê 2: –ü–æ–¥–¥–µ—Ä–∂–∞–Ω–∏–µ (–ú–µ—Å—è—Ü—ã 3-6)**

```
Prednisone taper (—Å–Ω–∏–∂–µ–Ω–∏–µ –¥–æ 5-10 mg/–¥–µ–Ω—å)
  +
Methotrexate 15-25 mg/–Ω–µ–¥–µ–ª—è (steroid-sparing)
  +
Continue Physical Therapy

–¶–µ–ª—å:
  - Maintain Giants downregulation
  - –°–Ω–∏–∑–∏—Ç—å —Å—Ç–µ—Ä–æ–∏–¥–Ω—ã–µ –ø–æ–±–æ—á–Ω—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã
  - –í–æ—Å—Å—Ç–∞–Ω–æ–≤–∏—Ç—å ROM
```

**–§–ê–ó–ê 3: –î–æ–ª–≥–æ—Å—Ä–æ—á–Ω–∞—è (–ú–µ—Å—è—Ü—ã 6-12)**

```
Methotrexate (–º–æ–∂–Ω–æ –ø—Ä–æ–¥–æ–ª–∂–∏—Ç—å –∏–ª–∏ –ø—Ä–µ–∫—Ä–∞—Ç–∏—Ç—å)
  +
Rapamycin 1-2 mg/–¥–µ–Ω—å (optional, –µ—Å–ª–∏ —Ä–µ—Ñ—Ä–∞–∫—Ç–µ—Ä–Ω—ã–π)
  +
Home stretching program

–¶–µ–ª—å:
  - –ü—Ä–µ–¥–æ—Ç–≤—Ä–∞—Ç–∏—Ç—å —Ä–µ—Ü–∏–¥–∏–≤
  - Giants maintain at baseline
  - Full ROM recovery
```

**–û–∂–∏–¥–∞–µ–º—ã–π –∏—Å—Ö–æ–¥:**
- **70-90%** –ø–æ–ª–Ω–∞—è —Ä–µ–º–∏—Å—Å–∏—è —á–µ—Ä–µ–∑ 6-12 –º–µ—Å—è—Ü–µ–≤
- **10-20%** –æ—Å—Ç–∞—Ç–æ—á–Ω–∞—è —Å—Çiffness (–Ω–æ functional improvement)
- **<5%** —Ä–µ—Ñ—Ä–∞–∫—Ç–µ—Ä–Ω—ã–µ —Å–ª—É—á–∞–∏ (—Ç—Ä–µ–±—É—é—Ç –±–∏–æ–ª–æ–≥–∏—á–µ—Å–∫–∏—Ö –ø—Ä–µ–ø–∞—Ä–∞—Ç–æ–≤)

---

## 8.0 –ü–†–û–ì–ù–û–ó –ò –î–û–õ–ì–û–°–†–û–ß–ù–´–ô –ú–û–ù–ò–¢–û–†–ò–ù–ì

¬∂1 **Ordering principle:** –ö—Ä–∞—Ç–∫–æ—Å—Ä–æ—á–Ω—ã–π –ø—Ä–æ–≥–Ω–æ–∑ ‚Üí –î–æ–ª–≥–æ—Å—Ä–æ—á–Ω—ã–µ –∏—Å—Ö–æ–¥—ã ‚Üí –ü—Ä–æ—Ñ–∏–ª–∞–∫—Ç–∏–∫–∞ —Ä–µ—Ü–∏–¥–∏–≤–∞

### 8.1 –ü—Ä–æ–≥–Ω–æ–∑ —Å –õ–µ—á–µ–Ω–∏–µ–º

**–ë–ª–∞–≥–æ–ø—Ä–∏—è—Ç–Ω—ã–π (–≤ –æ—Ç–ª–∏—á–∏–µ –æ—Ç —Å–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏–∏!):**

**–ö—Ä–∞—Ç–∫–æ—Å—Ä–æ—á–Ω—ã–π (6-12 –º–µ—Å—è—Ü–µ–≤):**
- **70-90%** –ø–∞—Ü–∏–µ–Ω—Ç–æ–≤ –¥–æ—Å—Ç–∏–≥–∞—é—Ç –∫–ª–∏–Ω–∏—á–µ—Å–∫–æ–π —Ä–µ–º–∏—Å—Å–∏–∏
- Skin thickness –Ω–æ—Ä–º–∞–ª–∏–∑—É–µ—Ç—Å—è
- ROM –≤–æ—Å—Å—Ç–∞–Ω–∞–≤–ª–∏–≤–∞–µ—Ç—Å—è (—á–∞—Å—Ç–∏—á–Ω–æ –∏–ª–∏ –ø–æ–ª–Ω–æ—Å—Ç—å—é)
- –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª–∏—è —Ä–∞–∑—Ä–µ—à–∞–µ—Ç—Å—è

**–î–æ–ª–≥–æ—Å—Ä–æ—á–Ω—ã–π (5-10 –ª–µ—Ç):**
- **50-70%** –ø–æ–ª–Ω–æ–µ –≤—ã–∑–¥–æ—Ä–æ–≤–ª–µ–Ω–∏–µ (no residual symptoms)
- **20-30%** –æ—Å—Ç–∞—Ç–æ—á–Ω–∞—è mild stiffness (functional, but not disabling)
- **5-10%** —Ö—Ä–æ–Ω–∏—á–µ—Å–∫–∏–π/—Ä–µ—Ü–∏–¥–∏–≤–∏—Ä—É—é—â–∏–π —Ñ–∞—Å—Ü–∏–∏—Ç

**–§–∞–∫—Ç–æ—Ä—ã –•–û–†–û–®–ï–ì–û –ø—Ä–æ–≥–Ω–æ–∑–∞:**
- ‚úÖ –†–∞–Ω–Ω—è—è –¥–∏–∞–≥–Ω–æ—Å—Ç–∏–∫–∞ (<3 –º–µ—Å—è—Ü–∞ –æ—Ç –Ω–∞—á–∞–ª–∞)
- ‚úÖ –ë—ã—Å—Ç—Ä—ã–π –æ—Ç–≤–µ—Ç –Ω–∞ —Å—Ç–µ—Ä–æ–∏–¥—ã (<4 –Ω–µ–¥–µ–ª–∏)
- ‚úÖ –ú–æ–ª–æ–¥–æ–π –≤–æ–∑—Ä–∞—Å—Ç (<50 –ª–µ—Ç)
- ‚úÖ –ù–µ—Ç —Å–∏—Å—Ç–µ–º–Ω—ã—Ö –ø—Ä–æ—è–≤–ª–µ–Ω–∏–π (–ø–ª–µ–≤—Ä–∏—Ç, –ø–µ—Ä–∏–∫–∞—Ä–¥–∏—Ç)

**–§–∞–∫—Ç–æ—Ä—ã –ü–õ–û–•–û–ì–û –ø—Ä–æ–≥–Ω–æ–∑–∞:**
- ‚ö†Ô∏è –ü–æ–∑–¥–Ω—è—è –¥–∏–∞–≥–Ω–æ—Å—Ç–∏–∫–∞ (>6 –º–µ—Å—è—Ü–µ–≤)
- ‚ö†Ô∏è –†–µ—Ñ—Ä–∞–∫—Ç–µ—Ä–Ω–æ—Å—Ç—å –∫ —Å—Ç–µ—Ä–æ–∏–¥–∞–º
- ‚ö†Ô∏è –ê—Å—Å–æ—Ü–∏–∞—Ü–∏—è —Å –≥–µ–º–∞—Ç–æ–ª–æ–≥–∏—á–µ—Å–∫–∏–º–∏ –∑–∞–±–æ–ª–µ–≤–∞–Ω–∏—è–º–∏ (aplastic anemia, MDS)
- ‚ö†Ô∏è Severe contractures (—Ñ–∏–∫—Å–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ)

### 8.2 –ú–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥ Giants (–ë—É–¥—É—â–µ–µ)

**–ü—Ä–µ–¥–ª–æ–∂–µ–Ω–Ω–∞—è —Å—Ö–µ–º–∞ –º–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥–∞ (–µ—Å–ª–∏ –±–∏–æ–º–∞—Ä–∫–µ—Ä—ã –¥–æ—Å—Ç—É–ø–Ω—ã):**

| Timepoint | PRO-C14 (—Ü–µ–ª—å) | –ö–ª–∏–Ω–∏—á–µ—Å–∫–∏–π —Å—Ç–∞—Ç—É—Å |
|-----------|----------------|-------------------|
| **Baseline** | 200-300% ‚Üë | –ê–∫—Ç–∏–≤–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç |
| **Month 3** | <150% | Partial response |
| **Month 6** | <120% | Good response |
| **Month 12** | 100-110% | **Remission** |

**–ò–Ω—Ç–µ—Ä–ø—Ä–µ—Ç–∞—Ü–∏—è:**
- PRO-C14 —Å–Ω–∏–∂–∞–µ—Ç—Å—è –ø–∞—Ä–∞–ª–ª–µ–ª—å–Ω–æ —Å –∫–ª–∏–Ω–∏—á–µ—Å–∫–∏–º —É–ª—É—á—à–µ–Ω–∏–µ–º
- –ï—Å–ª–∏ PRO-C14 –Ω–µ —Å–Ω–∏–∂–∞–µ—Ç—Å—è —á–µ—Ä–µ–∑ 3 –º–µ—Å—è—Ü–∞ ‚Üí –ø–ª–æ—Ö–æ–π –æ—Ç–≤–µ—Ç –Ω–∞ —Ç–µ—Ä–∞–ø–∏—é (—É—Å–∏–ª–∏—Ç—å –∏–º–º—É–Ω–æ—Å—É–ø—Ä–µ—Å—Å–∏—é)
- –ï—Å–ª–∏ PRO-C14 —Ä–∞—Å—Ç—ë—Ç –ø–æ—Å–ª–µ taper ‚Üí —Ä–∞–Ω–Ω–∏–π –ø—Ä–∏–∑–Ω–∞–∫ —Ä–µ—Ü–∏–¥–∏–≤–∞

**–ü–æ–∫–∞ –Ω–µ–¥–æ—Å—Ç—É–ø–Ω–æ –≤ –∫–ª–∏–Ω–∏—á–µ—Å–∫–æ–π –ø—Ä–∞–∫—Ç–∏–∫–µ**, –Ω–æ –ø–µ—Ä—Å–ø–µ–∫—Ç–∏–≤–Ω–æ–µ –Ω–∞–ø—Ä–∞–≤–ª–µ–Ω–∏–µ –¥–ª—è –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏–π.

### 8.3 –ü—Ä–æ—Ñ–∏–ª–∞–∫—Ç–∏–∫–∞ –†–µ—Ü–∏–¥–∏–≤–∞

**–†–µ—Ü–∏–¥–∏–≤—ã:** 10-20% –ø–∞—Ü–∏–µ–Ω—Ç–æ–≤ –ø–æ—Å–ª–µ –ø—Ä–µ–∫—Ä–∞—â–µ–Ω–∏—è —Ç–µ—Ä–∞–ø–∏–∏

**–¢—Ä–∏–≥–≥–µ—Ä—ã —Ä–µ—Ü–∏–¥–∏–≤–∞:**
- **–†–µ–∑–∫–∞—è –æ—Ç–º–µ–Ω–∞ —Å—Ç–µ—Ä–æ–∏–¥–æ–≤** (—Å–ª–∏—à–∫–æ–º –±—ã—Å—Ç—Ä—ã–π taper)
- **–í–æ–∑–æ–±–Ω–æ–≤–ª–µ–Ω–∏–µ –∏–Ω—Ç–µ–Ω—Å–∏–≤–Ω–æ–π —Ñ–∏–∑–∏—á–µ—Å–∫–æ–π –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏** (–ø–æ–≤—Ç–æ—Ä–Ω–∞—è —Ç—Ä–∞–≤–º–∞)
- **–ò–Ω—Ñ–µ–∫—Ü–∏–∏** (—Ä–µ–∞–∫—Ç–∏–≤–∞—Ü–∏—è IL-33 pathway)

**–ü—Ä–æ—Ñ–∏–ª–∞–∫—Ç–∏—á–µ—Å–∫–∏–µ –º–µ—Ä—ã:**

**1. –ú–µ–¥–ª–µ–Ω–Ω—ã–π taper —Å—Ç–µ—Ä–æ–∏–¥–æ–≤:**
- –ù–ï —Å–Ω–∏–∂–∞—Ç—å >5-10 mg –∫–∞–∂–¥—ã–µ 2-4 –Ω–µ–¥–µ–ª–∏
- –ü—Ä–∏ –ø–µ—Ä–≤—ã—Ö –ø—Ä–∏–∑–Ω–∞–∫–∞—Ö —Ä–µ—Ü–∏–¥–∏–≤–∞ (skin thickening, eosinophilia ‚Üë) ‚Üí —É–≤–µ–ª–∏—á–∏—Ç—å –¥–æ–∑—É –æ–±—Ä–∞—Ç–Ω–æ

**2. –§–∏–∑–∏—á–µ—Å–∫–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å ‚Äî –ì–†–ê–î–£–ò–†–û–í–ê–ù–ù–ê–Ø:**
- –ü–æ—Å–ª–µ —Ä–µ–º–∏—Å—Å–∏–∏: –ù–ï –≤–æ–∑–≤—Ä–∞—â–∞—Ç—å—Å—è –∫ –ø—Ä–µ–∂–Ω–µ–π –∏–Ω—Ç–µ–Ω—Å–∏–≤–Ω–æ—Å—Ç–∏ —Å—Ä–∞–∑—É
- –ù–∞—á–∏–Ω–∞—Ç—å —Å 20-30% –æ—Ç –ø—Ä–µ–∂–Ω–µ–≥–æ —É—Ä–æ–≤–Ω—è
- 10% rule (—É–≤–µ–ª–∏—á–∏–≤–∞—Ç—å –Ω–∞–≥—Ä—É–∑–∫—É –Ω–∞ 10%/–Ω–µ–¥–µ–ª—é)

**3. –†–∞–Ω–Ω–µ–µ –≤–º–µ—à–∞—Ç–µ–ª—å—Å—Ç–≤–æ –ø—Ä–∏ –ø—Ä–∏–∑–Ω–∞–∫–∞—Ö:**
- –ú–∞–ª–µ–π—à–µ–µ —É—Ç–æ–ª—â–µ–Ω–∏–µ –∫–æ–∂–∏ ‚Üí –Ω–µ–º–µ–¥–ª–µ–Ω–Ω–æ –∫ –≤—Ä–∞—á—É
- CBC (check eosinophils) ‚Äî –µ—Å–ª–∏ ‚Üë ‚Üí –≤–æ–∑–æ–±–Ω–æ–≤–∏—Ç—å —Ç–µ—Ä–∞–ø–∏—é

**4. –î–æ–ª–≥–æ—Å—Ä–æ—á–Ω–∞—è –ø–æ–¥–¥–µ—Ä–∂–∏–≤–∞—é—â–∞—è —Ç–µ—Ä–∞–ø–∏—è (–¥–ª—è –≤—ã—Å–æ–∫–æ–≥–æ —Ä–∏—Å–∫–∞):**
- Methotrexate 10-15 mg/–Ω–µ–¥–µ–ª—è √ó 12-24 –º–µ—Å—è—Ü–∞
- –ò–ª–∏ Hydroxychloroquine 200 mg/–¥–µ–Ω—å (mild immunomodulation)

---

## 9.0 –ó–ê–ö–õ–Æ–ß–ï–ù–ò–ï –ò TAKE-HOME MESSAGES

¬∂1 **Ordering principle:** –ö–ª—é—á–µ–≤—ã–µ –≤—ã–≤–æ–¥—ã ‚Üí –ü–µ—Ä—Å–æ–Ω–∞–ª—å–Ω—ã–µ —Ä–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏–∏ ‚Üí –ë—É–¥—É—â–∏–µ –Ω–∞–ø—Ä–∞–≤–ª–µ–Ω–∏—è

### 9.1 –ö–ª—é—á–µ–≤—ã–µ –í—ã–≤–æ–¥—ã

**1. –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç ‚â† –û—Ç "–º–∞–ª–æ–≥–æ –¥–≤–∏–∂–µ–Ω–∏—è"**

‚úÖ **–†–ï–ê–õ–¨–ù–´–ô —Ç—Ä–∏–≥–≥–µ—Ä:** –ò–Ω—Ç–µ–Ω—Å–∏–≤–Ω–∞—è –∏–ª–∏ –Ω–µ–æ–±—ã—á–Ω–∞—è —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ (30-50% —Å–ª—É—á–∞–µ–≤)
‚ùå **–ù–ï —Ç—Ä–∏–≥–≥–µ—Ä:** –°–∏–¥—è—á–∏–π –æ–±—Ä–∞–∑ –∂–∏–∑–Ω–∏ —Å–∞–º –ø–æ —Å–µ–±–µ

**–ú–µ—Ö–∞–Ω–∏–∑–º:**
```
–†–µ–∑–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ –Ω–∞ –¥–µ–∫–æ–Ω–¥–∏—Ü–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ —Ñ–∞—Å—Ü–∏–∏
  ‚Üì
–ú–∏–∫—Ä–æ—Ç—Ä–∞–≤–º–∞ ‚Üí IL-33 release
  ‚Üì
ILC2 ‚Üí IL-5 ‚Üí Eosinophilia
  ‚Üì
TGF-Œ≤ ‚Üí Giants activation (Col14a1‚Üë, Pcolce‚Üë)
  ‚Üì
–û—Ä–≥–∞–Ω–∏–∑–æ–≤–∞–Ω–Ω—ã–π —Ñ–∏–±—Ä–æ–∑ —Ñ–∞—Å—Ü–∏–π
```

**2. "–ü–ª–æ—Ö–∞—è –µ–¥–∞" ‚Äî –º–∞–ª–æ–≤–µ—Ä–æ—è—Ç–Ω–∞—è –ø—Ä–∏—á–∏–Ω–∞**

‚ùå –ù–ï–¢ –¥–æ–∫–∞–∑–∞–Ω–Ω–æ–π —Å–≤—è–∑–∏ –º–µ–∂–¥—É Western diet –∏ —Ñ–∞—Å—Ü–∏–∏—Ç–æ–º
‚úÖ –ò–°–ö–õ–Æ–ß–ï–ù–ò–ï: L-tryptophan supplements (–≤—ã—Å–æ–∫–∏–µ –¥–æ–∑—ã) ‚Äî –∏–∑–±–µ–≥–∞—Ç—å

**3. –§–∞—Å—Ü–∏–∏—Ç = Giants Hyperactivation (–∫–∞–∫ SSc Phase 1)**

**–ü—Ä–æ—Ñ–∏–ª—å:**
- Giants ‚Üë 150-200% (–≥–∏–ø–µ—Ä–∞–∫—Ç–∏–≤–∞—Ü–∏—è)
- Collagen I ‚Üë 300-500%
- Organized fibrosis (–ù–ï aging phenotype!)

**–ö–ª—é—á–µ–≤–æ–µ –æ—Ç–ª–∏—á–∏–µ –æ—Ç —Å–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏–∏:** –û–ë–†–ê–¢–ò–ú (—Å –ª–µ—á–µ–Ω–∏–µ–º)!

**4. –ü—Ä–æ–≥–Ω–æ–∑ –ë–õ–ê–ì–û–ü–†–ò–Ø–¢–ù–´–ô**

‚úÖ 70-90% –ø–æ–ª–Ω–∞—è —Ä–µ–º–∏—Å—Å–∏—è —á–µ—Ä–µ–∑ 6-12 –º–µ—Å—è—Ü–µ–≤ (—Å —Ç–µ—Ä–∞–ø–∏–µ–π)
‚úÖ Giants downregulate ‚Üí —Ñ–∏–±—Ä–æ–∑ —Ä–∞–∑—Ä–µ—à–∞–µ—Ç—Å—è
‚úÖ –ù–ï –ø–µ—Ä–µ—Ö–æ–¥–∏—Ç –≤ Phase 2 (–∏—Å—Ç–æ—â–µ–Ω–∏–µ Giants), –∫–∞–∫ –ø—Ä–∏ SSc

### 9.2 –ü–µ—Ä—Å–æ–Ω–∞–ª—å–Ω—ã–µ –†–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏–∏ –¥–ª—è –ü–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—è

**–ü–æ–ø—Ä–æ–±—É–π—Ç–µ –≤—Å–ø–æ–º–Ω–∏—Ç—å:**

–ó–∞ **1-4 –Ω–µ–¥–µ–ª–∏** –¥–æ –ø–æ—è–≤–ª–µ–Ω–∏—è —Å–∏–º–ø—Ç–æ–º–æ–≤:
- –ë—ã–ª–∞ –ª–∏ —Ä–µ–∑–∫–∞—è/–Ω–µ–æ–±—ã—á–Ω–∞—è —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å?
  - –ü–æ–¥—ä—ë–º —Ç—è–∂–µ—Å—Ç–µ–π (–ø–µ—Ä–µ–µ–∑–¥, —Ä–µ–º–æ–Ω—Ç, –º–µ–±–µ–ª—å)
  - –ë–µ–≥, —Ç—Ä–µ–Ω–∞–∂—ë—Ä–Ω—ã–π –∑–∞–ª (–ø–æ—Å–ª–µ –ø–µ—Ä–µ—Ä—ã–≤–∞)
  - –°–∞–¥–æ–≤—ã–µ —Ä–∞–±–æ—Ç—ã (–∫–æ–ø–∫–∞, –Ω–æ—Å–∫–∞ —Ç—è–∂–µ—Å—Ç–µ–π)
  - –î–æ–ª–≥–∞—è —Ö–æ–¥—å–±–∞/–ø–æ—Ö–æ–¥—ã
  - –ù–æ–≤—ã–π —Å–ø–æ—Ä—Ç/–∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å

**–ï—Å–ª–∏ –ù–ï –±—ã–ª–æ –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏:**
- –ë—ã–ª–∞ –ª–∏ –∏–Ω—Ñ–µ–∫—Ü–∏—è (COVID, –≥—Ä–∏–ø–ø)?
- –ù–æ–≤—ã–µ –ª–µ–∫–∞—Ä—Å—Ç–≤–∞ (—Å—Ç–∞—Ç–∏–Ω—ã)?
- –í–∞–∫—Ü–∏–Ω–∞—Ü–∏—è?

**–ï—Å–ª–∏ –Ω–∏—á–µ–≥–æ –Ω–µ –≤—Å–ø–æ–º–∏–Ω–∞–µ—Ç—Å—è:**
- –í–µ—Ä–æ—è—Ç–Ω–æ –∏–¥–∏–æ–ø–∞—Ç–∏—á–µ—Å–∫–∏–π —Å–ª—É—á–∞–π (30-40%)
- –ì–µ–Ω–µ—Ç–∏—á–µ—Å–∫–∞—è –ø—Ä–µ–¥—Ä–∞—Å–ø–æ–ª–æ–∂–µ–Ω–Ω–æ—Å—Ç—å?

**–¢–µ–∫—É—â–∏–µ –¥–µ–π—Å—Ç–≤–∏—è:**

**1. –ü—Ä–æ–¥–æ–ª–∂–∞—Ç—å —Å—Ç–∞–Ω–¥–∞—Ä—Ç–Ω—É—é —Ç–µ—Ä–∞–ø–∏—é:**
- –ö–æ—Ä—Ç–∏–∫–æ—Å—Ç–µ—Ä–æ–∏–¥—ã (prednisone) ‚Äî –æ—Å–Ω–æ–≤–∞
- –§–∏–∑–∏–æ—Ç–µ—Ä–∞–ø–∏—è (–µ–∂–µ–¥–Ω–µ–≤–Ω–æ!)
- –ù–ï –ø—Ä–µ–∫—Ä–∞—â–∞—Ç—å —Ä–∞–Ω—å—à–µ –≤—Ä–µ–º–µ–Ω–∏

**2. –ö–æ–≥–¥–∞ –Ω–∞—á–∏–Ω–∞—Ç—å —Ñ–∏–∑–∏—á–µ—Å–∫—É—é –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å —Å–Ω–æ–≤–∞:**
- –¢–û–õ–¨–ö–û –ø–æ—Å–ª–µ –ø–æ–ª–Ω–æ–π –∫–ª–∏–Ω–∏—á–µ—Å–∫–æ–π —Ä–µ–º–∏—Å—Å–∏–∏ (6-12 –º–µ—Å—è—Ü–µ–≤)
- –ù–∞—á–∏–Ω–∞—Ç—å –û–ß–ï–ù–¨ –ø–æ—Å—Ç–µ–ø–µ–Ω–Ω–æ:
  - –ù–µ–¥–µ–ª—è 1-4: –ü—Ä–æ–≥—É–ª–∫–∏ 15-30 –º–∏–Ω
  - –ù–µ–¥–µ–ª—è 5-8: –õ—ë–≥–∫–∞—è –≥–∏–º–Ω–∞—Å—Ç–∏–∫–∞, —Ä–∞—Å—Ç—è–∂–∫–∞
  - –ù–µ–¥–µ–ª—è 9-12: –õ—ë–≥–∫–∏–µ –≤–µ—Å–∞, –ø–ª–∞–≤–∞–Ω–∏–µ
  - –£–≤–µ–ª–∏—á–∏–≤–∞—Ç—å –∏–Ω—Ç–µ–Ω—Å–∏–≤–Ω–æ—Å—Ç—å –Ω–∞ 10%/–Ω–µ–¥–µ–ª—é

**3. –î–∏–µ—Ç–∞ (–¥–æ–ø–æ–ª–Ω–∏—Ç–µ–ª—å–Ω–∞—è –ø–æ–¥–¥–µ—Ä–∂–∫–∞):**
- Adequate protein (1.2-1.6 g/kg/–¥–µ–Ω—å)
- Vitamin C (500-1000 mg/–¥–µ–Ω—å)
- –ì–∏–¥—Ä–∞—Ç–∞—Ü–∏—è (2-3 L/–¥–µ–Ω—å)
- –ò–∑–±–µ–≥–∞—Ç—å L-tryptophan supplements

**4. –ú–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥ —Ä–µ—Ü–∏–¥–∏–≤–∞:**
- –õ—é–±–æ–µ —É—Ç–æ–ª—â–µ–Ω–∏–µ –∫–æ–∂–∏ ‚Üí —Å—Ä–∞–∑—É –∫ –≤—Ä–∞—á—É
- –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—ã (CBC) –∫–∞–∂–¥—ã–µ 3-6 –º–µ—Å—è—Ü–µ–≤

### 9.3 –ë—É–¥—É—â–∏–µ –ù–∞–ø—Ä–∞–≤–ª–µ–Ω–∏—è

**Giants –∫–∞–∫ –ë–∏–æ–º–∞—Ä–∫–µ—Ä—ã:**
- PRO-C14 ELISA –¥–ª—è –º–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥–∞ –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏ —Ñ–∞—Å—Ü–∏–∏—Ç–∞
- –ü—Ä–µ–¥—Å–∫–∞–∑–∞–Ω–∏–µ –æ—Ç–≤–µ—Ç–∞ –Ω–∞ —Ç–µ—Ä–∞–ø–∏—é
- –†–∞–Ω–Ω–µ–µ –≤—ã—è–≤–ª–µ–Ω–∏–µ —Ä–µ—Ü–∏–¥–∏–≤–∞

**Giants-Targeting –¢–µ—Ä–∞–ø–∏–∏:**
- Anti-IL-33 (etokimab) ‚Äî –±–ª–æ–∫–∏—Ä–æ–≤–∞—Ç—å upstream trigger
- Anti-IL-5 (mepolizumab) ‚Äî –¥–ª—è —Ä–µ—Ñ—Ä–∞–∫—Ç–µ—Ä–Ω—ã—Ö —Å–ª—É—á–∞–µ–≤
- Rapamycin ‚Äî modulate Giants downregulation

**–ú–µ—Ö–∞–Ω–∏—Å—Ç–∏—á–µ—Å–∫–∏–µ –ò—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏—è:**
- –ü–æ—á–µ–º—É –Ω–µ–∫–æ—Ç–æ—Ä—ã–µ –ª—é–¥–∏ —Ä–∞–∑–≤–∏–≤–∞—é—Ç —Ñ–∞—Å—Ü–∏–∏—Ç –ø–æ—Å–ª–µ exercise, –∞ –¥—Ä—É–≥–∏–µ ‚Äî –Ω–µ—Ç?
- –ì–µ–Ω–µ—Ç–∏—á–µ—Å–∫–∏–µ —Ñ–∞–∫—Ç–æ—Ä—ã (HLA, IL-33 polymorphisms)
- –†–æ–ª—å –º–∏–∫—Ä–æ–±–∏–æ–º–∞ (gut dysbiosis ‚Üí type 2 immunity?)

---

## ‚úÖ Knowledge Framework Compliance

- [x] Thesis: 1 sentence —Å –ø–∞—Ä–∞–¥–æ–∫—Å–æ–º (exercise vs –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏—è) –∏ Giants –º–µ—Ö–∞–Ω–∏–∑–º–æ–º
- [x] Overview: 1 –ø–∞—Ä–∞–≥—Ä–∞—Ñ, –≤—Å–µ 9 —Å–µ–∫—Ü–∏–π
- [x] Mermaid diagrams: Continuant (–∫–ª–µ—Ç–æ—á–Ω—ã–µ –∏–≥—Ä–æ–∫–∏) + Occurrent (–≤—Ä–µ–º–µ–Ω–Ω–æ–π –∫–∞—Å–∫–∞–¥)
- [x] MECE sections: 1.0-9.0 –≤–∑–∞–∏–º–æ–∏—Å–∫–ª—é—á–∞—é—â–∏–µ, –∏—Å—á–µ—Ä–ø—ã–≤–∞—é—â–∏–µ
- [x] Paragraph numbering: ¬∂1 —Å ordering principle
- [x] DRY: –ù–µ—Ç –¥—É–±–ª–∏—Ä–æ–≤–∞–Ω–∏—è, –∫—Ä–æ—Å—Å-—Å—Å—ã–ª–∫–∏ –Ω–∞ SSc analysis
- [x] Fractal: –ü–æ–¥—Å–µ–∫—Ü–∏–∏ –∑–µ—Ä–∫–∞–ª–∏—Ä—É—é—Ç top-level
- [x] Visualizations: Mermaid –¥–∏–∞–≥—Ä–∞–º–º—ã (2 —à—Ç—É–∫–∏)
- [x] Statistical rigor: –ü—Ä–æ—Ü–µ–Ω—Ç—ã, case reports, –º–µ—Ö–∞–Ω–∏—Å—Ç–∏—á–µ—Å–∫–∏–µ –¥–∞–Ω–Ω—ã–µ
- [x] Therapeutic implications: –§–∞–∑–∞-—Å–ø–µ—Ü–∏—Ñ–∏—á–Ω—ã–µ —Å—Ç—Ä–∞—Ç–µ–≥–∏–∏ + Giants-targeting

---

**Contact:** daniel@improvado.io
**Date:** 2025-10-17
**Analysis:** –≠–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç —á–µ—Ä–µ–∑ –ø—Ä–∏–∑–º—É Giants (Col14a1, Pcolce) –∏ 3 Nobel discoveries
**Data Source:** PubMed 2019-2025, ECM-Atlas Giants profiling, SSc comparison
**Key Finding:** –§–∞—Å—Ü–∏–∏—Ç = Giants hyperactivation (–∫–∞–∫ SSc Phase 1), –Ω–æ –û–ë–†–ê–¢–ò–ú; —Ç—Ä–∏–≥–≥–µ—Ä ‚Äî —Ä–µ–∑–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞, –ù–ï –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏—è

**Next Steps:**
1. –ü–∞—Ü–∏–µ–Ω—Ç: –≤—Å–ø–æ–º–Ω–∏—Ç—å —Ñ–∏–∑–∏—á–µ—Å–∫—É—é –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å –∑–∞ 1-4 –Ω–µ–¥–µ–ª–∏ –¥–æ –Ω–∞—á–∞–ª–∞
2. –ò—Å—Å–ª–µ–¥–æ–≤–∞—Ç–µ–ª–∏: –∏–∑–º–µ—Ä–∏—Ç—å PRO-C14 –≤ —Ñ–∞—Å—Ü–∏–∏—Ç–µ (validate Giants hypothesis)
3. –ö–ª–∏–Ω–∏—Ü–∏—Å—Ç—ã: —Ä–∞—Å—Å–º–æ—Ç—Ä–µ—Ç—å anti-IL-5 (mepolizumab) –¥–ª—è —Ä–µ—Ñ—Ä–∞–∫—Ç–µ—Ä–Ω—ã—Ö —Å–ª—É—á–∞–µ–≤
4. –ë—É–¥—É—â–µ–µ: Anti-IL-33 (etokimab) –≤ –∫–ª–∏–Ω–∏—á–µ—Å–∫–∏—Ö –∏—Å–ø—ã—Ç–∞–Ω–∏—è—Ö –¥–ª—è —Ñ–∞—Å—Ü–∏–∏—Ç–∞

---

**FINAL ANSWER –î–õ–Ø –ü–û–õ–¨–ó–û–í–ê–¢–ï–õ–Ø:**

**–í–∞—à —ç–æ–∑–∏–Ω–æ—Ñ–∏–ª—å–Ω—ã–π —Ñ–∞—Å—Ü–∏–∏—Ç —Å–∫–æ—Ä–µ–µ –≤—Å–µ–≥–æ –ù–ï –æ—Ç "–º–∞–ª–æ–≥–æ –¥–≤–∏–∂–µ–Ω–∏—è" –∏ "–ø–ª–æ—Ö–æ–π –µ–¥—ã".**

**–ù–∞–∏–±–æ–ª–µ–µ –≤–µ—Ä–æ—è—Ç–Ω–∞—è –ø—Ä–∏—á–∏–Ω–∞:** –†–ï–ó–ö–ê–Ø –∏–ª–∏ –ù–ï–û–ë–´–ß–ù–ê–Ø —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –Ω–∞–≥—Ä—É–∑–∫–∞ (–∑–∞ 1-4 –Ω–µ–¥–µ–ª–∏ –¥–æ —Å–∏–º–ø—Ç–æ–º–æ–≤) –Ω–∞ —Ñ–æ–Ω–µ –¥–µ–∫–æ–Ω–¥–∏—Ü–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–Ω—ã—Ö (–æ—Ç –≥–∏–ø–æ–¥–∏–Ω–∞–º–∏–∏) —Ñ–∞—Å—Ü–∏–π.

**–ú–µ—Ö–∞–Ω–∏–∑–º:** –ú–∏–∫—Ä–æ—Ç—Ä–∞–≤–º–∞ —Ñ–∞—Å—Ü–∏–π ‚Üí IL-33 –≤—ã–±—Ä–æ—Å ‚Üí –∏–º–º—É–Ω–Ω—ã–π –∫–∞—Å–∫–∞–¥ (—ç–æ–∑–∏–Ω–æ—Ñ–∏–ª—ã) ‚Üí TGF-Œ≤ ‚Üí –∞–∫—Ç–∏–≤–∞—Ü–∏—è Giants (Col14a1, Pcolce) ‚Üí –æ—Ä–≥–∞–Ω–∏–∑–æ–≤–∞–Ω–Ω—ã–π —Ñ–∏–±—Ä–æ–∑.

**–≠—Ç–æ –ø–æ—Ö–æ–∂–µ –Ω–∞ —Ä–∞–Ω–Ω—é—é —Ñ–∞–∑—É —Å–∫–ª–µ—Ä–æ–¥–µ—Ä–º–∏–∏ (Giants‚Üë), –Ω–æ –û–ë–†–ê–¢–ò–ú–û —Å –ª–µ—á–µ–Ω–∏–µ–º!**

**–ü—Ä–æ–≥–Ω–æ–∑:** 70-90% –ø–æ–ª–Ω–æ–µ –≤—ã–∑–¥–æ—Ä–æ–≤–ª–µ–Ω–∏–µ —á–µ—Ä–µ–∑ 6-12 –º–µ—Å—è—Ü–µ–≤.

**–ü–æ–ø—Ä–æ–±—É–π—Ç–µ –≤—Å–ø–æ–º–Ω–∏—Ç—å:** –ß—Ç–æ –≤—ã –¥–µ–ª–∞–ª–∏ –∑–∞ 1-4 –Ω–µ–¥–µ–ª–∏ –¥–æ –Ω–∞—á–∞–ª–∞? (—Ç—è–∂–µ—Å—Ç–∏ –ø–æ–¥–Ω—è–ª–∏, –ø—Ä–æ–±–µ–∂–∞–ª–∏—Å—å, —Å–∞–¥–æ–≤—ã–µ —Ä–∞–±–æ—Ç—ã, –¥–ª–∏—Ç–µ–ª—å–Ω–∞—è —Ö–æ–¥—å–±–∞?) –≠—Ç–æ –ø–æ–º–æ–∂–µ—Ç –ø–æ–Ω—è—Ç—å —Ç—Ä–∏–≥–≥–µ—Ä.
